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Chapter 1: General introduction
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a major health epidemic, which has impor-
tant consequences for patients and community, and still receives insufficient attention from 
the health care professionals and scientists [1, 2]. COPD is a leading cause of chronic morbid-
ity (affects 210 million people) and mortality (causes 3 million deaths per year) worldwide [3, 
4], and according to the World Health Organization (WHO), it is the fifth most common cause 
of death and the 10th most burdensome disease [5].
Definition
The first definition of chronic obstructive pulmonary disease (COPD) can be found in the 60’s 
and incorporates both terms “emphysema” and “chronic bronchitis” [6].
According to the Global Initiative for obstructive lung diseases (GOLD) [3], COPD is defined 
as a “preventable and treatable disease with some significant extra-pulmonary effects that 
may contribute to the severity in individual patients. The pulmonary component is char-
acterized by airflow limitation, which is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lungs to noxious 
particles or gases, such as cigarette smoke” [7]. COPD is clinically characterized by symptoms 
like cough, sputum production, and/or dyspnea. The diagnosis is confirmed by spirometry 
and accordingly has four stages, from mild (GOLD stage I) to very severe (GOLD stage IV) 
[3]. Patients with COPD typically have a decrease in both FEV1 and a FEV1/FVC ratio of less 
than 0.7. Using this ratio as cut-off point for all patients is currently questioned as it may 
underestimate COPD in the young and overestimate COPD in older populations [8, 9].
The GOLD definition has become globally accepted for the diagnosis of COPD and some 
crucial components of this definition have been incorporated by the European Respiratory 
Society (ERS) and by the American Thoracic Society (ATS) [10].
Epidemiology of COPD
Worldwide, the prevalence of COPD in the general population is estimated to be above 1% for 
all ages, and to be 8-10% in individuals 40 years or older [11, 12]. In Europe, COPD prevalence 
rates range from 4-10% in the adult population [13]. A meta-analysis of population-based 
studies on the prevalence of COPD (based on spirometry) reported a pooled prevalence of 
9.2% [13]. However, there are large differences in prevalence depending on the population 
being studied, the definition being used and the availability of spirometry data. Estimates 
based on physician diagnosis from medical record databases, lack sensitivity as mild to mod-
erate disease is often undiagnosed and thus the COPD prevalence will be underestimated 
[14, 15]. Overall, the prevalence tends to be higher in countries where smoking levels are 
high. In addition, prevalence estimates increase with age, and are higher in men than in 
women [16].
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Although numerous data on the prevalence of COPD are available, very few population-
based studies investigated the incidence of COPD. Among the studies that have been 
conducted, a wide range of incidence rates can be observed, varying between 2-16/1,000PY 
depending on the COPD definition being used and the population being studied [9, 17-24].
COPD is one of the few chronic diseases that caused an increase in mortality in recent 
years [25]. In 1990, the WHO estimated the European standardized mortality rate of COPD 
to be 50/100,000 in men and 20/100,000 in women [26, 27]. Data provided by the WHO in 
1997, showed that COPD was the cause of death in 4.7% men and 2.4% women [26, 27] in 
Europe, and the World Health Report of 1998 stated that 2.9 million adults die each year of 
this disease [27, 28], By 2020, it is expected that COPD will be the third-leading cause of death 
worldwide [29, 30], but a more recent WHO projection predicts COPD to become the fourth 
commonest cause of death by 2030 [31].
Pathophysiology
The pathophysiology of COPD includes chronic obstructive bronchiolitis with fibrosis and 
obstruction of the small airways, and emphysema with destruction of the lung parenchyma, 
loss of lung elasticity, closure of the small airways and enlargement of airspaces (figure 1) 
[32-34].
COPD and effect of smoking on lung function
In humans, at the age of 15 to 25 years, the lung function reaches its peak, and this remains 
relatively constant for a decade (“plateau” phase). With aging, the lung function starts to 
decline, and in non-smoking subjects, the speed decline is of forced expiratory volume in 
one second (FEV1) approximately 25 to 30 mL/year [13, 35]. At present, the exact mechanism 
Figure 1 Mechanisms of airflow limitation in COPD
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(Adapted from NEJM, [Barnes P. Chronic obstructive pulmonary disease. NEJM, 2000:343(4); 269-280][33]) 
 
 
Figure 2 Fletcher-Peto curve illustrating the effect of smoking on FEV1 
(Adapted from BMJ, [Fletcher C, Peto R. The natural history of COPD. BMJ, 1977:1; 1645-1648][37]) 
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Chapter 1: General introduction
for this loss of post-bronchodilator FEV1 with increasing age is not well understood [36]. In 
susceptible smokers, the decline rate of expiratory airflow is often twice more pronounced 
than the rate associated with normal aging. In addition, smoking, including passive smoking, 
may reduce the maximal FEV1 attained and shorten the “plateau” phase or even eradicate it 
[21,37]. This effect can be observed in figure 2. In a population study of 792 London working 
men, Fletcher et al. demonstrated an accelerated decline in lung function over time due to 
smoking [37].
This study was criticized because 1) the length of the study period was considered too 
short for a chronic disease such as COPD, 2) because, it did not take into account inter-
individual variations in the rate of lung function being lost [38, 39], 3) because the study did 
not include women nor elderly, and 4) finally spirometry examination was not standardized. 
More recently, Kohansal et al. performed a similar study overcoming the limitations of the 
previous study, and they demonstrated that lung function development differs between 
sexes in nearly every age category, but smoking has a similar deleterious role in both men 
and women (figure 3) [38].
More recently, Brusselle described a paradigm shift in COPD (figure 4). The new paradigm 
of COPD accounted for the fact that interactions between multiple environmental exposures 
and genetic factors determine lung function and COPD risk. Moreover, both impaired lung 
function growth in early life and/ or accelerated decline in lung function in adulthood are 
known to be involved in the pathogenesis of COPD [40].
Figure 2 Old “paradigm” of COPD: Fletcher-Peto curve illustrating the effect of smoking on FEV1
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Figure 3 Mean FEV1 values (expressed as percent of its value at age 25), by age for never-smokers (NS) and 
continuous smokers (CS). Data for men (A) and women (B)
 
Figure 3 Mean FEV1 values (expressed as percent of its value at age 25), by age for never-smokers (NS) and 
continuous smokers (CS). Data for men (A) and women (B) 
(Adapted from AJRCCM, [Kohansal R et al. The natural history of chronic airflow obstruction revisited. AJRCCM, 
2009:180(1); 3-10][38]) 
 
 
Figure 4 Therapy according to severity of COPD 
(Adapted from AJRCCM, [Rabe K et al. Global strategy for the diagnosis, management, and prevention of COPD. 
AJRCCM, 2007:176(6); 532-555] [7]) 
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(Adapted from AJRCCM, [Kohansal R t al. The natural history of chronic airflow obstruction revisited. AJRCCM, 
2009:180(1); 3-10][38])
Figure 4 New "paradigm" of COPD: impaired lung function growth and/ or decline in lung function.
(Adapted from N Engl J Med, [Brusselle G. Matrix metalloproteinase 12, asthma, and COPD. N Engl J Med, 
2009:361; 2664-65] [40])
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Risk factors
Over the last decade, several risk factors for the development of COPD have been described, 
and among those, cigarette smoking is by far the strongest one [41, 42]. Other risk factors 
include environmental tobacco smoke, indoor and outdoor pollution, such as biomass 
fuel [16], and occupational dusts and chemicals [43]. The last factors are more important in 
developing countries [44]. Additional risk factors include poor socioeconomic status [45], 
adulthood infections (including a history of pulmonary tuberculosis [46]), as well as chronic 
asthma and airway responsiveness, the two last ones being more controversial [47].
Symptoms
Cough is frequently the first symptom of COPD, and may be intermittent, accompanied by 
sputum production, or can also be unproductive. Other complaints include wheezing, and 
chest tightness. Dyspnea is typically progressive, persistent and worsens with increase in 
exercise, and is known to have a weak relationship with FEV1 [48]. Other conditions associ-
ated with COPD are cor pulmonale caused by secondary pulmonary hypertension, anxiety, 
depression, fatigue, anorexia and weight loss [32].
Growing evidence suggest that there are differences in the characteristics of COPD between 
men and women [49], including in the prevalence and experience of COPD symptoms. It is 
recognized that women with COPD are more likely to have dyspnea and depression, anxiety 
and fatigue, and less frequently report phlegm production [50, 51]. In addition, women often 
report lower exercise capacity, more airway hyperresponsiveness [52] and a general worse 
health related quality of life [53].
COPD disease course
The disease is often complicated by frequent and recurrent exacerbations that arise with 
increasing severity [54] and contribute to declining lung function [55]. Acute exacerbations 
of COPD are important events in the clinical course of the disease. An exacerbation of COPD 
is generally defined as an event in the natural course of the disease characterized by a change 
in the patient’s baseline dyspnea, cough, and/ or sputum that is beyond normal daily varia-
tions, is acute in onset and may warrant a change in regular medication [3]. The most com-
mon causes of exacerbations include lower airway infection and airway pollution, but in one 
third of severe exacerbations, the cause is unknown [3]. The severity of an exacerbation can 
vary from no more than a troublesome increase in respiratory symptoms to life-threatening 
respiratory failure [55].
Each exacerbation may have a large and sustained effect on health status. Although the 
initial recovery can be short, the period for full recovery may be long (several months) with 
consequent deterioration of lung function [55], and not all patients fully recover to baseline 
condition [57, 58].
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COPD treatment
None of the existing medications (see below) have been proven to change the long-term 
decline in lung function. Therefore, COPD pharmacotherapy is mainly used to decrease 
symptoms and to prevent exacerbations of disease. According to the GOLD guidelines, 
bronchodilators are the mainstay for symptomatic management of COPD [7]. Bronchodilator 
treatments include β2-agonists, anticholinergics (AC), and methylxanthines, used alone or in 
combination. Long-acting bronchodilators are found to be more effective and convenient 
than the short-acting agents [59].
Figure 5 describes the GOLD guidelines for the treatment of COPD. In patients with 
mild COPD, short-acting bronchodilators are given on an as needed basis. In patients with 
moderate COPD, regular treatment with one or more long-acting bronchodilators is added. 
In patients with severe COPD, in case of repeated exacerbations, inhaled glucocorticoids 
are added to the treatment with long-acting bronchodilators. Finally, in patients with very 
sevexre COPD, oxygen therapy is added to the previously described treatment regimen 
[3]. Long-acting bronchodilators are known to be more effective and convenient than the 
short-acting ones [59]; and consist of long-acting β2-agonists (LABA) (salmeterol, formoterol, 
and the recently released ultra-long LABA namely indacaterol), and the long-acting AC drug 
(tiotropium) [7].
Figure 5 Therapy according to severity of COPD
 
Figure 3 Mean FEV1 values (expressed as percent of its value at age 25), by age for never-smokers (NS) and 
continuous smokers (CS). Data for men (A) and women (B) 
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Chapter 1: General introduction
Most of the efficacy and safety data on respiratory drugs is generated from RCTs. These 
RCTs use stringent inclusion and exclusion criteria, which jeopardizes the extrapolation of 
the study findings to the general population, and often have a short duration of follow-
up. The efficacy and safety of tiotropium have been demonstrated in several randomized 
placebo-controlled trials [60-68], in one randomized placebo-controlled trial [69], and in a 
pooled clinical trial analysis of tiotropium safety and efficacy [70], with imprecise reductions 
observed for mortality and a significantly lower risk observed for COPD exacerbations [62]. 
Compared to LABA, tiotropium shows a decrease of 48% in the incidence of COPD exacerba-
tions [71]. Only few RCTs compared lung function and health outcomes between users of 
tiotropium and salmeterol, in patients with moderate to severe COPD [64, 72-74].
As most of the COPD patients need chronic treatment with respiratory drugs and concomi-
tantly use other drugs for the treatment of co-existing comorbidities, the safety of respiratory 
drugs under real life circumstances is crucial. Real life observational studies allow studying 
the safety but also the effectiveness or respiratory drugs.
Aims and outline of this thesis
COPD is a leading and still-increasing cause of chronic morbidity and mortality worldwide. As 
a result of its burden and the impact on health care, we aimed to study the epidemiology of 
COPD (chapter 2), to explore the effectiveness (chapter 3) and the safety (chapter 4) of drugs 
given for the treatment of COPD under real life conditions.
For these studies, we used data from the Integrated Primary Care Information (IPCI) data-
base. IPCI is a longitudinal observational database (dynamic cohort) that contains data from 
computer based patient records of GPs throughout the Netherlands. Within this database we 
defined 3 COPD or COPD drug user cohorts, which were the basis for all studies. 1) One cohort 
of COPD patients, included data from 1996 to 2006, and COPD was identified on the basis of 
COPD diagnosis codes without further validation. The disease severity was defined by the 
algorithm of Ernst el al. [75] (chapter 4.2). 2) A second cohort of COPD patients, contained 
data from 2000 to 2007, and all COPD cases were reviewed/validated by a medical doctor, 
and the doubtful ones reviewed by a specialist. COPD disease severity was determined using 
spirometry values, when available, or by previously published algorithms for COPD severity 
assessment [76-78] (chapters 2, 3, 4.3, 4.4 and 4.5). 3) A third cohort was created on the basis 
of COPD drug (tiotropium) users, using data between 2000 and 2010. The presence of COPD, 
diagnosed through COPD diagnosis codes or free text, was considered a separate covariate 
in the analysis. COPD severity was assessed based on the number of prescriptions of systemic 
corticosteroids and the number of antibiotics (chapter 4.1) in the one year prior to tiotropium 
use.
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The COPD cohort allowed us to study the incidence, prevalence, mortality and lifetime risk 
of COPD. In addition, we compared mortality rates, both in the general population and in the 
COPD cohort (chapter 2). 
Furthermore, we studied the effectiveness and safety of respiratory drugs. We investigated 
the association between the use of inhaled respiratory drugs and the risk of hospitalization 
for COPD exacerbation, where we compared the effectiveness of tiotropium with LABAs 
(chapter 3). 
As safety studies, we explored the use of tiotropium, administered either via Respimat® SMI 
or HandiHaler®, and the risk of all-cause mortality (chapter 4.1). In addition, we studied the 
association between the use of inhaled AC drugs and the risk of urinary retention (chapter 
4.2), and renal failure (chapter 4.3).
As tiotropium continues to be used in a wider population, and in order to further assess 
safety risks in clinical practice, we studied the cardiovascular safety and risk of death during 
use of inhaled AC drugs. This research was driven by the safety warning issued by the FDA in 
2008, on a small excess risk of stroke in patients treated with tiotropium compared to placebo 
(chapter 4.4).
At last, we analyzed the risk of severe COPD exacerbations in patients with COPD, when 
being exposed to β-blockers (chapter 4.5). 
The meaning and limitations of the studies are discussed in chapter 5 of this thesis and 
recommendations are made for future research.
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2.1
COPD in the general population: 
incidence, prevalence and survival
Summary
Worldwide, COPD is a leading cause of chronic morbidity and mortality. Although its preva-
lence is already well documented, very few studies have measured its incidence. We therefore 
investigated the prevalence, incidence and lifetime risk of COPD in the general population.
In a population-based study including subjects ≥ 40, with 12 months of history available in 
the Dutch IPCI database, we identified COPD cases by a two-step validation algorithm.
Among 185,325 participants with 601,283 years of follow-up, 7,308 subjects with COPD 
were identified, and 1,713 had incident COPD. The overall IR of COPD was 2.92/1,000PY 
(95%CI 2.78-3.06). The incidence of COPD was higher in men (3.54; 95%CI 3.33-3.77) than 
in women (2.34; 95%CI 2.17-2.52), and the overall baseline prevalence of COPD was 3.02% 
(95%CI 2.94-3.10). For people who had entered the study free of COPD at the age of 40, the 
risk of developing COPD within the next 40 years was 12.7% for men and 8.3% for women. In 
patients with very severe COPD, 26% died after 1 year of follow-up, whereas 2.8% died among 
the non-COPD subjects.
In the general population in the Netherlands, three on 1,000 subjects developed COPD per 
year. The incidence increased rapidly with age and was higher in men than in women. One in 
eight men and one in 12 women, being COPD free at the age of 40 will develop COPD during 
their further life. Mortality rates differed substantially between COPD patients and non-COPD 
subjects of the same age, underlining the burden of this disease.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by a largely irreversible ob-
struction of the airways, and encompasses both emphysema and chronic bronchitis [2]. The 
obstruction of the airways is usually both progressive, and often associated with an abnormal 
inflammatory response of the lungs to harmful particles or gases such as tobacco smoke. 
COPD is a leading and still-increasing cause of chronic morbidity and mortality worldwide 
[79], and according to the World Health Organization (WHO), it is the fifth most common 
cause of death and the 10th most burdensome disease [5]. Chapman et al [80] and Mannino 
et al [15] projected that between 1990 and 2020, COPD will become the third most common 
cause of death worldwide. A Dutch study predicts that an increase of 76% in the prevalence 
of COPD can be expected within approximately twenty years [81].
Although the prevalence of COPD has been well studied [17, 35, 82-84], few population-
based studies [9, 17-22, 85] have investigated its incidence. Among the studies that have been 
conducted, a wide range in incidence rates can be observed varying between 2-16/1,000 PY 
depending on the COPD definition being used and the population being studied [9, 17-24]. 
Little is known about trends in COPD prevalence, incidence and all-cause mortality [24].
COPD is one of the few chronic diseases that caused an increase in mortality in recent years 
[25]. In 1990, the WHO estimated the European standardized mortality rate of COPD to be 50 
per 100,000 in males and 20 per 100,000 in females [26, 27]. Data provided by the WHO in 
1997, showed that COPD was the cause of death in 4.7% of men and 2.4% of women [26, 27] 
in Europe, and the World Health Report of 1998 stated that 2.9 million adults die each year of 
this disease [27, 28]. Death rates in patients with COPD are usually lower among women than 
among men in all countries. At present, there are very few observational studies reporting 
mortality rates in COPD patients [28].
The objectives of our study were to investigate the prevalence, incidence, mortality and 
lifetime risk of COPD as a function of age and sex in the general population.
Methods
Setting
The study was conducted within the Integrated Primary Care Information (IPCI) database, a 
longitudinal observational database (dynamic cohort), that started in 1992 and contains data 
from computer based medical records of general practitioners (GPs) throughout the Neth-
erlands [86]. The database covers data from more than 400 GPs who currently capture data 
on more than 1 million patients [86]. In the Dutch health care system, patients are registered 
with a single GP who acts as a gatekeeper for and receiver of information from secondary 
care [87]. The GPs’ electronic medical records contain coded and anonymous data on patient 
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demographics, narratives, patient reported symptoms, signs, GP and specialist diagnoses 
(using the International Classification of Primary Care (ICPC) codes and free-text [88]), as well 
as prescriptions, physical findings, laboratory values, and summaries of specialist letters [86, 
88]. Downloads are made periodically and the information is sent to the gatekeeper who 
de-identifies all information before further access is provided.
Prescription data encompass product name, quantity dispensed, dosage regimens, 
strength and indication. The National Database of drugs, maintained by the Royal Dutch As-
sociation for the advancement of Pharmacy, enables the coding of prescriptions, according 
to the Anatomical Therapeutic Chemical (ATC) classification scheme recommended by the 
WHO [89-91]. The system complies with European Union guidelines on the use of medical 
research and has been proven valid for pharmaco-epidemiological research [91]. All obser-
vational research using IPCI data is conducted according to good pharmaco-epidemiological 
guidelines [92].
Source population
The source population comprised 185,325 men and women aged 40 or older, with at least 
one year of valid database history meaning that the practice had been contributing data 
to the IPCI database for at least one year and that the patient had been registered with the 
GP for at least one year. This one-year pre-enrollment period was required to guarantee suf-
ficient medical history prior to study entry. The study started on 1 January 2000 or the date 
at which one year of valid history was obtained. All patients were followed from study entry 
until the date of diagnosis of (incident) COPD, death or 1 July 2007, whichever occurred first.
COPD cohort
A broad automated search was conducted on ICPC COPD disease codes and narratives to 
identify all potential COPD patients. The medical records of all potential cases were reviewed 
by a medical doctor and classified as: definite COPD - diagnosis by a specialist or a GP diag-
nosis confirmed by spirometry (GOLD definition of FEV1/FVC<70%); probable COPD - COPD 
diagnosed by the GP with at least two records of COPD within one year of the first record of 
COPD. Doubtful COPD patients were further reviewed and classified by a pulmonologist (GB).
All COPD patients were further categorized into prevalent or incident COPD. Patients with 
a COPD diagnosis prior to study entry were classified as prevalent (pre-existing) COPD. If 
patients were disease free (no respiratory symptoms) at cohort entry and later developed 
COPD, they were considered as having incident (newly onset) COPD.
COPD severity was assessed at the time of cohort entry and changes in COPD severity were 
captured during follow-up. If spirometry was available, severity of COPD was determined 
according to the GOLD guidelines and not based on the true lower limit of normal (LLN) 
of FEV1 as information on height and race was not consistently reported in the database 
[93]. In all other patients, previously published algorithms for COPD severity assessment were 
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used [76-78]. In summary, patients were considered to have mild COPD at the time of their 
first symptoms of COPD, moderate COPD if patients were on regular bronchodilating treat-
ment (defined as at least 2 prescriptions of the same drug class within 6 months of the first 
prescription), and severe COPD if they were hospitalized for COPD, received a third courses of 
antibiotics for the treatment of lower respiratory tract infections in one year time, or received 
their second systemic corticosteroid course for the treatment of COPD exacerbations in one 
year time. Finally, patients were considered to have very severe COPD when they were pre-
scribed oxygen therapy for chronic use or were scheduled for lung transplantation.
Statistical analysis
To compare the baseline characteristics of the COPD cases with the characteristics of the total 
population (without COPD) at study entry the Mann-Whitney U test was applied for continu-
ous variables, and the Chi-square test for categorical variables. Age and gender-specific (in 
5-year age categories) incidence rates of COPD (IRs) per 1,000 person-years (PY) were calcu-
lated by dividing the number of incident COPD cases by the total number of PY accumulated 
by the study population, and censoring the patients with COPD at baseline (prevalent cases). 
Relative risks were calculated by dividing two different incidence rates of COPD. Weighted 
(3 year mean) annual incidence rates by sex were also calculated by dividing the number of 
incident cases in a given year by the total number of individuals at risk for COPD in PY. The 
95% confidence intervals (CI) were calculated according to a Poisson distribution (Episheet, 
Rothman). Cumulative prevalence of COPD by age and sex was calculated by dividing the 
number of people with prevalent COPD by the number of subjects present in the study with 
the same age and sex. For this analysis, all study participants were used, and 95% CI were 
calculated with the Wilson score method for a binominal distribution (Episheet, Rothman). 
The cumulative incidence and the lifetime risk of COPD was calculated on the basis of a Cox 
regression model adjusted for competing risk of death, as described by Rosthoj et al [94]. This 
model was used to calculate the age specific 10, 20, 30 and 40 years risks of COPD, adjusted 
for the competing risk of dying, in men and women being disease free at study entry.
To compare the mortality rates in subjects with or without COPD, 4 controls were sampled 
from the source population for each COPD patient, matched on age, sex, smoking status 
and calendar year (year of entry into the cohort). Mortality rates were calculated by dividing 
the number of deaths by the person years attributed, and stratified by sex. Survival analyses 
were conducted using Kaplan-Maier analysis [95]. To compare our incidence rates to the IRs 
as published in literature, we standardized our IR to the age distribution presented in the 
different studies (table 4). All statistical analyses were conducted with SPSS/PC 15.0 (SPSS 
Inc, Chicago, Ill).
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Results
Baseline characteristics
In the source population of 185,325 patients with at least one-year of valid history (601,283 
years of follow-up time), 18,643 COPD potential cases were identified (figure 1). The mean 
follow-up time was 3.4 years (standard deviation (SD), ± 3.2 years). After manual validation of 
the complete medical record, 7,308 patients were identified as having COPD of which almost 
half were male. Table 1 shows the baseline characteristics of the total source population at 
study entry (n=185,325) and the patients with COPD (n=7,308), both incident and prevalent. 
COPD patients were older, more frequently male, and had more co-morbidity than non-COPD 
patients at study entry (table 1).
Figure 1 Flow-chart
2.1 COPD in the general population: incidence, prevalence and 
survival 
 
Figure 1 Flow-chart 
Patients to validate 
18,643 patients 
 
Search algorithm
Source population: 
185,325 patients 
Probable diagnosis - COPD diagnosed by the 
GP with at least two records of COPD within 
one year of the first record of COPD 
Prevalent: 
5,595 patients 
Incident: 
1,713 patients 
Probable COPD dx: 
2,421 patients 
Definite COPD dx: 
3,174 patients 
Manual validation by 2 MDs 
COPD patients: 
7,308 patients 
Probable COPD dx: 
690 patients 
Definite COPD dx: 
1,023 patients 
52,210 hits 
Corresponds to
Prevalent COPD severity: 
1,630 mild COPD 
2,664 moderate COPD 
1,203 severe COPD 
98 very severe COPD  
Incident COPD severity: 
1,358 mild COPD 
227 moderate COPD 
123 severe COPD 
4 very severe COPD  
Definite diagnosis - diagnosis by a specialist 
or a GP diagnosis confirmed by spirometry 
(FEV1/FVC<70%) 
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Table 1 Description of source population and COPD cohort - Demographics
Characteristics
Source population
n=185,325
Overall COPD Incident COPD Prevalent COPD
No. % No. % No. % No. %
Number of COPD patients 7,308 3.9 7,308 100.0 1,713 23.4 5,595 76.6
 ♂ 89,697 48.4 4,153 57.3 995 58.1 3,158 56.4
 ♀ 95,628 51.6 3,155 42.7 718 41.9 2,437 43.6
Age (years)
 40-59 119,798 64.6 1,982 26.5 501 29.2 1,481 26.5
 60-69 30,930 16.7 1,872 25.6 473 27.6 1,399 25.0
 >= 70 34,597 18.7 3,454 47.9 739 43.1 2,715 48.5
Mean age (±SD) 56.5 ±13.3 67.8 ±12.1 64.7 ±11.8 67.8 ±12.3
Smoking history1 39,625 21.4
 never smoked 475 7.7 125 7.3 350 6.3
 current smoking 2,821 40.3 810 47.3 2,011 35.9
 past smoking 433 6.1 165 9.6 268 4.8
 smoking not specified 3,573 45.7 611 35.7 2,962 52.9
Severity at cohort entry1
Severity by spirometry
 Mild (GOLD stage I) 639 9.0 243 14.2 393 7.0
 Moderate (GOLD stage II) 923 13.3 187 10.9 736 13.2
 Severe (GOLD stage III) 558 8.1 73 4.3 485 8.7
 Very Severe (GOLD stage IV) 21 0.3 3 0.2 18 0.3
Severity by proxy
 Mild 2,352 30.7 1,115 65.1 1,237 22.1
 Moderate 1,968 26.7 40 2.3 1,928 34.5
 Severe 768 10.8 50 2.9 718 12.8
 Very Severe 81 1.2 1 0.1 80 1.4
Mean time since first diagnosis (years) (±SD) 0 0 3.16 ±4.47
Co-morbidity at cohort entry1
History of asthma 1,384 0.7 1,042 15.3 251 14.7 881 15.7
History of myocardial infarction 2,286 1.2 457 6.7 136 7.9 344 6.1
Angina pectoris 5,454 2.9 994 14.6 241 14.1 808 14.4
History of ischemic heart disease 1,783 1.0 188 2.8 47 2.7 154 2.8
History of stroke or TIA 3,471 1.9 391 5.8 97 5.7 319 5.7
Peripheral arterial disease 4,047 2.2 441 6.5 131 7.6 339 6.1
Heart failure 2,708 1.5 793 11.7 179 10.5 697 12.4
Ventricular arrhythmia 3,492 1.9 28 0.4 7 0.4 22 0.4
Hypertension 20,499 11.1 1,422 20.9 369 21.5 990 17.7
Lipid disorder 7,694 4.2 1,769 26.1 533 31.1 1,296 23.2
Diabetes 8,023 4.3 767 11.3 195 11.4 651 11.6
Renal insufficiency 1,371 0.7 184 2.7 54 3.2 174 3.1
History of malignancy 8,423 4.5 673 9.9 159 9.3 544 9.7
Pneumonia (year prior) 3,241 1.7 571 8.4 131 7.6 483 8.6
Parkinsonism 436 0.2 21 0.3 7 0.4 16 0.3
History of depressive disorders 9,449 5.1 540 8.0 172 10.0 416 7.4
Dementia diagnosis 436 0.2 23 0.3 4 0.2 22 0.4
1 At baseline for prevalent COPD patients or at the date of diagnosis for incident COPD patients
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A total of 5,595 patients (77%) in the COPD cohort had prevalent COPD at baseline and 
1,713 (23%) were incident COPD patients. Incident COPD patients were slightly younger than 
the prevalent ones (mean age 64.7, SD ± 11.8, versus 67.8, SD ± 12.3), and more often smoked 
or had smoked in the past (table 1). The mean and median age at first diagnosis did not 
change over time (data not shown). The majority of incident COPD patients had mild COPD 
at the time of first diagnosis.
Co-morbidity was similar between incident and prevalent COPD patients apart from a 
history of heart failure, which was more often recorded in prevalent COPD patients (12.3% 
versus 9.8%), and hypertension, lipid disorders and a history of depressive disorders, which 
were more common in incident COPD patients (table 1).
Incidence, prevalence, risk and mortality
The overall incidence of COPD in persons 40 years and older was 2.92/1,000PY (95%CI, 2.78-
3.06) (table 2). The incidence of COPD was higher in men than in women (with a relative risk 
(RR) of 1.5-fold higher in men). The incidence increased almost 10 fold from 0.78/1,000 PY at 
age 40-44 to 6.82/1,000PY at age 75-79 (figure 2).
The prevalence of COPD at cohort entry was 3.02%, 95%CI (2.94-3.10). The age-specific 
cumulative prevalence of COPD is shown in figure 4. As can be observed from this graph, 
the prevalence increased with age until the age of 81 years in men and 83 years in women. 
After this age, the prevalence did no longer increase and even gradually declined, especially 
in men. The prevalence of COPD was, for all age categories, higher in men than in women 
(figure 4).
For a man free of COPD at the age of 40, the risk to develop COPD was 0.8% (10 years), 2.8% 
(20 years), 7.2% (30 years) and 12.7% (40 years) respectively. For a woman of the same age, 
the risks were 0.8%, 2.3%, 5.0% and 8.3% (figure 5).
Table 2 Incidence of diagnosed COPD
Age groups, years Overall Men Women
IR 95%CI IR 95%CI IR 95%CI
40-44 0.78 0.62-0.97 0.76 0.54-1.04 0.80 0.57-1.09
45-49 1.04 0.85-1.26 1.16 0.89-1.50 0.92 0.68-1.23
50-54 1.71 1.46-1.99 1.87 1.51-2.29 1.54 1.21-1.93
55-59 2.40 2.08-2.76 2.69 2.22-3.23 2.12 1.70-2.61
60-64 3.47 3.02-3.96 4.41 3.70-5.20 2.54 2.02-3.16
65-69 5.36 4.74-6.04 7.45 6.40-8.64 3.51 2.84-4.29
70-74 6.57 5.83-7.39 8.94 7.65-10.39 4.74 3.92-5.68
75-79 6.82 5.98-7.74 9.95 8.35-11.77 4.84 3.96-5.86
80+ 5.46 4.76-6.24 8.91 7.34-10.72 3.87 3.17-4.69
All age categories 2.92 2.78-3.06 3.54 3.33-3.77 2.34 2.17-2.52
Ana BW 4.indd   27 03-03-11   12:30
28
Mortality rates were 2.0-fold higher for COPD patients than for the age and sex matched 
reference population. Mortality rates increased with COPD severity from 48.1/1,000PY 
(95%CI, 42.5-54.3/1,000PY) in mild to 262/1,000PY (95%CI, 179-371/1,000PY) in very severe 
COPD patients (table 3). Survival is lower in COPD patients than non-COPD subjects and is 
highly influenced by COPD severity (figure 3). The one-year risk of dying was 26% (95%CI 
18.4-35.4%) in the very severe COPD patients while the risk in the sex and age matched refer-
ence group was nearly ten times lower namely 2.8% (95%CI 0.92-8.17%).
Figure 2 Age- and gender specific incidence rates of diagnosed COPD (/1,000 PY) (top) and weighted (3 year 
mean) calendar year-specific incidence of COPD (bottom)
Figure 2 Age- and gender specific incidence rates of diagnosed COPD (/1,000 PY) (top) and weighted (3 year 
mean) cale ar year-specific incidence of COPD (bottom) 
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Discussion
In this large population based cohort study of the general Dutch population of 40 years 
and older, the overall incidence rate of diagnosed COPD was 2.92/1,000PY. The incidence 
increased with age, and was higher in men than in women. Based on these data the risk to be 
diagnosed with COPD in the coming 40 years was 12.7% for a 40-year-old male and 8.3% for a 
40-year-old female. Mortality was high; especially in very severe COPD patients with one-year 
mortality risks nearly 10-fold that of non-COPD subjects of the same age.
Figure 3 Survival among (top) men and (bottom) women diagnosed with COPD by severity status and reference 
population (controls are COPD free)
Figure 3 Survival among (top) men and (bottom) women diagnosed with COPD by severity status and reference 
population (controls are COPD free) 
 
Figure 3 Survival among (top) men and (bottom) women diagnosed with COPD by severity status and reference 
population (controls are COPD free) 
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Previous studies mainly focused on the prevalence of COPD as they often applied a cross 
sectional spirometry based approach to obtain the true prevalence of COPD (see table 4). 
Very few spirometry based incidence studies have been reported [9, 17-21]. Studies reporting 
diagnosed COPD, based on health care databases, were conducted in the UK and in Canada 
(table 4) [22-24]. The most recent incidence study, published in 2010, is a Canadian study 
investigating trends in incidence, prevalence and mortality of COPD over time [24]. For this 
Figure 4 Age-specific cumulative prevalence of COPD in men (grey) and women (black)
Figure 4 Age-specific cumulative prevalence of COPD in men (grey) and women (black) 
  
Figure 5 Age-related risk for COPD to develop over the coming 10, 20, 30, and 40 years in men (top) and women 
(bottom). CI= cumulative 
Table 3 Number of deaths and mortality rates (/1,000PY) in patients with and without COPD
COPD Non-COPD
All Mild Moderate Severe Very severe
Total number
patients, n (%) 7,308 2,989 (40.9) 2,891 (39.6) 1,326 (18.1) 102 (1.4) 24,722
Number of deaths 1,371 393 523 402 53 2,750
 ♂ 897 (65.4) 259 (65.9) 329 (62.9) 280 (69.6) 29 (54.7) 1,886 (68.6)
 ♀ 474 (34.6) 134 (34.1) 194 (37.1) 122 (30.3) 24 (45.3) 864 (31.4)
Mean (SD) age
at death 78.2 (±9.3) 78.2 (±9.8) 78.9 (±8.8) 77.7 (±9.2) 73.6 (±9.7) 79.7 (±8.6)
Age at death, n (%)
 40-59 53 (3.9) 18 (4.6) 15 (2.9) 15 (3.7) 5 (9.5) 89 (3.3)
 60-69 195 (14.2) 54 (13.7) 64 (12.2) 64 (16.0) 13 (24.5) 261 (9.5)
 >= 70 1,123 (81.9) 321 (81.7) 444 (84.9) 323 (80.3) 35 (66.0) 2,400 (98.2)
Mortality rate (/1,000PY), 95%CI
 ♂ 70.4 (65.9-75.1) 48.1 (42.5-54.3) 63.9 (57.3-71.1) 133.4 (118.5-149.8) 262.0 (179.1-370.9) 36.3 (34.7-38.0)
 ♀ 48.5 (44.3-53.0) 33.5 (28.2-39.6) 47.5 (41.1-54.5) 76.8 (64.0-91.3) 236.7 (195.5-404.9) 21.7 (20.3-23.2)
 All 60.9 (57.7-64.2) 41.9 (37.9-46.2) 56.6 (51.9-61.6) 109.0 (98.7-120.1) 249.9 (189.2-324.2) 30.0 (28.9-31.1)
*Matched for age, sex, smoking status and calendar year (year of entry in the cohort); 4 controls were sampled 
from the source population for each COPD patient
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Table 4 Overview of studies that have investigated the incidence of COPD (Overall rate of diagnosed COPD in our 
study 2.9/1,000PY)
Author Source population Country
COPD 
definition
Year of 
study
Cohort 
size
Follow-
up time
# incident 
COPD in 
cohort
Age 
in 
years
IR COPD
Spirometry based studies
van Durme et 
al [17]
Chest 2009
Population based
the Netherlands 
( Rotterdam)
Spirometry/ 
discharge 
letters
1990-2004 7,983 11 yrs 648 >= 55 9.2/1,000PY
Krzyzanowski 
M et al [18]
Am R Res Dis 
1986
Longitudinal data, 
random sample; older 
persons and those with 
chest complaints 
performed lung function 
tests
Poland (Cracow) Spirometry 1968-1981 4,612 13 yrs 1,864 19-70 5.0/1,000PY
Huhti E et al 
[19]
Eur J Res Dis 
1980
Non-selected population 
and standard question-
naire on respiratory 
symptoms filled in for 
each subject
Finland (Harjavalta) Spirometry 1961-1971 1,476 10 yrs 1,163 40-64
2.0/1,000PY 
and 
10.0/1,000PY 
smokers
de Marco R et 
al [21]
AJRCCM 2007
ECRHS on random 
sample of young adults.
Participants were invited 
by questionnaire. Of the 
responders, a random 
sample of 20% were 
invited for lung function 
examination
Belgium, Denmark, 
Estonia, France, Ger-
many, Iceland, Italy, 
the Netherlands, 
Norway, Spain, Swe-
den, Switzerland, UK
Spirometry 
(FEV1/FVC < 
70%)
ECRHS I: 
1991-1993
ECRHS II: 
1999-2002
5,002 8.9 yrs 123 20-44
2.8 /1,000PY
10 yrs CI 2.8%
Lindberg A, et 
al [20]
Chest 2006
Participants selected via 
postal questionnaire and 
a random sample was 
invited to a structured 
interview and spirometry 
in 1996 and 2003
Sweden (Noorbot-
ten)
Spirometry 
(GOLD)
85% (1,009) 
participated 
in 1996 and 
2003
963 7 yrs
45 (Gold II 
and more)
91 (Gold I 
and more)
46-77
6.7/1,000PY 
Gold II 
(CI 4.9%), 
13.5/1,000PY 
Gold I and 
more (CI 
11.0%)
Vestbo J et 
al [9]
General population 
sample without COPD 
at study entry, selected 
at random after age 
stratification;
participants were invited
Denmark (Copen-
hagen)
Spirometry
1976-1778
1981-1983
1992-1994
14,223 
(maxi-
mal)
9 yrs ?
>= 20 
years
19/1,000PY 
(5 yrs) and 
9/1,000PY (15 
yrs), 5 yrs CI 
9.7% and 15 
yrs CI 13.2%
Diagnosis based studies
Garcia Rodri-
guez et al [22]
Population based – 
GPRD
UK
OXMIS and 
Read Codes
1996- 808,513 ? 1,927 40-89 2.6/1,000PY
Huerta C et 
al [23]
Population based – 
GPRD
UK
Presence of 
recorded 
diagnosis
1993-1998 5,000 6 yrs 206 60-85 7.2/1,000PY
Gershon et 
al [24]
Population based – 
Claims database
Canada ICD codes 1996-2007
5-6.4 
million
12 yrs
61,998-
55,903
>=35
11.8-
8.5/1,000PY
* BTS criteria: FEV1/FVC ratio, <0.70; and FEV1, <80% predicted; GOLD criteria: FEV1/FVC ratio, <0.70
**GOLD: GOLD stage I to IV with FEV1/FVC ratio of <0.70; GOLDII: GOLD II and higher with FEV1/FVC ratio if <0.70 
and FEV1<80% predicted
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study, the Ontario Health Insurance Plan database was used and COPD was defined based on 
visits and hospitalization with ICD-9 or ICD-10 codes for COPD [24]. The incidence of COPD 
was high: 11.8/1,000 in 1996 and 8.5/1,000 in 2007 [24]. The rates of incidence and prevalence 
were much higher than observed in our study (even after standardization), but the study was 
very inclusive and did not validate COPD. Codes included terms such as chronic bronchitis 
Figure 5 Age-related risk for COPD to develop over the coming 10, 20, 30, and 40 years in men (top) and women 
(bottom). CI= cumulative
Figure 5 Age-related risk for COPD to develop over the coming 10, 20, 30, and 40 years in men (top) and women 
(bottom). CI= cumulative 
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and asthmatic bronchitis which not necessarily are synonyms of COPD [24]. Our COPD defini-
tion was much stricter requiring specialist diagnosed COPD or COPD diagnosed by GP in case 
of spirometry and/or at least 2 records of COPD within one year explaining our lower IRs.
Van Durme et al also studied the incidence of COPD in a prospective cohort of elderly in the 
Netherlands. , COPD was defined based on specialists/GPs (similar to ours) diagnosis as well 
as on tri-annual spirometry assessments. Our age standardized rate was 35% lower showing 
the level of underdiagnosis [17]. Using the indirect age standardization, the calculated stan-
dardized incidence rate was 0.49 (95%CI 0.46-0.52), which means that there is a difference 
in the two populations in weight, and in our population we expect 50% less patients with 
a COPD diagnosis. Our IR is probably much lower than in the study from Van Durme et al, 
as in the latter; spirometry was conducted on 44% of the study population whereas in our 
setting, spirometry was only conducted in case of respiratory complaints. Our IRs are more in 
line with the results of a recent population based cohort study, using similar data and similar 
methodology, from the UK GPRD database [22]. The incidence rate of diagnosed COPD in 
40-89 year-olds was 2.6/1,000 PY which is almost identical to the incidence rate we found 
(2.9/1,000 PY) [22]. In summary, there is a large heterogeneity between reported prevalence 
and incidence rates of the different studies, which can be explained by the method of assess-
ing and validating COPD and age differences.
In our study, all-cause mortality rates were higher in COPD patients than in patients without 
COPD of similar age and sex. Our mortality rates are much in line with the data from Soriano 
et al [28] and Gershon et al [24], who also studied mortality in COPD patients. In their study, 
Gershon et al describe mortality rates that vary between 5.7% in 1996 to 4.3% in 2007 [24], 
which is in line with the mortality rate of 6.1% that we found in our COPD patients. Soriano et 
al reported an overall death rate of 8.5% per year [28]. Furthermore, in comparison with data 
of patients with COPD followed by GPs [96], Lundback et al refer to a better survival among 
the subjects with COPD identified by an epidemiological population study, with a 5-year risk 
of dying of approximately 7% in subjects without either chronic bronchitis and asthma-like 
phenotype, and approximately 15% in subjects with chronic bronchitis [97]. Our 5-year risk 
of dying was somehow higher with 14% in non-COPD patients and 27% in COPD patients, 
probably not only because Lundback et all include younger patients in the beginning of their 
study, but also their definition of chronic bronchitis may differ from our COPD definition, and 
direct to a slightly different inclusion of patients in both studies.
Similar to previous literature [24, 28] we also found that mortality in patients with COPD is 
still higher in men than in women. A partial explanation could be that, on average, women 
with COPD have still less severe disease than men, because women used to smoke less or 
were not inhaling tobacco as frequently as men.
As for all observational studies, our study has strengths and weaknesses. The strength of 
this study is the population-based design; its large cohort size and the detailed information 
that is available on underlying co-morbidity. Furthermore, the large population in this study 
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is representative of the general population, which eliminates selection bias. To avoid inclu-
sion of false positive cases we followed a rigorous validation algorithm and used data from 
spirometry and specialist referral letters if available. In addition, we assessed COPD severity 
according to spirometry data or according to an algorithm already successfully used by other 
research groups [76-78]. Unfortunately, as this is a population-based study, we did not have 
spirometry data on all subjects. For this reason we believe that we probably underestimated 
the true incidence rate of COPD in the general population. This is one of the reasons why 
our COPD incidence rate is lower than in those studies where COPD was assessed mainly by 
spirometry. In our study, patients diagnosed to have COPD are mainly the ones presenting 
themselves with respiratory symptoms. Probably a considerable proportion of patients with 
respiratory symptoms get accustomed to these complaints and never consult their GP [98]. 
Another limitation is the fact that the GOLD definition of COPD (FEV1/FVC<70%) for patients 
with spirometry data instead of the use of LLN values for FEV1/FVC. However, it is known that 
this ratio declines with age, and so the true lower limit of normal (LLN) for FEV1/FVC also 
declines. This may result in misclassification of disease, with an overdiagnosis in the elderly 
and underdiagnosis in the young age categories [99]. The sex differences in the incidence 
may also be influenced by this reasoning since the cross over point for a plot of the fixed 
ratio FEV1/FVC and the true LLN against age is at a later age in women [93]. We are aware of 
this limitation, but as information on height and race is not systematically reported in the 
database, we were not able to calculate the LLN and had to use the fixed ratio of FEV1/FVC 
[100].
In conclusion, in the Netherlands around 3 on 1,000 subjects are newly diagnosed with 
COPD per year, however, the true incidence of COPD, based on spirometry criteria, may be 
30-40% higher. The lifetime risk that COPD would be diagnosed over the coming 40 years, if 
diagnostic criteria and processes remain the same, was 12.7% for a 40 year-old-man still free 
of COPD and 8.3% for a woman. If ascertainment increases this is likely to be higher. Mortality 
rates are substantially higher in patients with COPD than in the general population, which 
emphasizes the need for better primary and secondary prevention in patients with COPD.
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Effectiveness of long-acting 
bronchodilators in COPD
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Comparative effectiveness of 
tiotropium and long-acting β2-
agonists in preventing severe COPD 
exacerbations
Abstract
Aim: To compare the risk of chronic obstructive pulmonary disease (COPD) exacerbations 
requiring hospitalization, between COPD patients treated with tiotropium and those treated 
with long-acting β2-agonists (LABA).
Methods: A nested case-control study was conducted in a cohort of COPD patients using 
data from the Dutch IPCI database from 2000 to 2007. Cases were all COPD patients diagnosed 
with a first COPD exacerbation requiring hospitalization. To each case, all eligible controls 
were matched on age, sex and index-date. COPD severity was assessed either via spirometry 
or proxy. The odds of hospitalization for COPD exacerbation during use of tiotropium was 
compared to the odds during use of LABA. Conditional logistic regression analysis was used 
to calculate adjusted odds ratios (ORadj) with 95% confidence intervals (CIs).
Results: Within the cohort of 6,788 COPD patients, 619 had at least one COPD exacerba-
tion requiring hospitalization during follow-up. The one-year risk of exacerbations requiring 
hospitalization was 2.2% (95%CI 1.8%-2.6%) in mild/moderate and 10% (95%CI 8.2-11.8%) 
in severe/very severe COPD patients. The risk of hospitalizations for COPD exacerbations 
was lower during use of tiotropium compared to use of LABA (ORadj 0.69, 95%CI 0.40-1.19) 
although not statistically significant.
Conclusion: In this primary care-based study of COPD patients, there was a statistically non-
significant reduced risk for COPD hospitalizations with tiotropium compared to LABA.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and 
mortality worldwide. The disease is often complicated by exacerbations that ensue with 
increasing severity [54] and contribute to declining lung function and health status [55]. 
Hurst et al recently concluded that although exacerbations become more frequent and more 
severe as COPD progresses, the rate at which they occur appears to reflect an independent 
susceptibility phenotype [101]. An exacerbation of COPD is defined as “an event in the 
natural course of the disease characterized by a change in the patient’s baseline dyspnea, 
cough, and/or sputum and beyond normal day-to-day variations, that is acute in onset and 
may warrant a change in regular medication in a patient with underlying COPD” [102, 103]. 
Exacerbations contribute considerably to the morbidity associated with COPD [104]. More-
over, exacerbations lead to an increase in health care costs, disability, and result in premature 
death. As a consequence, exacerbations are currently considered to be one of the most 
relevant outcome parameters in randomized controlled trials in patients with COPD [103].
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 
bronchodilators are the mainstay for symptomatic management of COPD [105]. Bronchodila-
tor treatments include short-acting and long-acting β2-agonists (LABA), short-acting and 
long-acting anticholinergics (LAAC), and methylxanthines. Long-acting bronchodilators are 
found to be more effective and convenient than the short-acting agents [59]. Tiotropium is 
currently the only EMA/FDA approved long-acting inhaled anticholinergic bronchodilator, 
which should be used once daily for long-term maintenance treatment of COPD. The efficacy 
and safety of tiotropium have been demonstrated in several randomized placebo-controlled 
trials [60-68], in one ipratropium-controlled trial [69], and in a pooled clinical trial analysis 
of tiotropium safety [70]. Compared to placebo, inhaled LABA (salmeterol or formoterol) 
reduced the risk of severe COPD exacerbations requiring withdrawal or hospitalization, and 
compared with LABA, tiotropium resulted in a decrease of 48% in the incidence of COPD 
exacerbations [71].
Only few RCTs compared lung function and health outcomes between users of tiotropium 
and salmeterol, in patients with moderate to severe COPD [64, 72-74]. However, these trials 
(total of 2,483 patients only and 1,079 patient years) focused mainly on lung function as pri-
mary endpoint and were possibly not powered to study equivalence or differences between 
the two drugs regarding less common hard clinical endpoints such as COPD exacerbations 
leading to hospitalization. No RCTs comparing tiotropium and formoterol in patients with 
COPD focusing on hospitalisation due to COPD exacerbation are available; however, a RCT 
has been designed to investigate the comparative efficacy of two long-acting bronchodila-
tors tiotropium 18 μg daily and salmeterol 50 μg twice daily on exacerbations, but results 
have not been published yet [104]. In modern health care it is important not only to dem-
onstrate the efficacy of drugs against placebo, but also to compare effectiveness between 
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treatment alternatives in clinical practice. The need to conduct comparative effectiveness 
studies is clear from the increasing resources that are made available for this research [106].
The objective of this nested case control study, in a large cohort of 6,788 COPD patients 
with 23,930 person-years of follow-up, was to compare the effectiveness of tiotropium and 
LABA in the prevention of hospitalizations for COPD exacerbations in clinical practice.
Methods
Setting
A nested case-control study was conducted in a cohort of COPD patients from the Integrated 
Primary Care Information Project (IPCI) database. IPCI is a population-based longitudinal 
database that contains the complete computer-based medical records of currently more 
than 400 General Practitioners (GPs) throughout the Netherlands [86]. In the Dutch health 
care system, patients are registered with a single GP who acts as a gatekeeper of medical 
care and information from primary care visits, hospital admission and outpatient visits and 
therefore the medical records do not only capture GP diagnoses and symptoms but also the 
results and summaries of specialist care. At present, the IPCI database contains information 
on more than 1 million patients. This database contains anonymized patient identification 
information (age, sex, patient identification number, and GP registration information), nar-
ratives, symptoms, signs, GP and specialist diagnoses, prescriptions, laboratory values, and 
summaries of specialist letters [86, 88]. The system complies with European Union guidelines 
on the secondary use of health care data for medical research and has been proven valid for 
pharmaco-epidemiological studies [91]. All observational research on the IPCI database is 
being conducted according to good pharmaco-epidemiological guidelines [92].
The source population consisted of all patients in the IPCI database who were 40 years of 
age or older, and with at least one year of valid history available in the database. The study 
period started in January 2000 and ended in May 2007.
COPD cohort
The study population consisted of all patients present during the study period, with at least 
one year of medical history, diagnosed with COPD and a minimum age of 40 years at time 
of study entry. COPD patients were identified from diagnoses and narratives. The medical 
records of all potential cases were reviewed by a medical doctor and classified as: definite 
COPD - diagnosis by a specialist or a GP diagnosis confirmed by spirometry (FEV1/FVC<70%); 
probable COPD - COPD diagnosed by the GP with at least two records of COPD within one 
year of the first record of COPD. All doubtful COPD patients were further reviewed and clas-
sified by a pulmonologist (GB). All COPD patients were further categorized into prevalent 
or incident COPD. Patients with a COPD diagnosis prior to entry into the source population 
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(e.g. COPD diagnosed in 1995) were defined as having prevalent (existing) COPD. Start date 
for these patients in the COPD cohort was the start of follow-up for the source population. 
If patients were disease free at time of start in the source population, and later developed 
COPD, they were considered as having incident (newly onset) COPD. Start date for these 
patients in the COPD cohort was the date of incident COPD.
COPD severity was assessed at the time of cohort entry and changes in COPD severity were 
captured during follow-up, which meant that we allowed severity to change over time. If spi-
rometry was available, severity of COPD was determined according to the GOLD guidelines; 
in all other patients, previously published algorithms for COPD severity assessment were 
used [76-78]. In summary, patients were considered to have mild COPD at the time of their 
first symptoms of COPD, moderate COPD if patients were on regular bronchodilatory treat-
ment (defined as at least 2 prescriptions of the same drug class within 6 months of the first 
prescription), and severe COPD if they were hospitalized for COPD, or at the time they had 
their third course of antibiotics for the treatment of respiratory infections in one year time, or 
at the time they had their second systemic corticosteroid course for the treatment of COPD 
exacerbations. Finally, patients were considered to have very severe COPD when they were 
prescribed oxygen therapy or were scheduled for lung transplantation because of COPD.
All COPD patients were followed from cohort entry until the first COPD exacerbation re-
quiring hospitalization, death or end of follow-up, whichever came first.
Cases and controls
All COPD exacerbations were identified in the electronic medical records and adjudicated by 
two medical doctors, a third doctor arbitrated in case of discrepancies. For this study we only 
considered COPD exacerbations that resulted in hospitalization. The index date was the date 
of the first COPD exacerbation leading to hospitalization after study entry.
To each case, all available controls were matched from the COPD cohort on index date, 
gender and year of birth. Due to this sampling approach, controls could be re-sampled at 
different moments in time and their contribution should be considered in person-time (mo-
ments) rather than subjects (32). This also means that the number of controls per case varies 
and the proportions may be slightly different.
Exposure
Exposure was categorized by type of drug, timing, duration and dose. All information was 
obtained from the prescription records. The following types of bronchodilating and anti-
inflammatory drugs were considered as study drugs: tiotropium as long-acting anticholiner-
gic agent (LAAC), short-acting anticholinergic agents (SAAC), single-ingredient short-acting 
β2-agonists (SABA), single-ingredient long-acting β2-agonists (LABA, such as salmeterol and 
formoterol), inhaled corticosteroids (ICS), xanthines and fixed combination therapies (ICS 
and LABA). Drugs were grouped to look at class effects. The ACs as a class consisted of LAAC 
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and SAAC, and the class of β2-agonists comprised of SABA and LABA. ICS was either classified 
separately or adjusted for depending on the analysis (patients with fixed combinations of 
ICS and LABA counted in the respective bronchodilator class). Drug exposure was further 
categorized by timing of use in current use (last prescription covered the index date or ended 
less than 30 days prior to the index date), past use (last prescription ended more that 30 days 
prior to the index date), or no use. The primary analysis compared the effect on hospitalized 
COPD exacerbations between current use of tiotropium and LABA.
Covariates
As potential confounders we considered the severity of COPD as well as various co-morbid-
ities and concomitant drug use. For the primary analysis we used the COPD severity status 
one year prior to the index date, since severity could be an intermediate factor between the 
exposure and hospitalization for COPD exacerbation. In addition, we conducted a sensitivity 
analysis in which we adjusted for severity just prior to the index date.
Other covariates included were smoking history, use of concomitant medication (at least 
use in the month prior to the index date) and concomitant diseases such as heart failure, 
ischemic heart diseases, diabetes mellitus, lipid disorders, malignancies and diseases affect-
ing the central nervous system. Finally, resource use, by means of the number of GP office and 
home visits as well as a home bound life style (two or more home visits in the last month prior 
to the index date) were taken into account.
Analysis
The risk of hospitalization for a COPD exacerbation was calculated for the COPD cohort while 
stratifying by COPD severity using Kaplan-Meyer survival analysis. To study potential differ-
ences in co-morbidity between patients being prescribed LABA, tiotropium, or LABA and 
tiotropium together (same prescription dates), we compared patient characteristics between 
the three groups at the time of the first prescription of any of these drugs after cohort entry. 
Patients could only appear in tiotropium group and in LABA group if with different dates, 
or in the tiotropium plus LABA group when those were prescribed in the same date, not 
being possible to appear in the tiotropium alone or LABA alone a posteriori. Differences in 
co-morbidity and use of concomitant medication were tested using a non-parametric, Mann-
Whitney U test for continuous variables and the Chi-square test for categorical variables.
Conditional logistic regression analysis was used to estimate the matched unadjusted 
and adjusted risk estimates and 95% CI for the comparison between tiotropium and LABA. 
Patients currently using both tiotropium and LABA at the same time for more than 15 days 
were classified separately. In a sensitivity analysis we considered these combined users as 
either all tiotropium or LABA to look at the robustness of our estimates. All models were 
adjusted for at least COPD severity, duration of COPD, and smoking. In addition we adjusted 
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for all factors that were univariately associated with the outcome (p<0.10), and also changed 
the effect estimate of tiotropium by more than 5%.
Stratified analyses were conducted by gender, calendar year, severity of COPD (mild/
moderate versus severe/very severe) and, incident or prevalent COPD at study entry. We 
tested effect modification by adding an interaction term in the conditional logistic regression 
model (multiplicative interaction). Only if the interaction term based on the effect modifier 
of interest and current use of tiotropium turned out to be statistically significant (p<0.05) in 
the adjusted model, effect measure modification was considered to be present. All statisti-
cal analyses were conducted with the statistical software packages SPSS/PC 15.0 (SPSS Inc, 
Chicago, Ill).
Results
COPD Cohort
From the source population of 185,325 participants 40 years and older, 6,788 patients were 
diagnosed with COPD of which 23% were newly diagnosed during the study period (incident 
COPD). The median follow-up time per COPD patient was 3.5 years, with a total follow-up 
time of 23.930 person-years. Baseline characteristics of the COPD cohort (at time of cohort 
entry and at time of first prescriptins) are described in table 1. For 30% of COPD patients 
the severity was based on FEV1 according to GOLD (spirometry). In the remaining 70%, the 
Table 1 Patient characteristics at time of cohort entry and at time of first prescriptions for LABA or tiotropium or 
tiotropium plus LABA during FU
Time At cohort entry At start of first prescription during follow-up
Characteristics
COPD cohort 
No.(%)
Tiotropium 
No.(%)*†
LABA No.(%)*
Tiotropium plus 
LABA No.(%)*†1
Number of patients 6,788 1,048 3,214 153
Gender
 ♂ 3,889 (57.3) 639 (61.0) 1,829 (56.9) 84 (54.9)
 ♀ 2,899 (42.7) 409 (39.0) 1,385 (43.1) 69 (45.1)
Age (mean, SD) 67.3 (±12.2) 69.1 (±11.0) 67.6 (±11.9) 67.3 (±11.0)
 40-59 (No.,%) 1,797 (26.5) 225 (21.5) 863 (26.9) 39 (25.5)
 60-69 (No.,%) 1,739 (25.6) 278 (26.5) 828 (25.8) 43 (28.1)
 70+ (No.,%) 3,252 (47.9) 545 (52.0) 1,523 (47.3) 71 (46.4)
Smoking history
 No smoking 525 (7.7) 82 (7.8) 265 (8.2) 6 (3.9)
 Current smoking 2,737 (40.3) 520 (49.6) 1,413 (44.0) 66 (43.1)
 Past smoking 417 (6.1) 105 (10.0) 202 (6.3) 11 (7.2)
 Smoking unknown 3,101 (45.7) 340 (32.4) 1,334 (41.5) 70 (45.8)
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Table 1 (continued)
Time At cohort entry At start of first prescription during follow-up
Characteristics
COPD cohort 
No.(%)
Tiotropium 
No.(%)*†
LABA No.(%)*
Tiotropium plus 
LABA No.(%)*†1
Severity at cohort entry
 Mild 2,694 (39.7) 237 (22.6) 763 (23.8) 29 (19.0)
 Moderate 2,713 (40.0) 489 (46.7) 1,508 (46.9) 70 (45.8)
 Severe 1,280 (18.9) 301 (28.7) 874 (27.2) 50 (32.7)
 Very Severe 101 (1.5) 21 (2.0) 69 (2.1) 4 (2.5)
Mean time since first diagnosis 2.4 (±4.1) 2.1 (±1.7) 0.9 (±1.2) 1.1 (±1.5)
Co-morbidity (history) at cohort entry or at time of first prescription
Asthma 1,042 (15.4) 176 (16.8) 625 (19.4) 17 (11.1)
Myocardial infarction 457 (6.7) 80 (7.6) 231 (7.2) 13 (8.5)
Angina pectoris 994 (14.6) 166 (15.8) 518 (16.1) 26 (17.0)
Ischemic heart disease 188 (2.8) 46 (4.4) 98 (3.0) 5 (3.3)
History of stroke or TIA 391 (5.8) 69 (6.6) 193 (6.0) 7 (4.6)
Peripheral arterial disease 441 (6.5) 107 (10.2) 233 (7.2) 20 (13.1)
Heart failure 793 (11.7) 136 (13.0) 395 (12.3) 17 (11.1)
Ventricular arrhythmia 335 (6.3) 9 (0.9) 15 (0.5) 0
Hypertension 1,422 (21.0) 266 (25.4) 334 (10.4) 22 (14.4)
Hyperlipidemia 1,769 (26.1) 387 (36.9) 937 (29.2) 58 (37.9)
Diabetes mellitus 767 (11.3) 151 (14.4) 382 (11.9) 22 (14.4)
Renal insufficiency 184 (2.7) 37 (3.5) 85 (2.6) 4 (2.6)
Tumors 673 (10.0) 147 (14.0) 389 (12.1) 22 (14.4)
Pneumonia 571 (8.4) 149 (14.2) 353 (11.0) 18 (11.8)
Depressive disorders 540 (8.0) 105 (10.0) 305 (9.5) 24 (15.7)
Number GP visits (mean, SD) 5.7 (±5.0) 6.2 (±4.8) 6.2 (±5.1) 5.9 (±5.2)
Home bound lifestyle 58 (1.1) 9 (0.9) 7 (0.2) 1 (0.7)
Previous use of drugs
 Ipratropium 1,393 (20.5) 438 (41.8) 1,117 (34.8) 39 (25.5)
 SABA 1,427 (21.0) 394 (37.6) 1,190 (37.0) 49 (32.0)
 ICS 1,919 (28.3) 543 (51.8) 2,290 (71.3) 114 (74.5)
 Xanthines 182 (2.7) 48 (4.6) 127 (4.0) 5 (3.3)
 Oral steroids 579 (8.5) 561 (44.0) 990 (30.8) 52 (34.0)
The values in bold were statistic significant in Chi-square test comparing tiotropium, or TIO+LABA against LABA.
*First prescription of tiotropium in tiotropium group or LABA in LABA group. †LABA is the reference category. †1 
First prescription of tiotropium and LABA at the same date. Patients can only appear in TIO and in LABA group if 
with different dates, but not in the TIO+LABA group and then TIO alone or LABA alone (this category corresponds 
to the first prescription of both drugs at the same date). Abbreviations: ICS (inhaled corticosteroids), GP (general 
practitioner), LABA (long-acting β2-agonists), SABA (short-acting β2-agonists), TIA (transient ischemic attack), SD 
(standard deviation).
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severity of COPD was determined using a proxy as previously described [76-78]. Up to 80% of 
patients had mild or moderate COPD at cohort entry.
Since COPD has lately been recognized as a systemic disease, we thoroughly characterized 
extra-pulmonary co-morbidities in the COPD cohort. The most frequent co-morbidities were 
angina pectoris, hypertension, heart failure, hyperlipidemia, diabetes mellitus and tumors 
(table 1).
Table 1 also describes the characteristics of cohort members starting with LABA, tiotropium 
or tiotropium & LABA (same prescription dates), during follow-up. Almost half of the COPD 
patients had moderate COPD at the time of first prescription of any of these drugs (table 1). 
In general, patients receiving tiotropium were slightly older and had more co-morbidities 
than patients starting on LABA. Age, smoking history, and some comorbidities differed sig-
nificantly between persons starting on LABA or tiotropium (table 1). The small group (n=153) 
of patients receiving both tiotropium and LABA as first prescription during follow-up tended 
to have more severe COPD compared to the LABA and tiotropium users.
Hospitalization due to COPD exacerbations
Within the cohort, 619 patients were hospitalized for a COPD exacerbation of which 351 
(56.7%) were male (table 2). The mean age of the cases was 72.2 (SD=±10.2) years. COPD 
severity (severe/very severe) was strongly related to hospitalization for COPD. The one-year 
risk of at least one exacerbation requiring hospitalization was 2.2% (95%CI 1.8%-2.6%) for 
mild/moderate COPD patients and 9.7% (95%CI 8.2%-11.8%) for severe/very severe COPD 
patients (figure 1).
Table 2 Characteristics of cases and controls and crude OR for a COPD exacerbation leading to hospitalization
Characteristics
Cases
N=619 (%)
Control moments 
N=24,820 (%)
Matched OR*
(95% CI)
Age (mean, SD) 72 (10.2) 72.7 (7.9)
 Male 351 (56.7) 17,055 (68.7)
Smoking
 Never 43 (6.9) 2,510 (10.1) Reference
 Current 260 (42.0) 9,361 (37.7) 1.59 (1.14-2.21)
 Past 27 (4.4) 1,896 (7.6) 0.89 (0.54-1.45)
 Missing 289 (46.7) 11,033 (44.5) 1.46 (1.05-2.03)
COPD severity
 Mild 67 (10.8) 5,648 (22.8) Reference
 Moderate 155 (25.0) 12,503 (50.4) 1.03 (0.77-1.34)
 Severe 344 (55.6) 6,305 (25.4) 4.75 (3.64-6.21)
 Very severe 53 (8.6) 358 (1.4) 12.2 (8.33-18.0)
Number of GP visits (mean, SD) 7.8 (6.3) 5.7 (4.7) 1.07 (1.06-1.08)
Home bound lifestyle 26 (4.2) 221 (0.9) 4.83 (3.15-7.4)
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Table 2 (continued)
Characteristics
Cases
N=619 (%)
Control moments 
N=24,820 (%)
Matched OR*
(95% CI)
Co-morbidity (history of events)
 Myocardial infarction 60 (9.7) 2,346 (9.5) 1.17 (0.89-1.54)
 Angina pectoris 134 (21.6) 4,444 (17.9) 1.33 (1.09-1.63)
 Other ischemic heart disease 24 (3.9) 1,044 (4.2) 1.01 (0.67-1.54)
 Peripheral arterial disease 71 (11.5) 2,175 (8.8) 1.36 (1.05-1.75)
 Stroke 52 (8.4) 2,140 (8.6) 0.98 (0.73-1.32)
 Arrhythmia (atrial fibrillation, other) 57 (9.2) 2,559 (10.3) 0.88 (0.67-1.17)
 Hypertension 145 (23.4) 6,319 (25.5) 0.88 (0.73-1.06)
 Heart failure 181 (29.2) 3,759 (15.1) 2.56 (2.11-3.09)
 Hyperlipidemia 174 (28.1) 8,584 (34.6) 0.78 (0.65-0.94)
 Diabetes mellitus (type I, type II) 103 (16.6) 3,595 (14.5) 1.22 (0.98-1.51)
 Renal disease 34 (5.5) 1,029 (4.1) 1.46 (1.02-2.10)
 Pneumonia 152 (24.6) 3,053 (12.3) 2.29 (1.89-2.77)
 Depressive disorders 71 (11.5) 2,004 (8.1) 1.31 (1.02-1.69)
 Tumors (non-cerebral) 109 (17.6) 3,633 (14.6) 1.27 (1.03-1.58)
Concomitant medication (current versus non use)
Central nervous system drugs
 Hypnotics and sedatives 96 (15.5) 2,524 (10.2) 1.54 (1.23-1.94)
 Anxiolytics 83 (13.4) 2,206 (8.9) 1.49 (1.18-1.90)
 Antidepressants (SSRI) 31 (5.0) 755 (3.0) 1.51 (1.04-2.19)
Anticholinergic drugs (except respiratory) 19 (3.1) 608 (2.4) 1.25 (0.78-1.99)
Drugs affecting cerebrovascular and cardiovascular disease
 Nitrates 52 (8.4) 1,481 (6.0) 1.43 (1.06-1.92)
 Platelet inhibitors 118 (19.1) 4,749 (19.1) 1.08 (0.88-1.33)
 Anti-hypertensives 275 (44.4) 10,158 (40.9) 1.20 (1.00-1.40)
 Corticosteroids (systemic) 207 (33.4) 2,044 (8.2) 5.93 (4.97-7.09)
 Antibiotics 147 (23.7) 2,030 (8.2) 3.50 (2.89-4.25)
 NSAIDs 35 (5.7) 1,834 (7.4) 0.73 (0.52-1.03)
 Vitamin K antagonists 56 (9.0) 2,013 (8.1) 1.20 (0.90-1.59)
 Lipid lowering drugs 60 (9.7) 2,862 (11.5) 0.87 (0.66-1.15)
Other respiratory drugs
 Mucolytics 105 (17.0) 1,454 (5.9) 3.52 (2.82-4.39)
 Short-acting anticholinergics 245 (39.6) 6,389 (25.7) 2.87 (2.32-3.55)
 Short-acting β2 agonists 257 (41.5) 5,106 (20.6) 4.55 (3.49-5.92)
 Inhaled corticosteroids 273 (44.1) 8,699 (35.0) 2.18 (1.73-2.74)
 Xanthines 44 (7.1) 635 (2.6) 3.60 (2.61-4.97)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA= not applicable as fewer 
than 5 exposed subjects). Proportions seem to be different because we do not always have the same number of 
controls per each case. *Matched on age, gender and index date.
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Underlying co-morbidities that significantly increased the risk of hospitalization were 
angina pectoris, peripheral arterial disease, heart failure, renal insufficiency, pneumonia, 
depression and cancer. Current smoking and use of concomitant medication (as proxy 
for underlying co-morbidities) such as opioids, hypnotics & sedatives, anxiolytics, and an-
tidepressants were also related to the outcome (table 2). Current use of oral steroids and 
antibiotics was strongly associated with an increased risk of hospitalisation due to COPD 
exacerbation but this is explained by protopathic bias where these drugs are initiated for the 
first symptoms of the COPD exacerbation.
Comparative effectiveness of tiotropium versus LABA
In this primary care-based study, we observed a non-statistically significant reduced risk of 
COPD exacerbations leading to hospitalization for tiotropium as compared to LABA (ORadj 
0.69; 95%CI 0.40-1.19). In patients who used both tiotropium and LABA concomitantly, the 
probability of exacerbations was increased (ORadj 1.27, 95%CI 0.78-2.07) as compared to LABA 
alone. Assignment of the combined users group to either tiotropium or LABA (reference) 
showed that the estimate for tiotropium remained below 1 with either choice. Within the 
LABA group, the risk of exacerbations requiring hospitalizations did not differ between 
formoterol and salmeterol (ORadj 1.07; 95%CI 0.79-1.45). Restricting the analysis to patients 
who used their long-acting bronchodilator for at least 30 days at the index date (to avoid 
protopathic bias) did not change the effect materially (ORadj 0.76; 95%CI 0.44-1.33) (table 3).
Figure 1 Risk of hospitalization for COPD exacerbation over time (years)
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Stratified analysis were conducted to inspect effect modification, however no major 
heterogeneity in effect estimates of tiotropium against LABA was seen across gender, cal-
endar time, and smoking (figure 2). A slightly stronger effect was observed in severe and 
very severe COPD patients with an ORadj 0.62 (95%CI 0.28-1.34) when compared to mild and 
moderate COPD patients with an ORadj 0.74 (95%CI 0.33-1.68). Sensitivity analyses addressing 
some assumptions and biases also showed no major impact on the effect estimates. When 
stratifying for patients visiting pulmonologist yes or no, no major differences in risk estimates 
could be observed. In patients with severity assessment by spirometry the protective effect 
for tiotropium was stronger than in patients for whom COPD severity was assessed by proxy 
ORadj 0.57 (95%CI 0.20-1.66), versus ORadj of 0.82 (95%CI 0.42-1.59).
In patients without a history of asthma, the protective effect seemed to be stronger (ORadj 
0.57, 95% CI 0.30-1.00) compared to patients with a history of asthma (ORadj 0.89; 95% CI 
0.22-3.71).
Table 3 Association between use of tiotropium (LABA as reference category) and hospitalizations for COPD 
exacerbations
Drugs class
Cases
N=619
(%)
Control
moments
N=24,820 (%)
Matched OR
(95%CI)*
Adjusted OR
(95%CI)
Model 1
Adjusted OR
(95%CI)
Model 2
Current use of LABA or tiotropium alone or in combination
Main drug effect
 LABA no tiotropium 196 (31.7) 5,582 (22.5) Reference Reference1 Reference1
 Tiotropium no LABA 18 (2.9) 756 (3.0) 0.60 (0.36-1.00) 0.69 (0.40-1.19) 0.69 (0.40-1.19)
 Tiotropium + LABA† 22 (3.6) 445 (1.8) 1.42 (0.89-2.26) 1.21 (0.74-1.98) 1.27 (0.78-2.07)
Duration of use
 LABA <30 days 10 (1.6) 205 (0.8) Reference Reference Reference
 Tiotropium <30 days 1 (0.2) 86 (0.3) NA NA NA
 LABA ≥30 days 186 (30.0) 5,377 (21.7) Reference Reference Reference
 Tiotropium ≥30 days 17 (2.7) 670 (2.7) 0.65 (0.38-1.10) 0.77 (0.44-1.34) 0.76 (0.44-1.33)
Type of LABA
 Salmeterol 111 (17.9) 3,379 (13.6) Reference Reference Reference
 Formoterol 85 (13.7) 2,203 (8.9) 1.21 (0.90-1.61) 1.05 (0.77-1.42) 1.07 (0.79-1.45)
Reference category is “LABA” (NA= not applicable as fewer than 5 exposed subjects). Tiotropium HandiHaler® use.
* Matched on age, gender and index date
Model 1: adjusted for severity of COPD at index date, duration of COPD and smoking
Model 2: adjusted for severity of COPD one year prior to the index date, duration of COPD and smoking (final 
model in the analysis)
1: Additionally adjusted for number systemic corticosteroids, mucolytics and ICS, SABA, and xanthines.
† Use of both drugs started at least 2 weeks prior to index date
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Discussion
This COPD cohort study showed several important findings. First, tiotropium reduced the risk 
of COPD exacerbations leading to hospitalizations in COPD patients in real life as compared 
to LABA, although this was not statistically significant. This effect was not modified by sex 
and was strongest in patients whose COPD severity could be assessed by spirometry and in 
patients without a medical history of asthma. Second, the effect of formoterol and salmeterol 
on COPD exacerbations leading to hospitalization did not differ. To our knowledge, our data 
are one of the first to compare the effectiveness of tiotropium and LABA (salmeterol and 
formoterol) in clinical practice, by means of an observational study.
Third, we demonstrated that several underlying co-morbidities such as angina pectoris, 
peripheral arterial disease, heart failure, renal insufficiency, pneumonia, depressive disorders 
and cancer are risk factors for a COPD exacerbation leading to hospital admission.
The efficacy of tiotropium and LABA on the reduction of COPD exacerbations leading to 
hospitalization has mainly been studied in placebo controlled RCTs. In summary, these RCTs 
Figure 2 Stratified analyses on association between tiotropium use and the association with hospitalizations due 
to COPD exacerbation
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have shown that both LABA and tiotropium were efficacious in reducing the risk of hospital-
ization related to COPD in comparison to placebo with risk estimates around 0.70, both for 
tiotropium and LABA [62, 68, 70, 71, 107].
Some RCTs have compared the effect of tiotropium and LABA on the risk of surrogate 
endpoints and hospitalization for COPD exacerbations. Rodrigo et al [71] conducted a sys-
Table 4 Stratified analyses by COPD severity on association between respiratory drug use and hospitalizations 
due to COPD exacerbation
Drugs class
Mild & Moderate COPD
Cases
N=222
(%)
Control 
moments
N=18,157 (%)
Matched OR 
(95%CI)*
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI) 
Model 2
Current use of LABA or tiotropium alone or in combination
Main drug effect
 LABA no tiotropium 60 (27.0) 3,615 (19.9) Reference Reference1 Reference1
 Tiotropium no LABA 8 (3.6) 542 (3.0) 0.84 (0.39-1.81) 0.75 (0.33-1.71) 0.75 (0.33-1.70)
 Tiotropium + LABA† 8 (3.6) 275 (1.5) 1.85 (0.84-4.08) 2.22 (0.96-5.15) 2.20 (0.95-5.10)
Duration of use
 LABA ≥30 days 55 (24.8) 3,463 (19.1) Reference Reference Reference
 Tiotropium ≥30 days 7 (3.2) 476 (2.6) 0.83 (0.37-1.89) 0.75 (0.31-1.78) 0.73 (0.31-1.74)
Type of LABA
 Salmeterol 111 (17.9) 2,320 (12.8) Reference Reference Reference
 Formoterol 85 (13.7) 1,295 (7.1) 1.10 (0.64-1.88) 1.10 (0.62-1.94) 1.11 (0.63-1.96)
Drugs class
Severe & Very severe COPD
Cases
N=397 (%)
Control 
moments
N=6,663 (%)
Matched OR 
(95%CI)*
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI) 
Model 2
Current use of LABA or tiotropium alone or in combination
Main drug effect
 LABA no tiotropium 136 (34.3) 1,967 (29.5) Reference Reference1 Reference1
 Tiotropium no LABA 10 (2.5) 214 (3.2) 0.56 (0.27-1.16) 0.63 (0.29-1.37) 0.61 (0.28-1.32)
 Tiotropium + LABA† 14 (3.5) 170 (2.6) 1.31 (0.70-2.46) 1.08 (0.56-2.07) 1.07 (0.56-2.05)
Duration of use
 LABA ≥30 days 131 (33.0) 1,914 (28.7) Reference Reference Reference
 Tiotropium ≥30 days 10 (2.5) 194 (2.9) 0.61 (0.30-1.27) 0.72 (0.33-1.57) 0.69 (0.32-1.52)
Type of LABA
 Salmeterol 73 (18.4) 1,059 (15.9) Reference Reference Reference
 Formoterol 63 (15.9) 908 (13.6) 0.97 (0.67-1.40) 0.92 (0.63-1.35) 0.93 (0.64-1.37)
Reference category is “LABA” (NA= not applicable as fewer than 5 exposed subjects). Tiotropium HandiHaler® use.
* Matched on age, gender and index date
Model 1: adjusted for severity of COPD at index date, duration of COPD and smoking
Model 2: adjusted for severity of COPD one year prior to the index date, duration of COPD and smoking (final 
model in the analysis)
1: Additionally adjusted for number systemic corticosteroids, mucolytics and ICS, SABA, and xanthines.
† Use of both drugs started at least 2 weeks prior to index date
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tematic review with meta-analysis of 27 RCTs (with more than one month in duration), using 
data of 20,527 patients with COPD, GOLD II or III. They concluded that compared with LABA, 
tiotropium resulted in a decrease of severe COPD exacerbations (RR 0.52; 95% CI 0.31-0.86) 
[71]. In their meta-analysis of nine RCTs and 8,002 patients included, Barr et al [62] found 
similar reductions in hospitalizations for COPD exacerbations when comparing tiotropium 
with ipratropium or salmeterol, but neither of these differences was statistically significant. 
Briggs et al [73] and Brusasco et al [72] also reported a reduced risk of hospitalisation for 
COPD exacerbation in patients treated with tiotropium compared to salmeterol. In their 
12-week RCT of 653 COPD patients, when comparing tiotropium with salmeterol, Briggs et 
al [73] reported an OR 0.43 (95%CI, 0.13-1.42), and Brusasco et al [72] an OR 0.59 (95%CI, 
0.29-1.23), in their RCT of 1,207 patients with COPD; however, these short-term studies were 
possibly underpowered to discern significant differences in COPD related hospitalizations. In 
their network meta-analysis of exacerbations, Baker et al report for tiotropium versus LABA 
an OR 0.82 (95%CI 0.72-0.93) for the mixed-treatment comparison meta-analysis of 43 RCTs 
using and a total of 31,020 patients [108]. To resume, most of the published studies report a 
better performance of tiotropium when compared to LABA with regard to the prevention of 
COPD exacerbations.
Although we have data from RCTs on the efficacy of tiotropium, compared to LABA, on the 
risk reduction of severe COPD exacerbation, data from RCTs cannot always be extrapolated to 
the general population as RCTs use stringent inclusion and exclusion criteria, and severity dif-
fered, as in some of the RCTs, patients had to have moderate-to-severe COPD to be included 
in the study. For this reason, it is important to study the effectiveness of tiotropium on the risk 
of COPD exacerbation requiring hospitalization under real life circumstances.
As for all observational studies, our study has strengths, but also limitations. The main 
strengths are the size and quality of our data. Great emphasis was put on the assessment 
of the disease severity and endpoints that were all manually validated by at least 2 medi-
cally trained persons. The external validity of our data can be deducted by the fact that our 
risk estimates and incidence rates are in line with published data. Being observational, the 
study is sensitive to bias and confounding. We tried to limit misclassification of the outcome 
by manually reviewing the electronic medical records of all cases by two medically trained 
researchers who were blinded to drug exposure. Only the definite cases of exacerbations 
requiring hospitalization were included in our analysis.
Misclassification of exposure might be an issue in our study as exposure was assessed 
based on the prescription data, rather than dispensing data or actual patient intake, and 
could thus underestimate or overestimate patient exposure. In addition, in a chronic disease 
such as COPD, prescriptions initiated by the specialist may have been missed. To study the 
potential of exposure bias, a sensitivity analysis was conducted by stratifying on patients 
not seen by a pulmonologist and patients who consulted a pulmonologist. For the group of 
patients not seen by a pulmonologist, by definition, all prescriptions for respiratory drugs are 
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available in the database. The results for this group of patients were similar to the results of 
the overall dataset suggesting that bias due to misclassification of exposure is minimal.
To limit confounding by indication, we decided to use current use of LABA as reference 
category assuming that patients being treated with LABA are more similar to patients be-
ing treated with tiotropium regarding COPD severity and underlying co-morbidity. Baseline 
characteristics of tiotropium and LABA users at the time of first prescription showed indeed 
that COPD severity was very similar in tiotropium and LABA users whereas the underlying 
comorbidity was higher in the tiotropium-exposed group compared to the LABA exposed 
group, implying that our effect estimate for tiotropium versus LABA is a conservative es-
timate and that the actual risk might in reality be lower. Significant efforts were put into 
adjusting for COPD severity, by assessing COPD severity longitudinally, which allowed for 
flexibility in the timing for adjustment, which is an improvement over regular practice in 
pharmacoepidemiological studies in the area of COPD. However, we were aware that spirom-
etry was only available for 30% of subjects meaning that residual confounding by severity 
cannot be excluded. When stratifying by spirometry versus proxy, the trend remained, which 
indicates that the proxy measure used was quite accurate. Residual confounding by severity 
may explain why the risk of exacerbations was higher in patients using both tiotropium and 
LABA together as compared to LABA alone. Furthermore, protopathic bias may play a role 
but was dealt with in the study. One could well hypothesize that general practitioners initi-
ate the use of inhaled bronchodilators as treatment for the first worsening of symptoms of 
these endpoints. Conducting a sensitivity analysis only including those patients who used 
the drugs for more than 30 days controlled for this bias.
Finally, we demonstrated that the reduced risk of COPD exacerbation was mainly observed 
in COPD patients without a medical history of asthma compared to patients with a medical 
history of asthma. This finding is important as tiotropium; is currently under investigation as 
add-on treatment in adults with persistent asthma [109].
In conclusion, in a nested case-control study in a primary care based COPD cohort, we 
demonstrated a statistically non-significant trend towards a reduced risk for COPD hospital-
izations with tiotropium compared to LABA.
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4.1
Use of tiotropium Respimat® Soft Mist 
Inhaler vs. tiotropium HandiHaler® 
and mortality in patients with COPD
Abstract
Background: Tiotropium is a long-acting once daily-inhaled anticholinergic that can be 
delivered via HandiHaler®, a dry powder inhaler or via Respimat® Soft Mist Inhaler (SMI), a 
novel, propellant-free inhaler which has been developed and proposed as an alternative 
delivery device. Data from RCTs suggest that use of tiotropium Respimat® is associated with 
an increased risk of mortality.
Objectives: To explore the risk of mortality in a cohort of users of tiotropium administered 
via Respimat® SMI versus HandiHaler®.
Methods: Within the Dutch primary care IPCI database, we first defined a source population 
of patients being 40 years or older with at least 1 year of follow-up. The study period ran from 
2000 to 2010. All patients were followed from start of study until the patient died or end 
of follow-up. From this source population, we defined a cohort of tiotropium users, either 
being prescribed Respimat® SMI or HandiHaler®. Based on tiotropium prescription data, we 
defined episodes of tiotropium use (Respimat® SMI or HandiHaler®) taking gaps and overlap 
of prescriptions into account. The risk of mortality, within these episodes of drug use, was 
calculated using a Cox proportional hazard regression analysis. Crude and adjusted hazard 
ratios (HR) were calculated with corresponding 95% confidence intervals (CI).
Results: Within the total source population of 501,474 patients we defined a tiotropium 
cohort of 11,753 users, 272 patients died while being exposed to either tiotropium Handi-
Haler® or tiotropium Respimat® SMI. Use of tiotropium Respimat® SMI, compared to use of 
tiotropium HandiHaler®, was associated with a 50% increased risk of dying (crude HR 1.51, 
95% CI 1.09 - 2.09), but this effect attenuated upon adjustment for baseline differences (HRadj 
1.21, 95% CI 0.85 – 1.73). No dose response relationship could be observed. No association 
with cardiovascular and cerebrovascular death could be observed.
Conclusions: Use of tiotropium Respimat® SMI versus tiotropium HandiHaler®, is not associated 
with an statistically increased risk of dying. We can exclude an excess risk of more than 73%.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and 
it is known that the rate of COPD-related death is increasing [110]. COPD is characterized by 
a progressive decline in lung function, which cannot be reversed by treatment. In 2004, the 
Food and drug administration (FDA) approved the use of tiotropium in the USA, delivered by 
the HandiHaler® device, a single-dose dry powder inhaler (DPI) [111], and the first long-acting 
anticholinergic bronchodilator for the treatment of COPD [112], but in the Netherlands it was 
marketed in 2002. Tiotropium exerts his action via a prolonged (24-hour) blockade of the 
muscarinic M3-receptors [113].
Tiotropium HandiHaler® (Spiriva®) is known to be a potent long-acting bronchodilator whose 
clinical benefits have been established in several clinical studies [62, 66-68]. The lung function 
improvements and the safety associated with tiotropium HandiHaler® have been well established 
in clinical trials of COPD patients [64, 67, 69, 72, 114, 115], including the UPLIFT (Understanding 
Potential Long term Impacts on Function with Tiotropium) study which is the largest long term 
RCT studying the efficacy and safety of tiotropium HandiHaler® conducted so far.
A new generation, propellant-free inhaler, known as the Respimat® Soft Mist Inhaler (SMI), 
has been developed and proposed as an alternative device for use with tiotropium [116]. 
Based on its lower velocity, Respimat® SMI improves lung drug deposition, reduces oropha-
ryngeal deposition, and may require a lower dose of drug than normally used with either 
DPIs of MDIs [113, 117].
In 2008, concerns were raised on the cardiovascular and cerebrovascular safety of tiotro-
pium. These concerns were based on 1) a report to the FDA, issued by Boehringer Ingelheim, 
the manufacturer of tiotropium, on pooled data from 29 placebo-controlled trials showing 
an increased risk of stroke in patients treated with tiotropium, and 2) a meta-analysis and 
case-control study reporting an increased risk for mortality and/or cardiovascular events in 
patients who received inhaled anticholinergics (ipratropium or tiotropium). [112, 118, 119] 
In their initial report to the FDA, Boehringer Ingelheim also reported an increased risk of 
mortality with tiotropium Respimat® SMI device (not yet approved in the US) based on data 
from 3 one-year placebo controlled trials. In January 2010, the FDA warning on the use of 
tiotropium HandiHaler® was overruled, based on data from the UPLIFT study and updated 
meta-analysis (including data from the UPLIFT study), stating that the available data did no 
longer support an association between the use of tiotropium HandiHaler® and an increased 
risk of stroke, heart attack or death from cardiovascular causes [120].
As the UPLIFT study only included a treatment regimen of tiotropium HandiHaler® versus 
placebo, evidence about the risk of mortality in patients treated with tiotropium Respimat® 
SMI is still limited. We therefore conducted a cohort study to compare the risk of mortality in 
patients treated with tiotropium Respimat® SMI using treatment with tiotropium HandiHaler® 
as reference category.
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Methods
Setting
The study was conducted in the Integrated Primary Care Information Project (IPCI) database. 
IPCI is a population-based longitudinal observational database that contains the complete 
computer-based medical records of more than 400 General Practitioners (GPs) throughout 
the Netherlands, who voluntarily chose to supply data to the database [86]. In the Dutch 
health care system, patients are registered with a single GP who acts as a gatekeeper of 
medical care and information from primary care visits, hospital admission and outpatient 
visits. At present, the ICPI database contains information on more than one million active 
patients. The IPCI database contains anonymized patient identification information (age, 
sex, patient identification number, and GP registration information), narratives, symptoms, 
signs, GP and specialist diagnoses, prescriptions, physical findings, laboratory values and 
summaries of specialist letters. The International Classification of Primary Care (ICPC) is the 
coding system for patient complaints and diagnoses, but they can also be entered as free 
text [88]. Therefore, the medical records do not only capture GP diagnosis and symptoms, 
but also the results and summaries of specialist care. Prescription data encompass product 
name, quantity dispensed, dosage regimens, formulation, strength and indication. The Na-
tional Database of drugs, maintained by the Royal Dutch Association for the Advancement 
of Pharmacy, enables the coding of prescriptions, according to the Anatomical Therapeutic 
Chemical (ATC) classification scheme recommended by the WHO [90]. This system complies 
with European Union guidelines on the secondary use of health care data for medical re-
search and has been proven valid for pharmaco-epidemiological research [91]. Guidelines on 
good pharmaco-epidemiological research are rigorously followed by all researchers working 
on the IPCI database [92].
Source population
The source population consisted of all patients registered in the IPCI database, 40 years or 
older and with at least one-year of valid database. This meant that the practice had been 
contributing data to the IPCI database for at least one year and that the patient had been 
registered with the GP for at least one year. This one-year pre-enrollment period was required 
to characterize the patients in terms of co-existing comorbidity. The study period lasted from 
01.01.2000 up to 30.09.2010.
Tiotropium cohort
All patients who received a prescription for tiotropium (either Respimat® SMI or HandiHaler®), 
during follow-up (split in an inception and prevalent user group), were included in the tiotro-
pium cohort. Cohort entry was the date of first prescription (inception cohort) or start of 
follow-up for prevalent users.
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From the tiotropium prescriptions, episodes of use were delineated taking into account 
potential overlap and gaps. If the subsequent prescription overlapped the previous prescrip-
tion, with more than 20%, the two prescriptions were combined into one episode and the 
stop date of that episode was the date of the second prescription. In case the prescriptions 
overlapped for less than 20%, the prescriptions were combined into one episode and the stop 
date of the episode was the stop date of the second prescription extended by the number 
of days of overlap. In case of a gap between two prescriptions, these prescriptions were only 
combined into one episode if the duration of the gap was less than 20% of the duration of 
the first prescription. Subsequent prescriptions were only combined into 1 episode of use in 
case of equal formulation (either Respimat® SMI or HandiHaler®). A patient was considered as 
being a switcher when switching from Respimat® SMI to HandiHaler® or vice-versa.
COPD covariate
For reasons of power, we considered all prescriptions of tiotropium, irrespective of indication 
of use. Co-existing COPD was considered as a separate variable in the analysis. A patient was 
classified as having COPD based on 1) either the presence of ICPC specific codes for COPD 
namely ICPC R95 (chronic obstructive pulmonary disease) or ICPC R91 (chronic bronchitis), or 
2) free text searching including “COPD” OR “chronic bronchitis” OR “emphysema”.
COPD severity was assessed at the start date of each treatment episode, and was based 
on the number of prescriptions of systemic corticosteroids or the number of antibiotics for 
the treatment of lower respiratory tract infections, all measured in the one year prior to the 
episode start. In addition, we took previous hospitalizations for COPD exacerbations and the 
number of GP visits in the one-year prior to treatment episode start into account.
Follow-up
Subjects were followed from episode start of tiotropium use (either Respimat® SMI or Handi-
Haler®) until the stop date of the episode of use, the end of follow-up or death whichever 
occurred first.
Death
All deaths occurring in the tiotropium cohort were identified by a broad search in the data-
base on ICPC code “A96” (death) and death as reason for end of follow-up in the IPCI database. 
The cause of death was classified into respiratory death, cardio and cerebrovascular death, 
death related to lung cancer, death related to cancer (excluding lung cancer), other causes 
or cause unknown. This classification allowed us to conduct subanalysis by cause of death.
Covariates
As covariates we considered smoking history, underlying comorbidities (asthma, angina 
pectoris, ischemic heart disease, peripheral arterial disease, myocardial infarction, stroke or 
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transient ischemic attack (TIA), heart failure, ventricular arrhythmia, hypertension, dyslipid-
emia, cancer, pneumonia, parkinsonism, depression, dementia, diabetes, and renal failure) 
and use of concomitant medications, all assessed at the start date of the episode of tiotro-
pium use. Concomitant drug use included central nervous system drugs, drugs affecting the 
cerebrovascular and cardiovascular system, and drugs affecting the respiratory system.
Statistical analysis
To compare the baseline characteristics of the patients using tiotropium Respimat® SMI or 
tiotropium HandiHaler®, at time of start of treatment episode, the Mann-Whitney U test was 
applied for continuous variables, and the Chi-square test for categorical variables.
Cox proportional hazards regression analyses were conducted to calculate crude (unad-
justed) and adjusted hazard ratios (HR) and their 95% CI of all cause death associated with 
the use of tiotropium Respimat® SMI versus HandiHaler®. The final model was built upon 
adjustment for smoking, COPD severity (by proxy), previous use of tiotropium and adjusting 
on all factors that changed the crude HR with more than 5%.
Subanalyses were done on cause of death, and diagnosis of COPD. Sensitivity analysis 
were done excluding episodes of switching. All statistical analyses were conducted with the 
statistical software packages SPSS/PC 15.0 (SPSS Inc, Chicago, III).
Results
Cohort of tiotropium users
Within the total source population of 501,474 patients we identified 11,753 tiotropium users, 
having a total of 30,217 episodes of tiotropium use (either HandiHaler® or Respimat® SMI). The 
mean (SD) age of the patients at the start of the first tiotropium treatment episode was 67.9 
(11.7) years and 52.5% of patients were male. 5,337 out of the 11,753 patients (45.4%) were al-
ready prescribed a treatment with tiotropium (either HandiHaler® or Respimat® SMI) at cohort 
entry and thus could be considered as being prevalent users. The mean duration of tiotropium 
use was 114 days per treatment episode (SD 208 days). Baseline characteristics of patients at 
start of first prescription of either tiotropium HandiHaler® or tiotropium Respimat® SMI are de-
scribed in table 1. COPD severity (measured by proxy) and cardiovascular co-morbidity (angina 
pectoris, peripheral artery disease, myocardial infarction, stroke or transient ischemic attack 
(TIA), heart failure, ventricular arrhythmia, hypertension, dyslipidemia), cancer and pneumo-
nia (in the one year prior to episode start), differed significantly between users of tiotropium 
HandiHaler® or tiotropium Respimat® SMI (table 1). The use of concomitant medication such 
as opioids, anticholinergic drugs, nitrates, systemic corticosteroids, antibiotics, lipid lowering 
drugs, antiplatelets, diuretics, calcium channel blockers (CCB), anti-arrhythmic drugs, leukotri-
ene receptor antagonists (LTRA), short-acting anticholinergics (SAAC), short-acting β-agonists 
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(SABA), long-acting β-agonists (LABA), also differed significantly between persons prescribed 
tiotropium HandiHaler® versus patients being prescribed tiotropium Respimat® SMI (table 1).
All cause mortality
During a total tiotropium exposure of 9,433 treatment years, 272 patients died. The incidence 
rate of dying was 42.6 per 1,000 person-years (PY) during tiotropium Respimat® SMI exposure 
and 27.1 per 1,000PY during tiotropium HandiHaler® exposure.
Table 2 describes the crude and adjusted hazard ratio of risk of dying in patients receiv-
ing tiotropium Respimat® SMI versus tiotropium HandiHaler®. From the 272 patients who 
died, 227 (83.4%) were receiving tiotropium HandiHaler® while 45 were receiving tiotropium 
Respimat® SMI (16.5%). In the crude analysis, use of tiotropium Respimat®, compared to use 
Table 1 Patient characteristics at start of first treatment episode during FU
Characteristics
Tiotropium Handihaler 
Nº.(%)
Tiotropium Respimat* 
Nº.(%)
Number of patients 10,290 2,064
Age (mean, SD) 67.9 (11.6) 68.0 (11.7)
Gender
 ♂ 5,391 (52.4) 1,088 (52.7)
 ♀ 4,899 (47.6) 976 (47.3)
Smoking history 7,133 (69.3) 1,487 (72)
COPD 9,062 (88.1) 1,829 (88.6)
COPD severity
 Number of antibiotics in 1 year prior (mean, SD) 1.5 (0.9) 1.5 (0.7)
 Number of systemic corticosteroids in 1 year prior (mean, SD) 2.2 (2.0) 2.8 (2.7)
 Number of GP visits in the 1 year prior (mean, SD) 7.5 (6.7) 9.8 (7.8)
 Hospitalization for COPD exacerbation in 1 year prior 169 (1.6) 83 (4.0)
Co-morbidity (medical history of any of the conditions)
Asthma 3,063 (29.8) 639 (31.0)
Angina pectoris 1,269 (12.3) 282 (13.7)
Ischemic heart disease 713 (6.9) 155 (7.5)
Peripheral arterial disease 1,230 (12.0) 300 (14.5)
Myocardial infarction 654 (6.4) 180 (8.7)
Stroke or TIA 779 (7.6) 204 (9.9)
Heart failure 1,001 (9.7) 258 (12.5)
Ventricular arrhythmia 887 (8.6) 205 (9.9)
Hypertension 3,803 (37.0) 849 (41.1)
Dyslipidemia (lipid disorders) 1,572 (15.3) 382 (18.5)
Cancer 1,420 (13.8) 370 (17.9)
Pneumonia (1 year before) 563 (5.5) 171 (8.3)
Parkinsonism 80 (0.8) 20 (1.0)
Ana BW 4.indd   60 03-03-11   12:30
61
Chapter 4.1: Use of tiotropium Respimat® Soft Mist Inhaler vs. tiotropium HandiHaler® and mortality in patients with COPD
Table 1 (continued)
Characteristics
Tiotropium Handihaler 
Nº.(%)
Tiotropium Respimat* 
Nº.(%)
Depression 1,324 (12.9) 266 (12.9)
Dementia 146 (1.4) 27 (1.3)
Diabetes mellitus 1,716 (16.7) 392 (19.0)
Renal failure 609 (5.9) 169 (8.2)
Use of concomitant medication at start of prescription
Central nervous system drugs
 Opioids 498 (4.8) 121 (5.9)
 Hypnotic and sedatives 1,032 (10.0) 218 (10.6)
 Anxiolytics 1,043 (10.1) 197 (9.5)
 Antidepressants (SSRI) 468 (4.5) 110 (5.3)
 Antipsychotics 141 (1.4) 22 (1.1)
 Anti-Parkins drugs 61 (0.6) 18 (0.9)
 Anticholinergics 343 (3.3) 92 (4.5)
 Antihistaminics 512 (5.0) 107 (5.2)
Drugs affecting cerebrovascular and cardiovascular disease
 Nitrates 594 (5.8) 140 (6.8)
 Vitamin K antagonists 812 (7.9) 187 (9.1)
 Lipid lowering drugs 2,459 (23.9) 577 (28.0)
 Antiplatelets 2,204 (21.4) 535 (25.9)
 Diuretics 2,109 (20.5) 479 (23.2)
 β-blockers 2,080 (20.2) 462 (22.4)
 CCB 1,239 (12.0) 301 (14.6)
 ACE inhibitors 2,781 (27.0) 640 (31.0)
 Anti-arrhythmic drugs 164 (1.6) 34 (1.6)
Other drugs
 Corticosteroids 1,010 (9.8) 318 (15.4)
 Antibiotics 2,055 (20.0) 512 (24.8)
 NSAIDs 820 (8.0) 155 (7.5)
Respiratory drugs
 Mucolytics 491 (4.8) 155 (7.5)
 LTRA 178 (1.7) 59 (2.9)
 SAAC (Ipratropium) 699 (6.8) 224 (10.9)
 SABA 1,569 (15.2) 430 (20.8)
 LABA 3,129 (30.4) 679 (32.9)
 ICS 3,505 (34.1) 763 (37.0)
 Xanthines 119 (1.2) 28 (1.4)
The bold values are statistically significant different between tiotropium Respimat® SMI against tiotropium 
HandiHaler®.
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of tiotropium HandiHaler®, was associated with a 50% increased risk of dying (crude HR 1.51, 
95%CI 1.09-2.09) (table 2). This effect attenuated upon adjustment for age, gender, COPD 
severity, use of diuretics or mucolytics, previous episodes of tiotropium use, and calendar 
time (HRadj 1.21, 95%CI 0.85-1.73) (table 2). No dose response relationship could be observed: 
the risk of dying in users of tiotropium Respimat® SMI 2.5 µg daily was similar to the one of 
tiotropium Respimat® SMI 5 µg daily.
Subanalyses
Cause of death was cardiovascular or cerebrovascular in 66 patients (24.3%), respiratory 
in 43 patients (15.8%), cardiovascular and respiratory in 15 patients (5.5%), lung cancer in 
46 patients (16.9%), other cancers in 31 patients (11.4%), death due to other causes in 24 
patients (8.8%) and for 47 patients (17.3%), the cause of death could not be defined based on 
the information in the medical record.
The risk of cardio-and cerebrovascular death was not increased (HRadj 0.97, 95%CI 0.46-
2.04) (table 3). It should be noted however; that the power for cause of death analyses was 
due to low numbers. 
In the majority of users of tiotropium, (87.8%), the indication for tiotropium use was 
COPD. In patients with COPD, the adjusted risk of dying for patients treated with tiotropium 
Respimat® SMI was 1.22 (95%CI 0.84-1.77) whereas it was 0.88 (95%CI 0.24-3.27) in patients 
without COPD (table 4).
Table 2 Crude and adjusted Hazard Ratios (HRs) for all-cause mortality in users of tiotropium Respimat® versus 
users of tiotropium HandiHaler®
Tiotropium 
Respimat®
Tiotropium 
Respimat® 2.5 µg
Tiotropium 
Respimat® 5 µg
Variable HR (95% CI) HR (95% CI) HR (95% CI)
Unadjusted (crude) 1.51 (1.09 - 2.09) 2.14 (1.22 – 3.76) 1.35 (0.92 – 1.96)
Covariates included in the Cox model to calculate adjusted HRs
 Age 1.54 (1.11 - 2.13) 1.83 (1.04 – 3.22) 1.45 (0.99 – 2.10)
 + Gender 1.53 (1.10 - 2.12) 1.87 (1.07 – 3.28) 1.43 (0.98 – 2.08)
 + smoking 1.54 (1.11 - 2.12) 1.87 (1.06 – 3.28) 1.43 (0.98 – 2.08)
 + use of corticosteroids in 1 year prior to episode start 1.40 (1.01 – 1.94) 1.53 (0.87 – 2.71) 1.36 (0.93 – 1.97)
 + number of GP visits in 1 year prior to episode start 1.26 (0.91 – 1.75) 1.36 (0.76 – 2.40) 1.23 (0.84 – 1.79)
 + hospitalization for COPD in 1 year prior to episode start 1.22 (0.88 - 1.70) 1.32 (0.74 – 2.34) 1.18 (0.81 – 1.73)
 + use of Antibiotics for treatment of LRTI in 1 year prior to 
episode start
1.22 (0.87 - 1.70)
1.32 (0.74 – 2.34) 1.18 (0.81 – 1.73)
 + adjustment for use of mucolytics and diuretics* 1.15 (0.82 – 1.60) 1.18 (0.66 – 2.10) 1.13 (0.77 – 1.66)
 + number of previous episodes of tiotropium Respimat® and/or 
HandiHaler® use
1.15 (0.82 – 1.60)
1.18 (0.66 – 2.10) 1.13 (0.77 – 1.66)
 + calendar time (year of start date treatment episode) 1.21 (0.85 – 1.73) 1.23 (0.68 – 2.22) 1.20 (0.81 – 1.80)
* variables that changed the crude HR with more than 5%
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Sensitivity analyses
A sensitivity analysis was conducted excluding treatment episodes that consisted of switch-
ing of tiotropium formulation. Upon exclusion of these episodes, the risk of dying (HRadj 1.29, 
95%CI 0.90-1.86), related to the use of tiotropium Respimat® SMI did not differ substantially 
from the risk estimated for the complete dataset (HRadj 1.21, 95%CI 0.85-1.73).
Table 3 Crude and adjusted Hazard Ratios (HRs) for all-cause mortality in users of tiotropium Respimat® versus 
users of tiotropium HandiHaler®
Cardiovascular and cerebrovascular mortality (n= 66)
Variable HR (95% CI)
Unadjusted (crude) 1.17 (0.58 – 2.37)
Covariates included in the Cox model to calculate adjusted HRs
 Age 1.19 (0.59 – 2.42)
 + Gender 1.19 (0.59 – 2.41)
 + smoking 1.19 (0.59 – 2.42)
 + use of corticosteroids in 1 year prior to episode start 1.16 (0.57 – 2.31)
 + number of GP visits in 1 year prior to episode start 1.07 (0.52 – 2.19)
 + hospitalization for COPD in 1 year prior to episode start 1.06 (0.51 – 2.16)
 + use of Antibiotics for treatment of LRTI in 1 year prior to episode start 1.06 (0.52 – 2.17)
 + adjustment for use of mucolytics and diuretics* 1.01 (0.49 – 2.07)
 + nº. of previous episodes of tiotropium Respimat® and/or HandiHaler® use 0.98 (0.48 – 2.02)
 + calendar time (year of start date treatment episode) 0.97 (0.46 – 2.04)
*- variables that changed the crude HR with more than 5%
Table 4 Sensitivity analysis: Crude and adjusted Hazard Ratios (HRs) for all-cause mortality in users of tiotropium 
Respimat® versus users of tiotropium HandiHaler®
Mortality in patients with COPD (n= 245)
Variable HR (95% CI)
Unadjusted (crude) 1.56 (1.11 – 2.19)
Fully adjusted model* 1.22 (0.84 – 1.77)
Mortality in patients without COPD (n= 27)
Variable HR (95% CI)
Unadjusted (crude) 0.91 (0.27 – 3.06)
Fully adjusted model* 0.88 (0.24 – 3.27)
Mortality in patients excluding switchers (n=268)
Variable HR (95% CI)
Unadjusted (crude) 1.57 (1.12 – 2.20)
Fully adjusted model* 1.29 (0.90 – 1.86)
*Adjusted for age, gender, smoking, use of systemic corticosteroids in 1 year prior to episode start, number of GP 
visits in 1 year prior to episode start, hospitalization for COPD exacerbation, use of antibiotics for treatment of 
LRTI in 1 year prior to episode start, diuretics, mucolytics, previous episodes of tiotropium use and calendar time.
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Discussion
In this observational cohort study in the general Dutch population of patients being 40 years 
or older, we found that the risk of dying was higher in patients being exposed to tiotropium 
Respimat® SMI compared to tiotropium HandiHaler®, but this effect disappeared almost 
entirely upon adjustment. Stratification by type of death showed that the risk of cardiovas-
cular death in tiotropium Respimat® SMI vs. tiotropium HandiHaler® was not increased. In 
the past, concerns were raised on the cardiovascular safety and mortality in patients treated 
with tiotropium HandiHaler® [118, 119]. The current available data do not longer support 
this potential association and the FDA reported that tiotropium HandiHaler® can be used in 
patients with COPD as long as the instructions, as mentioned in the drug label, are respected 
[121]. In their initial report to the FDA, Boehringer Ingelheim reported a potential increase 
of death from any cause in association with tiotropium Respimat®. These data were derived 
from three, one-year, placebo-controlled trials reporting an imbalance in mortality favoring 
placebo. In the combined trials, the risk of dying was 70 % higher in tiotropium Respimat® 
treated patients compared to placebo (RR 1.7, 95%CI 1.1-2.8) [120]. Boehringer Ingelheim is 
currently conducting a large safety study to elucidate the risk of dying in patients treated 
with tiotropium Respimat® SMI, using tiotropium HandiHaler® as reference category.
Data on the safety of tiotropium in Respimat® SMI mainly result from randomized clinical 
trials (RCTs), using placebo as reference and with a short duration of follow-up. In a pooled 
analysis of two 30-week, double blind double-dummy, crossover studies, 207 patients 
were randomized to receive once daily tiotropium Respimat® SMI, tiotropium HandiHaler® 
or placebo [116]. Although this study showed non-inferiority of tiotropium Respimat® SMI 
in comparison to tiotropium HandiHaler® in terms of improvement of lung function (FEV1) 
and no significant differences in terms of mortality, there was a significantly higher systemic 
exposure in patients treated with tiotropium Respimat® SMI 10 µg daily. A more recent study 
in Japanese COPD patients, but with shorter duration of follow-up, compared the safety and 
efficacy of tiotropium 5 µg via Respimat® SMI to 18 µg tiotropium HandiHaler®. In this study 
as well, no difference in safety and efficacy of both formulations could be observed [111].
Similar to the data from these clinical trials, we could not observe an increased all-cause 
mortality or cardiovascular mortality in patients treated with tiotropium Respimat® SMI com-
pared to tiotropium HandiHaler®. In the past, safety concerns on the use of tiotropium mainly 
related to cardiovascular safety, which cannot be confirmed by the UPLIFT study or by our 
data. Stratification between patients with or without diagnosis of COPD did not show major 
differences apart from a somewhat lower risk in patients without COPD diagnosis. This is of 
importance, especially since the recent publication of the TALC (Tiotropium bromide as an 
Alternative to increased inhaled glucocorticoid in asthma patients inadequately controlled 
on a Lower dose of inhaled Corticosteroid) study, demonstrating that – when added to ICS– 
tiotropium improved symptoms and lung function in patients with inadequately controlled 
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asthma [122]. The publication of this study will certainly increase the off-label prescription 
and use of tiotropium in patients with asthma, and information of the safety of these drugs 
in patients with asthma is important.
As for all observational studies, our study has strengths, but also limitations. The main 
strength of this study is the study design, its large cohort size and the detailed informa-
tion that is available on underlying co-morbidity. In addition, the source population being 
used is representative from the general population, which eliminates selection bias. Being 
observational, the study is sensitive to bias and confounding. To adjust for COPD severity, 
we used an algorithm already successfully used by other research groups [76-78]. Despite 
these measures, remaining confounding by indication, including COPD severity might still 
be an issue. Ideally COPD severity should be assessed by pulmonary function, preferably 
post-bronchodilation. In primary care however, pulmonary function is not routinely assessed 
and not systematically recorded in the database. Finally, due to the nature of the database, 
exposure was based on prescription data rather than on actual drug intake.
In conclusion, we did not observe a higher risk of mortality in patients treated with tiotro-
pium Respimat® compared to tiotropium HandiHaler® in the adjusted analyses.
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Inhaled anticholinergic drugs and the 
risk of acute urinary retention
Abstract
Objective: Acute urinary retention (AUR) has been associated with the use of inhaled anti-
cholinergic drugs, which are used as first-line treatment of chronic obstructive pulmonary 
disease (COPD). This association has not yet been investigated and quantified under real life 
circumstances.
Materials and methods: We conducted a nested case-control study within a cohort of COPD 
patients from the Integrated Primary Care Information (IPCI) database. The cohort consisted 
of all COPD patients ≥ 45 years, registered between 1996 and 2006, with at least 12 months 
of valid history. Cases were patients with a first diagnosis of AUR. To each case, controls were 
selected matched on age, gender and index date. Multivariate conditional logistic regression 
analysis was used to calculate adjusted odds ratios (ORadj) with 95% confidence intervals 
(95%CI).
Results: Within the cohort of 22,579 COPD patients, 209 cases were identified. Current use 
of inhaled anticholinergic drugs was associated with a 40% increase in risk for AUR (ORadj 
1.40; 95%CI 0.99-1.98) compared to non-users. Among current users, the risk was highest 
for the recent starters (ORadj 3.11; 95%CI: 1.21-7.98). The risk of long-acting anticholinergic 
drug tiotropium was not substantially different from that of the short-acting anticholinergic 
ipratropium. The association was not dose-dependent, but changed by mode of administra-
tion, with nebulizers having the highest risk (ORadj 2.92; 95%CI, 1.17-7.31). Especially in male 
COPD patients with benign prostatic hyperplasia the association was strongest (ORadj 4.67; 
95%CI, 1.56-14.0).
Conclusion: Current use of inhaled anticholinergic drugs increases the risk of AUR especially 
in patients with benign prostatic hyperplasia or if administered via nebulizer.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease characterized by a largely ir-
reversible obstruction of the airways, and encompasses both emphysema and chronic 
bronchitis. COPD is a leading cause of chronic morbidity and mortality worldwide [2]. The 
primary goal of COPD treatment is to reduce the symptoms of breathlessness and to improve 
quality of life. Bronchodilator medications are central to the symptomatic management of 
COPD and encompass inhaled β2-agonists and anticholinergics. For both types of inhaled 
bronchodilators, short-acting (multiple administrations per day) and long-acting (once daily) 
drugs are available. The long-acting β2-agonists (salmeterol, formoterol) and the long-acting 
anticholinergic drug (tiotropium) are recommended as maintenance treatment in patients 
with moderate to very severe COPD [7]. However, systemic use of anticholinergic drugs has 
been associated with acute urinary retention (AUR) [123], which causes significant morbidity 
and mortality [124]. Both COPD and AUR are highly prevalent diseases in elderly males [125].
Anticholinergic drugs bind to muscarinic receptors and thereby inhibit the parasympa-
thetic chain which causes bronchodilation and reduces mucous secretion [126], but also 
impairs contraction of the detrusor muscle which could lead to urinary retention [125]. 
The association between systemic use of anticholinergics and AUR has been demonstrated 
before, but little is known about the effects of inhaled anticholinergics on AUR [127]. In addi-
tion short-acting (ipratropium and oxitropium) and long-acting (tiotropium) anticholinergic 
drugs may have different effects [128]. Although the systemic effect of inhaled anticholin-
ergics is expected to be low, as absorption via the gastro-intestinal tract and the lungs is 
limited, adverse effects from inhaled anticholinergic products have been described [123]. 
In addition, case reports, case series and clinical trials reported the occurrence of urinary 
retention or urinary outflow obstruction in association with short- and long-acting inhaled 
anticholinergic drugs [129-131]. Recently published, the UPLIFT study reported an increase 
of AUR in patients being treated with tiotropium compared to placebo (0.34 vs. 0.21 case 
per 100 patient-years at risk; Relative Risk (RR) 1.65, 95% confidence interval (CI) 0.92-2.93) 
[132]. To our knowledge, the association between the use of inhaled anticholinergics and the 
occurrence of AUR has never been quantified in real life by means of observational studies, 
where users may differ substantially from selected patients participating in clinical trials. For 
this reason, we conducted a case control study nested in a cohort of COPD patients.
Materials and methods
Database setting
The study was conducted within the Integrated Primary Care Information (IPCI) database, 
a longitudinal observational database (dynamic cohort) that started in 1992, and contains 
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data from computer based patient records of general practitioners (GPs) throughout the 
Netherlands [133]. The database covers data from more than 500 GPs and encompasses ap-
proximately 1 million patients [134].
In the Dutch health care system, patients are registered with a single GP who acts as a 
gatekeeper of medical care. The electronic medical records from the GP contain coded and 
anonymous data on patient demographics, symptoms and diagnoses (using the Interna-
tional Classification of Primary Care (ICPC) and free text), clinical findings, referrals, labora-
tory findings and hospitalizations [133, 135]. Summaries of the hospital discharge letters 
and information from specialists are entered in a free text format, and hard copies can be 
provided upon request. The database as well holds all GP prescriptions with details on brand 
name, quantity, formulation, strength, indication, prescribed daily dose, the Anatomical 
Therapeutic Chemical (ATC) classification code, and the physician-linked indication [89, 136]. 
To maximize completeness of the data, GPs are not allowed to use paper-based records [125].
Source population
The source population for this study comprised 191,085 men and women 45 years or older, 
with at least 12 months of valid database history (i.e. the practice had been contributing data 
to the IPCI database for at least 12 months and the patient had been registered with the GP 
for at least 12 months). A one year pre-enrollment period was required in order to be able 
to characterize the patients. Follow-up started on January 1st, 1996, or the date at which 12 
months of valid history was obtained, whichever date was latest.
Study design
To guarantee high exposure prevalence, we conducted a case-control study within a cohort 
of COPD patients (both incident and prevalent COPD). A patient was considered to have 
COPD if there was a coded diagnosis for COPD (ICPC R95 or R91), a diagnosis of COPD in the 
narratives (free text search) or the use of at least 2 bronchodilating drugs during follow-up 
[137].
Within the COPD cohort, all subjects were followed from cohort entry (start date of follow-
up for prevalent COPD patients or date of diagnosis of COPD for incident COPD patients) 
until the first episode of AUR, the end of the study period (30th September 2006), the time 
of transferring out of the practice, or death, whichever event occurred first. Patients with a 
history of AUR prior to the study entry were excluded.
Cases and controls
AUR was defined as the sudden inability to pass any urine, requiring catheterization.
Within the COPD cohort, all potential cases of AUR were selected by searching on diagnosis 
codes (ICPC U05.2) and narratives including “urinary”, “retention” and “urinary catheteriza-
tion” as terms. All potential cases of AUR were manually reviewed by 2 medical doctors and 
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categorized into 3 groups (definite, possible or no AUR). Reviewers were blinded to drug 
exposure throughout the entire validation process. The date of first symptoms of AUR was 
considered as the index date. Only the definite cases of AUR were used in the main analysis; 
a sensitivity analysis was performed using both definite and possible cases. For each case, we 
used as controls all individuals who had the same age and sex as the case and were in the 
cohort and AUR free at the index date. Controls were repeatedly sampled according to the 
incidence density sampling approach and therefore represent control moments rather than 
persons.
Exposure to anticholinergic drugs
All prescriptions for the inhaled anticholinergic drugs were retrieved from the prescription 
database. Exposure to these agents was classified as current (last prescription covered the 
index date or <30 days prior to it), a recent past (last prescription ended ≥30 days and <180 
days prior to the index date), distant past (last prescription ended ≥180 days prior to the 
index date) or never use. For current users of anticholinergic drugs, the effect of daily dose, 
frequency of use, time since first use and mode of administration was investigated. Daily dose 
was expressed in defined daily doses (DDD); 1DDD is the average dose of a drug for an adult 
for the main indication, as defined by the WHO [89].
To study the effect of time since first use, we categorized current users of inhaled anticholin-
ergic drugs into recent starters (patients who received their prescription for an inhaled anti-
cholinergic drug within 2 weeks prior to the index date while not having used anticholinergic 
drugs in the past 2 years) and chronic users (patients currently using inhaled anticholinergic 
drugs for more than 2 weeks). To study the mode of administration, we categorized current 
use of inhaled AC drugs into use via metered-dose (MDI), dry powder inhaler or nebulizer. To 
study the frequency of use, we categorized current use of inhaled anticholinergic drugs into 
three categories (=<1, >1 and <4, or >=4 times per day).
Covariates
Data on the presence of different risk factors for AUR - including benign prostatic hyperplasia 
(BPH) - were extracted from the computerized patient records in the IPCI database through a 
computerized search on the respective ICPC (for concomitant diseases) or ATC (for concomi-
tant medication) codes. BPH was defined as ICPC code “Y85 = benign prostatic hyperplasia”. 
Only risk factors prior to the index date were taken into account and this was equally done 
for both cases and controls [138]. Risk factors included current use of concomitant drugs 
known to cause AUR (other drugs with anticholinergic effects [antihistaminics, antipsychot-
ics and tricyclic antidepressants (TCA’s)], analgesic narcotics, benzodiazepines and diuretics), 
other respiratory drugs (inhaled β2-mimetics, inhaled corticosteroids, xanthines and oral 
corticosteroids). In addition, we checked for a medical history of BPH, prostate cancer, urinary 
incontinence, diabetes mellitus, cardiac diseases (heart failure and myocardial infarction), 
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cancer, and stroke prior to the index date and a recent (within 30 days prior to the index date) 
history of urinary tract infection, constipation and immobility [139]. The severity of COPD 
was quantified in line with the paper from Ernst et al, taking into account the number of 
dispensed prescriptions of respiratory medications (β2-mimetics, inhaled corticosteroids, and 
xanthines, excluding the study drugs), the number of prescriptions for oral corticosteroids, 
and/or the presence of hospitalization with a primary diagnosis of COPD, all measured in the 
year before the index date [140].
Statistical analysis
All statistical analyses were conducted with SPSS/PC 12.0 (SPSS Inc, Chicago, Ill). The associa-
tion between inhaled anticholinergic drugs and AUR was studied by means of a conditional 
logistic regression analysis. To check for confounders, we first included, together with the ex-
posure of interest (anticholinergics), all covariates that were univariately associated with the 
outcome. Each risk factor that changed the OR for the anticholinergic drugs with more than 
10% was included into the fully adjusted model [141]. In the final model, we also adjusted 
for COPD severity as well as for those factors that changed the odds ratio (OR) for current 
exposure of anticholinergic drugs with more than 10%. Effect modification was investigated 
for presence of BPH and gender. Finally, we included both definite and probable AUR cases to 
check whether the estimate would decrease as expected.
Results
Patient characteristics
Within the cohort of 22,579 COPD patients 45 years or older, we identified 209 definite and 27 
possible cases of AUR. The 209 definite AUR cases that were included in the primary analysis 
were matched to 16,164 controls. Mean age in the cases was 77.2 (SD= ± 9.4) years and 73.9 
(SD= ± 8.1) years in controls.
Compared to controls, the AUR cases were more likely to suffer from immobility and to be 
affected by prostate cancer, BPH, a recent urinary tract infection or constipation (Table 1). 
Use of systemic drugs with anticholinergic effects (such as antihistamines and TCAs), inhaled 
β2-mimetics, inhaled corticosteroids, analgesic narcotics, benzodiazepines, diuretics and 
systemic corticosteroids were risk factors for AUR in this COPD cohort (Table 2).
Association of acute urinary retention (AUR) with inhaled anticholinergic drugs
Current use of any inhaled anticholinergic drug was associated with a 50% increase in risk for 
AUR (ORadj 1.51; 95%CI, 1.08-2.12). After adjusting for COPD severity the risk of AUR associated 
with inhaled anticholinergic drugs decreased (ORadj 1.40; 95%CI, 0.99-1.98) (Table 3). Past use 
of inhaled anticholinergic drugs, either recent or distant past, was not associated with an in-
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creased risk of AUR. Among current users of inhaled anticholinergic drugs, the risk – adjusted 
for COPD severity – was highest for recent starters (prescription started less than 2 weeks 
prior to the index date), with an ORadj of 3.11 (95%CI, 1.21-7.98), whereas the risk for chronic 
users (current use for more than 2 weeks) was 1.33 (95%CI, 0.94-1.90) (Table 3).
We did not observe differences in the risk of AUR between long-acting and short-acting an-
ticholinergic drugs: ORadj for tiotropium was 1.55; 95% CI, 0.80-3.00, whereas it was 1.37; 95% 
CI, 0.96-1.98 for ipratropium (Table 3); this “comparability in risk” remained in all subgroup 
analyses. The association between the use of inhaled anticholinergic drugs and AUR did not 
show a clear dose-response effect and no association with frequency of inhalation could be 
observed (Table 3).
Administration of AC drugs through nebulizers was associated with the strongest risk of 
AUR (ORadj 2.92; 95%CI, 1.17-7.31), whereas other modes of administration did not signifi-
cantly increase the risk of AUR (Table 3).
Table 1 Patient characteristics and the association with AUR
Characteristic
Cases
(n=209) (%)
Controls
(n=16,164) (%)
aORmatched* (95% CI)
Age
 <50 2 (1.0) 127 (0.8)
 50-65 23 (11.0) 2,348 (14.5)
 >65 184 (88.0) 13,689 (84.7)
Gender
 Male 178 (85.2) 13,918 (86.1)
 Female 31 (14.8) 2,246 (13.9)
Comorbidity
 Benign prostatic hyperplasiab 31 (14.8) 1,143 (7.1) 1.94 (1.29-2.91)
 Prostate cancerb 11 (5.3) 273 (1.7) 2.56 (1.35-4.85)
 Urinary tract infection 16 (7.7) 79 (0.5) 16.28 (9.19-28.8)
 Urinary incontinence 10 (4.8) 574 (3.6) 1.05 (0.55-2.04)
 Constipation 24 (11.5) 488 (3.0) 3.28 (2.09-5.15)
 Diabetes mellitus 31 (14.8) 1,933 (12.0) 1.31 (0.89-1.93)
 Cardiac diseases 87 (41.6) 6,843 (42.3) 0.96 (0.73-1.27)
 Stroke 20 (9.6) 1,229 (7.6) 1.12 (0.69-1.79)
 Dementia 2 (1.0) 85 (0.5) N.A.
 Neurological disorders 2 (1.0) 100 (0.6) N.A.
 Cancer 20 (9.6) 1,125 (7.0) 1.37 (0.86-2.19)
 Immobility 96 (45.6) 1,800 (11.1) 5.80 (4.29-7.85)
Abbreviations: AUR (acute urinary retention); CI (confidence interval); N.A. (non-accessible); OR (odds ratio)
ª OR for current use vs. no use; b only for males
* Matched by age, gender and index date
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Effect modification by gender and benign prostatic hyperplasia (BPH) and sensitivity 
analysis
To study effect modification by gender and underlying comorbidity, we stratified cases and 
controls by gender and the presence of BPH. The association between inhaled anticholinergic 
drugs and AUR was much stronger in males than in females (ORadj 1.73; 95%CI, 1.20-2.51 and 
Table 2 Medication use and AUR
Concomitant medication
Cases 
(n=209) (%)
Controls 
(n=16,164) (%)
ORmatched a* (95% CI)
Inhaled β2 mimetics 62 (29.7) 3,485 (21.6) 1.63 (1.17-2.26)
 LABA 19 (9.1) 1,426 (8.8) 1.25 (0.76-2.06)
 SABA 37 (17.7) 1,780 (11.0) 1.84 (1.25-2.71)
 Combination LABA-SABA 6 (2.9) 279 (1.7) 2.18 (0.94-5.04)
Inhaled Corticosteroids 66 (31.6) 4,213 (26.1) 1.59 (1.14-2.20)
Antihistaminics 10 (4.8) 421 (2.6) 2.07 (1.08-3.96)
Cough suppressants/expectorants 18 (8.6) 957 (5.9) 1.45 (0.88-2.40)
Xanthines 5 (2.4) 335 (2.1) 1.11 (0.45-2.74)
ACE inhibitors 40 (19.1) 3,181 (19.7) 1.04 (0.73-1.49)
Narcotic analgesics 22 (10.5) 514 (3.2) 3.67 (2.30-5.88)
5-α-reductase inhibitors (G04CB)1 5 (2.4) 150 (0.9) 1.92 (0.70-5.32)
α-blockers (C02CA,G04CA)1 35 (16.7) 885 (5.5) 3.68 (2.49-5.44)
Antipsychotics 4 (1.9) 126 (0.8) 2.07 (0.74-5.73)
Antidepressants 16 (7.7) 652 (4.0) 2.42 (1.43-4.10)
 TCA 7 (3.3) 162 (1.0) 3.93 (1.80-8.55)
 SSRI 7 (3.3) 376 (2.3) 1.66 (0.77-3.58)
 Other 2 (1.0) 120 (0.7) 1.63 (0.40-6.68)
Benzodiazepines 42 (20.1) 2,368 (14.6) 1.50 (1.05-2.15)
β-blockers 28 (13.4) 2,120 (13.1) 1.04 (0.69-1.57)
Calcium channel blockers 26 (12.4) 1,878 (11.6) 1.03 (0.68-1.57)
Class Ia antiarrhytmics 31 (14.8) 1,656 (10.2) 1.33 (0.90-1.97)
Diuretics 65 (31.1) 3,037 (18.8) 1.82 (1.32-2.51)
NSAIDs 15 (7.2) 765 (4.7) 1.61 (0.93-2.79)
Systemic corticosteroids 25 (12.0) 857 (5.3) 2.62 (1.68-4.07)
Urinary antispasmodics (G04BD)2 6 (2.9) 144 (0.9) 2.82 (1.22-6.54)
Abbreviations: AUR (acute urinary retention); β (beta); CI (confidence interval); LABA (long-acting beta agonist); 
NSAIDs (nonsteroidal anti-inflammatory drugs); N.A. (non-accessible); NSAIDs (non-steroidal anti-inflammatory 
drugs); OR (odds ratio); SABA (short-acting beta agonist); SSRI (selective serotonin reuptake inhibitor); TCA 
(tricyclic antidepressants)
ª OR for current use vs. no use
* Matched by age, gender and index date
1 Medication used for BPH.
2 Medication used for overactive bladder.
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Table 3 Use of inhaled anticholinergics and the risk of AUR
Cases (n = 209) 
(%)
Controls (n = 
16,164) (%)
ORmatched* 
(95% CI)
ORadj†1/†2/†3 
(95% CI)
ORadj‡ 
COPD severity 
(95%CI)
Anticholinergics Use †1
No use 91 (43.5) 8,676 (53.7) reference Reference reference
Current use 69 (33.0) 3,463 (21.4) 1.85 (1.34-2.56) 1.51 (1.08-2.12) 1.40 (0.99-1.98)
 Type AC †1
  Tiotropium 12 (5.7) 625 (3.9) 1.75 (0.92-3.31) 1.64 (0.85-3.15) 1.55 (0.80-3.00)
  Ipratropium 57 (27.3) 2,838 (17.6) 1.88 (1.33-2.64) 1.49 (1.04-2.13) 1.37 (0.96-1.98)
Recency current use †2
 < 2 weeks 5 (2.4) 123 (0.8) 4.12 (1.64-10.4) 3.28 (1.29-8.38) 3.11 (1.21-7.98)
 ≥ 2 weeks 64 (30.6) 3,340(20.7) 1.77 (1.28-2.47) 1.53 (1.10-2.14) 1.33 (0.94-1.90)
Dosage †3
 Tiotropium
  PDD = 1** 12 (5.7) 625 (3.9) 1.75 (0.92-3.32) 1.62 (0.84-3.13) 1.55 (0.80-3.00)
 Ipratropium
  PDD < 1 24 (11.5) 1,070 (6.6) 2.01 (1.27-3-19) 1.50 (0.92-2.44) 1.47 (0.91-2.37)
  PDD ≥ 1 33 (15.8) 1,768 (10.9) 1.79 (1.19-2.70) 1.37 (0.89-2.12) 1.31 (0.85-2.02)
Frequency †1
 ≤ 1 11 (5.3) 665 (4.1) 1.54 (0.80-2.97) 1.41 (0.72-2.76) 1.34 (0.68-2.63)
 > 1 and < 4 29 (13.9) 1,462 (9.0) 1.82 (1.19-2.80) 1.52 (0.98-2.37) 1.44 (0.92-2.24)
 ≥ 4 29 (13.9) 1,336 (8.3) 2.05 (1.33-3.15) 1.54 (0.98-2.42) 1.39 (0.88-2.21)
Type administration †2
 MDIa 27 (12.9) 1,134 (7.0) 2.07 (1.33-3.22) 1.60 (1.02-2.50) 1.37 (0.85-2.18)
 Dry powder 36 (17.2) 2,239 (13.9) 1.54 (1.04-2.29) 1.46 (0.98-2.18) 1.35 (0.90-2.03)
  Tiotropium 1.86 (0.99-3.49) 1.82 (0.96-3.46) 1.66 (0.86-3.21)
  Ipratropium 1.42 (0.91-2.23) 1.34 (0.86-2.11) 1.24 (0.78-1.98)
 Nebulizera 6 (2.9) 90 (0.6) 7.40 (3.13-17.5) 4.09 (1.69-9.92) 2.92 (1.17-7.31)
Recent past use 20 (9.6) 1,276 (7.9) 1.46 (0.89-2.38) 1.22 (0.73-2.02) 1.15 (0.70-1.91)
Distant past use 29 (13.9) 2,749 (17.0) 1.00 (0.65-1.53) 0.94 (0.60-1.46) 0.96 (0.62-1.48)
Abbreviations: AC (anticholinergic); adj (adjusted); AUR (acute urinary retention); CI (confidence interval); COPD 
(chronic obstructive pulmonary disease); MDI (metered dose inhaler); OR (odds ratio); PDD (prescribed daily 
dosage)
a Only Ipratropium
* Matched by age, gender and index date
** Given dosage for tiotropium (PDD=1)
†1 Adjusted for immobility, systemic corticosteroids
†2 Adjusted for immobility
†3 Adjusted for immobility, β2 mimetics, systemic corticosteroids
‡ Adjusted for immobility and for COPD severity
The column at the right gives the OR for the final model (always adjusting for COPD severity)
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ORadj 0.28; 95%CI, 0.08-1.00 respectively), although the number of female cases was very low 
(Table 4). The risk of AUR was the highest in patients with BPH (ORadj 4.67; 95%CI, 1.56-14.0) 
(Table 4).
Table 4 Use of inhaled anticholinergics and the risk of AUR: stratifications (BPH, gender)
Stratification 
according to BPH
Cases 
(n = 31) (%)
Controls 
(n = 1,143) (%)
ORmatched* 
(95% CI)
ORadj†1 
(95% CI)
ORadj‡ 
COPD severity (95%CI)
BPH
Anticholinergics Use
 No use 10 (32.3) 593 (51.9) Reference Reference reference
 Current use 14 (45.2) 235 (20.6) 5.77 (2.04-16.8) 5.35 (1.83-15.6) 4.67 (1.56-14.0)
  Type AC
   Tiotropium 3 (9.7) 60 (5.2) 5.69 (1.02-31.8) 5.57 (0.94-33.1) 4.02 (0.66-24.6)
   Ipratropium 11 (35.5) 175 (15.3) 5.77 (1.98-16.9) 5.30 (1.74-16.1) 4.73 (1.53-14.6)
 Recent past use 1 (3.2) 88 (7.7) N.A. N.A. N.A.
 Distant past use 6 (19.4) 227 (19.9) 1.74 (0.48-6.24) 1.94 (0.54-6.97) 1.96 (0.53-7.26)
Stratification 
according to gender
Cases 
(n = 209) (%)
Controls 
(n = 16,164) (%)
ORmatched* 
(95% CI)
ORadj†1 
(95% CI)
ORadj‡ 
COPD severity (95%CI)
Males 178 13,918
 Anticholinergics Use
 No use 69 (38.8) 7,304 (52.5) Reference Reference reference
 Current use 66 (37.1) 3,117 (22.4) 2.21 (1.56-3.13) 1.93 (1.36-2.75) 1.73 (1.20-2.51)
 Type AC
  Tiotropium 10 (5.6) 545 (3.9) 1.84 (0.91-3.72) 1.81 (0.88-3.72) 1.65 (0.80-3.42)
  Ipratropium 56 (31.5) 2,572 (18.5) 2.30 (1.60-3.31) 1.96 (1.35-2.82) 1.75 (1.19-2.57)
 Recent past use 19 (10.7) 1,139 (8.2) 1.71 (1.02-2.86) 1.50 (0.89-2.55) 1.39 (0.82-2.37)
 Distant past use 24 (13.5) 2,358 (16.9) 1.06 (0.66-1.70) 1.04 (0.64-1.68) 1.01 (0.63-1.64)
Females 31 2,246
 Anticholinergics Use
 No use 22 (71.0) 1,372 (61.1) Reference Reference reference
 Current use 3 (9.7) 346 (15.4) 0.46 (0.14-1.56) 0.37 (0.11-1.28) 0.28 (0.08-1.00)
  Type AC
   Tiotropium 2 (6.5) 80 (3.6) N.A. N.A. N.A.
   Ipratropium 1 (3.2) 266 (11.8) N.A. N.A. N.A.
 Recent past use 1 (3.2) 137 (6.1) N.A. N.A. N.A.
 Distant past use 5 (16.1) 391 (17.4) 0.81 (0.30-2.20) 0.87 (0.32-2.36) 0.78 (0.28-2.15)
Abbreviations: AC (anticholinergic); adj (adjusted); AUR (acute urinary retention); BPH (benign prostatic 
hyperplasia); CI (confidence interval); COPD (chronic obstructive pulmonary disease); MDI (metered dose inhaler); 
OR (odds ratio); N.A. (non-accessible)
* Matched for age, gender and index date
†1 Adjusted for immobility
‡ Adjusted for immobility and for COPD severity
The column at the right gives the OR for the final model (always adjusting for COPD severity)
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Sensitivity analysis including both definite and possible cases of AUR reduced the asso-
ciation between AC drugs and AUR (ORadj 1.32; 95%CI, 0.95-1.83, for current users of inhaled 
anticholinergic drugs, and ORadj 2.62; 95%CI, 1.02-6.72, for recent starters) (data not shown).
Discussion
This study shows that inhaled anticholinergic drugs increase the risk of AUR in COPD patients, 
especially in men with BPH and when using nebulizers. To our knowledge, this is the first 
study quantifying the association between the use of inhaled anticholinergic drugs and the 
risk of AUR under real life circumstances.
The association between the use of inhaled anticholinergic drugs and AUR has been 
described in case reports and randomized clinical trials. Pras and Lozewicz reported four 
cases of urinary retention associated with ipratropium bromide. All these male patients were 
approximately 70 years old, had a medical history of BPH and used ipratropium via nebulizer 
[129, 130]. Our estimate is lower than the estimates recently reported in a pooled clinical 
trial analysis and a meta-analysis. The pooled analysis of 19 randomized, double-blinded, 
placebo-controlled trials with tiotropium in patients with obstructive lung disease showed 
a RR of 10.9, 95% CI, 1.26-94.88 in patients using tiotropium against placebo, but the con-
fidence intervals were wide due to low numbers [142]. A recent meta-analysis by Barr et al 
showed a non-significant association between the use of tiotropium and the risk of AUR (OR 
2.5, 95% CI 0.5-14) [131]. The UPLIFT study reported a non-significant relative risk of 1.65 
(95%CI, 0.92-2.93) in patients using tiotropium against placebo, this estimate is in line with 
our findings[132].
The risk of AUR in our study was the highest in patients who recently started their inhaled 
anticholinergic treatment. This might be explained by the fact that chronic users tolerate their 
treatment better compared to recent starters. Several studies have indeed demonstrated 
that most of the anticholinergic side effects occur early upon initiating a drug [129, 130]. 
Martin-Merino et al. recently published the results of their case control study on the associa-
tion between the use of oral anticholinergic drugs and AUR and also found that the risk of 
AUR was the highest during early treatment with no clear dose-response relationship [127].
In our nested case control study, we did not observe different risks between tiotropium 
and ipratropium. The meta-analysis of Barr et al demonstrated that the risk of dry mouth was 
higher in tiotropium users compared to placebo or ipratropium (OR 4.6, 95%CI 3.0-7.1 vs. OR 
2.1, 95%CI 1.05-4.2) [131].
As we could not observe a difference in risk of AUR for tiotropium compared to ipratropium, 
we hypothesize that dry mouth might be more due to a local buccal effect than a systemic 
effect [143]. Indeed, it is known that the magnitude of systemic effects of long-acting anti-
cholinergic drugs are similar to those of short acting anticholinergic drugs [69, 123].
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The association between inhaled anticholinergic drugs and AUR was strongest for nebulizer 
therapy. Systemic effects might be higher for nebulized therapy compared to drugs admin-
istered via metered dose inhaler or dry powder inhaler [144-146], probably because higher 
doses are administered during a longer time of inhalation [147]. However, the higher risk of 
AUR in patients treated with nebulized anticholinergic drugs could as well be explained by 
confounding by COPD severity. Patients with severe to more severe COPD are less mobile, 
which by itself is one of the major risk factors for AUR. In addition, patients with severe to very 
severe COPD experience more difficulties in using dry powder aerosol or MDI and also have 
more frequent COPD exacerbations justifying the need for nebulizer therapy. As confounding 
by severity could be an issue, we adjusted for immobility and COPD severity defined by the 
algorithm of Ernst et al [140]. Upon adjustment, the association between the use of inhaled 
anticholinergic drugs and AUR remained.
The association between the use of inhaled anticholinergic drugs and AUR was the high-
est in male patients with BPH, although recent systematic reviews and meta-analyses have 
shown that the risk of urinary retention in patients being treated with antimuscarinic drugs 
(oxybutynin, tolterodine, etc.) for the treatment of overactive bladder - a condition that in 
males is often associated with BPH - is low [148-150]. These randomized controlled trials 
(RCTs) however use stringent inclusion and exclusion criteria, often have a short duration 
of follow-up and monitor patients closely by means of repeated uroflowmetry [149]. We 
believe that the risk of urinary retention in patients using these drugs is probably higher in 
a real life non-controlled setting, which is in line with our observations of a (non-adjusted) 
risk estimate of AUR of 2.82 in patients being treated with oral antimuscarinic drugs. As BPH 
and COPD are prevalent diseases in elderly males, it might be advisable, prior to initiation of 
inhaled anticholinergic drugs, to check if voiding dysfunctions are present and if present, to 
closely monitor the patient by means of regular uroflow measurements.
RCTs have shown that, in patients with BPH, 5ARIs especially in combination with an 
α-blocker, reduce the risk of AUR and BPH surgery [151-153]. We did not observe a protective 
effect of current use of 5ARIs, alone or in combination, on the risk of AUR. It should be em-
phasized however that our case-control study was not designed to study the effectiveness 
of 5 ARIs and α-blockers for the treatment of BPH. This type of research would better be 
conducted by means of a cohort study taking severity of BPH into account.
As for all observational research, our data need to be interpreted with caution. First, the 
exposure was assessed based on GP prescriptions, rather than dispensing data or actual 
patient intake, and could thus under- or overestimate patient exposure. It is likely however 
that this exposure misclassification was non-differential (evenly distributed between cases 
and controls), and thus did not influence the association between the use of inhaled anti-
cholinergic drugs and AUR. To avoid information bias by misclassification of the outcome, all 
cases were manually reviewed by medically trained researchers who were blinded to drug 
exposure, and only the definite cases of AUR were included in our analysis. Indeed, when we 
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conducted a sensitivity analysis, including both definite and possible cases of AUR, we found 
that the association between anticholinergic drugs and AUR became less strong, but still 
significant in recent starters and in male with BPH. Finally, selection bias was unlikely since 
cases and controls were obtained from the same source population of COPD patients, using 
prospectively collected medical records.
In conclusion, our study shows that the risk of AUR is increased in COPD patients recently 
starting inhaled anticholinergics (irrespective of duration of action) and most particularly 
in males with BPH. This latter observation is important since both BPH and COPD are highly 
prevalent diseases in elderly males. It might be advisable to consider alternatives for anticho-
linergic drugs (e.g. inhaled long-acting β2-mimetics) in COPD patients with BPH.
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Inhaled anticholinergic drugs and 
the risk of renal failure
Abstract
Background: Data from a pooled clinical trial analysis on the safety of tiotropium reported 
the occurrence of renal failure during use of tiotropium. In addition, several cases of renal 
failure, both for ipratropium bromide and tiotropium, were reported to the adverse drug 
reaction database-“Vigisearch” from the WHO. To our knowledge, the association between 
inhaled anticholinergic drugs and the occurrence of renal failure has never been studied in 
clinical practice.
Objectives: To compare the risk of renal failure, in COPD patients treated with inhaled anti-
cholinergic drugs.
Methods: We conducted a nested case-control study in a cohort of COPD patients using 
data from the Dutch Integrated Primary Care Information (IPCI) medical record database. The 
study period ran from 2000 to 2007. Cases were all COPD patients who, during follow-up, 
were diagnosed with renal failure (acute or chronic). To each case, all eligible controls were 
matched on age, sex and indexdate. COPD severity was assessed either via spirometry or via 
proxy. Exposure was assessed using prescription records. The odds of renal failure during use 
of inhaled anticholinergic drugs (ipratropium bromide or tiotropium) was compared to the 
odds during no use or use of inhaled β2-agonists. Conditional logistic regression analysis was 
used to calculate adjusted odds ratios (ORadj) with 95%CI.
Results: Within the cohort of 6,788 COPD patients, 83 new cases of renal failure were identi-
fied. Current use of anticholinergic drugs overall (ipratropium or tiotropium) was not associ-
ated with an increased risk of renal failure as compared to no use (ORadj 0.78, 95% CI 0.43-1.42) 
or current use of β2-agonists (ORadj 1.42, 95%CI 0.57-3.54).
Conclusion: Current use of anticholinergic drugs was not associated with an increased risk of 
renal failure as compared to no use or use of β2-agonists.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the seventh most frequent chronic disease 
and is expected to rank fourth by 2020 [105]. This makes COPD a leading cause of chronic 
morbidity and mortality worldwide [2]. It is characterized by a largely irreversible obstruc-
tion of the airways, and encompasses both emphysema and chronic bronchitis. The primary 
goal of COPD treatment is to reduce the symptoms of breathlessness and to improve the 
quality of life. Bronchodilator medications are central to the symptomatic management of 
COPD and encompass inhaled β2-agonists and anticholinergics. For both types of inhaled 
bronchodilators, short-acting (multiple administrations per day) and long-acting (once daily) 
drugs are available. The long-acting β2-agonists (salmeterol, formoterol) and the long-acting 
anticholinergic drug (tiotropium which bind to M3 subtype muscarinic receptors) are recom-
mended as maintenance treatment in patients with moderate to very severe COPD [105]. 
Kesten et al. recently studied the safety of tiotropium, a long acting inhaled anticholinergic 
drug used for the symptomatic treatment of chronic obstructive pulmonary disease (COPD), 
by pooling safety data from 26 randomized clinical trials (RCTs) on tiotropium against pla-
cebo. They found that renal failure, as adverse event, was somewhat less frequently reported 
for tiotropium compared to placebo (risk difference (RD) -0.02, 95%CI -0.20-0.16)). In contrast, 
renal failure, as serious adverse event, was more often reported for tiotropium, but this differ-
ence was not statistically significant (RD 0.07, 95%CI -0.14-0.28) [154]. In addition, using data 
from the WHO adverse drug reaction database (Vigisearch), several reports on renal failure 
during use of tiotropium or ipratropium bromide were reported between 2000 and 2010 
[155].
Renal failure is defined as a deterioration of kidney function that results in the retention 
of waste products, and can broadly be divided into two categories: acute renal failure (ARF) 
and chronic kidney disease (CKD) [156]. ARF is, as the name implies, a rapidly progressive 
loss of renal function [157], and the level of renal impairment varies from moderate to severe 
requiring renal replacement therapy [158]. CKD usually develops slowly and shows few initial 
symptoms; it is a gradually loss of renal function over a period of time. CKD might be the 
long-term result of irreversible acute disease or be part of a disease progression of underly-
ing diabetic nephropathy, hypertension or glomerular nephritis [157]. The prevalence of CKD 
increases with age and in elderly patients, CKD is often unrecognized, as it is likely to coincide 
with other chronic diseases including chronic obstructive pulmonary disease (COPD) [159, 
160].
Animal and human studies have shown that acetylcholine is important to preserve renal 
blood flow through a relaxation of the interlobular arteries as well as the glomerular arterioles. 
It is unknown whether use of anticholinergic drugs, and in particular inhaled anticholinergic 
drugs; increase the risk of renal failure. 
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We conducted a nested case-control study in a large cohort of 6,788 COPD patients with 
23,930 person-years of follow-up in the Netherlands, to compare the risk of renal failure, 
in COPD patients treated with inhaled anticholinergic drugs compared to no use or use of 
inhaled β2-agonists. 
Methods
Setting
A nested case-control was conducted in a cohort of COPD patients from the Integrated 
Primary Care Information Project (IPCI) database. IPCI is a population-based longitudinal 
database that contains the complete computer-based medical records of currently more 
than 400 General Practitioners (GPs) throughout the Netherlands, who voluntarily chose to 
supply data to the database [86]. In the Dutch health care system, patients are registered 
with a single GP who acts as a gatekeeper of medical care and information from primary care 
visits, hospital admission and outpatient visits and therefore the medical records do not only 
capture GP diagnoses and symptoms but also the results and summaries of specialist care 
[161]. At present, the IPCI database contains information on more than 1 million patients. 
This database contains anonymized patient identification information (age, sex, patient 
identification, and GP registration information), narratives, patient reported symptoms, 
signs, GP and specialist diagnoses, prescriptions, physical findings, laboratory values, and 
summaries of specialist letters [86, 88]. The International Classification of Primary Care (ICPC) 
is the coding system for patient complaints and diagnoses, but these can as well be entered 
as free text [162]. Prescription data encompass product name, quantity dispensed, dosage 
regimens, strength, and indication. The National Database of drugs, maintained by the Royal 
Dutch Association for the Advancement of Pharmacy, enables the coding of prescriptions, ac-
cording to the Anatomical Therapeutic Chemical (ATC) classification scheme recommended 
by the WHO [90]. The system complies with European Union guidelines on the use of medical 
data for medical research and has been proven valid for pharmaco-epidemiological studies 
[91]. All observational research on the IPCI database is being conducted according to good 
pharmaco-epidemiological guidelines [92].
The source population consisted of all patients in the IPCI database who were 40 years of 
age or older, and with at least one year of valid history available in the database. The study 
period started in January 2000 and ended in May 2007.
COPD cohort
COPD patients were identified from diagnoses and narratives. The medical records of all po-
tential cases were reviewed by a medical doctor and classified as: definite COPD - diagnosis 
by a specialist or a GP diagnosis confirmed by spirometry (FEV1/FVC<70%); probable COPD 
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- COPD diagnosed by the GP with at least two records of COPD within one year of the first 
record of COPD. All doubtful COPD patients were further classified by a pulmonologist (GB). 
Patients with a COPD diagnosis prior to study entry were classified as prevalent (existing) 
COPD. If patients were disease free at cohort entry and later developed COPD, they were 
considered as having incident (newly onset) COPD.
COPD severity was assessed at the time of cohort entry and changes in COPD severity were 
captured during follow-up. If spirometry was available, severity of COPD was determined 
according to the GOLD guidelines; in all other patients, previously published algorithms for 
COPD severity assessment were used [76-78]. In summary, patients were considered to have 
mild COPD at the time of their first symptoms of COPD; moderate COPD if patients were 
on regular bronchodilatory treatment (defined as at least 2 prescriptions of the same drug 
class within 6 months of the first prescription), and severe COPD if they were hospitalized 
for COPD, or at the moment they had their third courses of antibiotics for the treatment of 
lower respiratory tract infections in one year time, or at the time they had their second sys-
temic corticosteroid course for the treatment of COPD exacerbations. Finally, patients were 
considered to have very severe COPD when they were prescribed oxygen therapy or were 
scheduled for lung transplantation because of COPD.
All COPD patients were followed from cohort entry until a first diagnosis of renal failure 
(either acute or chronic), death or end of follow-up, whichever came first.
Cases and controls
All renal failure cases were identified in the electronic medical records and adjudicated by 
two medical doctors who were blinded to the exposure, and a third doctor arbitrated in case 
of discrepancies. As acute renal failure is an event requiring hospitalization, only acute renal 
failure confirmed by the specialist was considered as a case. Chronic kidney disease (CKD) 
was defined as patients requiring dialysis (end stage renal failure), CKD confirmed by the 
specialist or renal failure based on age adjusted clearance formulas (using 4v-MDRD formula) 
for at least 3 months apart [163]. Patients with a diagnosis of renal failure prior to cohort entry 
were censored for this outcome, and also excluded for being a control. A case was considered 
as being a patient newly diagnosed with acute or chronic kidney disease. The index date was 
the date of the first diagnosis of renal failure (either acute or chronic) after study entry.
To each case, all available controls were matched from the COPD cohort on index date, 
gender and year of birth. Due to this sampling approach [164], controls could be re-sampled 
at different moments in time and their contribution should be considered in person-time 
(moments) rather than subjects.
Exposure
Exposure was categorized by type of drug, timing, duration and dose. All information was 
obtained from the prescription records. The following types of bronchodilating and anti-in-
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flammatory drugs were considered as study drugs: tiotropium as long-acting anticholinergic 
agent (LAAC), short-acting anticholinergic agents (SAAC), single-ingredient long-acting β2-
agonists (LABA), single-ingredient short-acting β2-agonists (SABA), inhaled corticosteroids 
(ICS) and xanthines. Drugs were grouped to look at class effects. The anticholinergics as a 
class consisted of LAAC and SAAC, and the class of β2-agonists comprised of SABA and LABA. 
In an attempt to separate out the effects of the individual bronchodilating drugs while recog-
nizing that COPD treatment is often a multidrug regimen we created the following mutually 
exclusive categories: only inhaled anticholinergic drugs, only β2-agonists or only xanthines. 
Patients who used multiple bronchodilating products were classified as users of a multiple 
drug combination. Drug exposures were further categorized by timing of use in current use 
(last prescription covers the index date or ends less than 30 days prior to the index date), past 
use (last prescription ended more that 30 days), or no use. The main analysis compared the 
effect on renal failure between current use of anticholinergics and current use of β2-agonists.
Covariates
As potential confounders we considered the severity of COPD as well as various co-morbid-
ities and concomitant drug use. For the primary analysis we used the COPD severity status 
one year prior to the index date, since severity could be an intermediate factor between 
the exposure and renal failure. In addition, we conducted sensitivity analyses in which we 
adjusted for severity just prior to the index date.
Other covariates included were smoking history, use of concomitant medication (at least 
one month prior to the index date) and diseases including heart diseases, diabetes mellitus, 
lipid disorders, malignancies and. Finally, resource use, by means of the number of GP office 
and home visits as well as a home bound life style (two or more home visits in the last month 
prior to the index date) were taken into account.
Analysis
Conditional logistic regression analysis was used to estimate the matched unadjusted and ad-
justed risk estimates for the comparison between current use of anticholinergics and non-use 
(allowing use of other COPD drugs) or current use of β2-agonists. All models were adjusted for at 
least COPD severity (either at index date or one year prior to it), duration of COPD, and smoking. In 
addition, we adjusted for the factors that were univariately associated with the outcome (p<0.10), 
and also changed the effect estimate of current use of anticholinergics by more than 5%. Risk 
estimates were only calculated in case the exposure category included at least 5 exposed cases. 
Stratified analysis was conducted by type of renal failure, namely acute or CKD. All statistical analy-
ses were conducted with the statistical software packages SPSS/PC 15.0 (SPSS Inc, Chicago, Ill).
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Results
COPD Cohort and case-control set
From the source population of 185,325 participants 40 years and older, 6,788 patients were 
diagnosed with COPD of which 23% were newly diagnosed during the study period (incident 
COPD). The median follow-up time per COPD patient was 3.5 years, with a total follow-up time 
of 23,930 person-years. Baseline characteristics of this COPD cohort are described in table 1. 
For 30% we could estimate the severity based on FEV1 (spirometry). In the remaining 70%, 
a proxy, as described in the methods sections, measured the severity of COPD. Up to 80% of 
patients had mild or moderate COPD at cohort entry. The most frequent co-morbidities were 
angina pectoris, hypertension, heart failure, hyperlipidemia, diabetes mellitus, and tumors 
(table 1).
Within the COPD cohort, 83 new cases of renal failure were identified, of which 73 were 
chronic and 10 acute cases. Of the cases, 64 (77.1%) were male and the mean age of the cases 
was 73.8 (SD=±8.6) years. Underlying co-morbidities that increased the risk of renal failure 
were a medical history of angina pectoris, heart failure, hypertension, hyperlipidemia and 
diabetes mellitus. Use of concomitant medication (as proxy for underlying co-morbidities) 
such as anti-hypertensives, vitamin K antagonists and lipid lowering drugs were also related 
to the outcome (table 1).
Compared to no use, current use of inhaled anticholinergic drugs (ipratropium and tiotro-
pium) was not associated with an increased risk of renal failure (ORadj 0.78, 95%CI 0.43-1.42) 
(table 2). Current use of ipratropium was not associated with an increased risk of renal failure 
and no dose relation or a relation by type of formulation could be observed (table 2). Due 
to low numbers (N=4), the association between current use of tiotropium and renal failure 
could not be investigated.
Current use of other respiratory drugs was not associated with an increased risk of renal 
failure and a trend for a decreased risk of renal failure was observed for LABA (ORadj 0.61, 
95%CI 0.31-1.20) (data not shown).
When using current use of β2-agonists as reference category, current use of inhaled 
anticholinergic drugs slightly increased the risk of renal failure but this association was not 
statistically significant (ORadj 1.42, 95%CI 0.57-3.54). Due to low exposure numbers, the effect 
of current use of ipratropium and tiotropium separately could not be quantified (table 2).
Stratified analysis
The main analyses were repeated stratifying between acute and CKD. Using CKD as outcome, 
current use of inhaled anticholinergics, as compared to no-use, was not associated with an 
increased risk (ORadj 0.74, 95% CI 0.39-1.42). A slightly increased risk (ORadj 1.77, 95%CI 0.67-
4.66), but not statistically significant, was observed for inhaled anticholinergic drugs com-
pared to current use of inhaled β2-agonists (table 3). Using acute renal failure as outcome, 
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Table 1(a) Patient characteristics at time of cohort entry and characteristics for cases (renal failure) and controls
Characteristics
COPD cohort
N=6,788 (%)
Cases
N=83 (%)
Control moments 
N=3,975 (%)
Matched OR*
(95% CI)
Gender
 Male 3,889 (57.3) 64 (77.1) 3,420 (86.0)
Age (mean, SD) 67.3 (±12.2) 75.5 (±8.49) 75.1 (±5.98)
 40-59 (No.,%) 1,797 (26.5) 5 (6.0) 124 (3.1)
 60-69 (No.,%) 1,739 (25.6) 20 (24.1) 1,059 (26.6)
 70+ (No.,%) 3,252 (47.9) 58 (69.9) 2,792 (70.2)
Smoking history
 Never 525 (7.7) 12 (14.5) 418 (10.5) Reference
 Current 2,737 (40.3) 27 (32.5) 1,397 (35.1) 0.71 (0.35-1.43)
 Past 417 (6.1) 5 (6.0) 340 (8.6) 0.60 (0.21-1.75)
 Missing 3,101 (45.7) 39 (47.0) 1,816 (45.7) 0.73 (0.37-1.44)
Severity at cohort entry
 Mild 2,694 (39.7) 19 (22.9) 842 (21.2) Reference
 Moderate 2,713 (40.0) 40 (48.2) 1,850 (46.5) 0.87 (0.50-1.53)
 Severe 1,280 (18.9) 21 (25.3) 1,225 (30.8) 0.74 (0.39-1.39)
 Very severe 101 (1.5) 3 (3.6) 56 (1.4) NA
Mean time since first diagnosis 2.4 (±4.1) 2.6 (±4.2) 2.8 (±4.3) 0.99 (0.99-1.00)
Co-morbidity (history of events)
 History of asthma 1,042 (15.4) 5 (6.0) 479 (12.1) 0.44 (0.17-1.12)
 History of myocardial infarction 457 (6.7) 11 (13.3) 494 (12.4) 1.18 (0.62-2.24)
 Angina pectoris 994 (14.6) 26 (31.3) 739 (18.6) 1.91 (1.18-3.10)
 Ischemic heart disease 188 (2.8) 4 (4.8) 160 (4.0) NA
 History of stroke or TIA 441 (6.5) 10 (12.0) 412 (10.4) 1.20 (0.61-2.37)
 Peripheral arterial disease 391 (5.8) 10 (12.0) 330 (8.3) 1.52 (0.77-2.99)
 Heart failure 793 (11.7) 32 (38.6) 702 (17.7) 2.96 (1.85-4.75)
 Ventricular arrhythmia 335 (6.3) 8 (9.6) 448 (11.3) 0.85 (0.41-1.79)
 Hypertension 1,422 (21.0) 28 (33.7) 917 (23.1) 1.73 (1.09-2.77)
 Lipid disorder 1,769 (26.1) 38 (45.8) 1,231 (31.0) 2.27 (1.43-3.61)
 Diabetes mellitus (type I, type II) 767 (11.3) 23 (27.7) 590 (14.8) 2.32 (1.41-3.81)
 Migraine 95 (1.4) 0 (0) 25 (0.6) NA
 History of malignancy 673 (10.0) 8 (9.6) 610 (15.3) 0.58 (0.28-1.22)
 Concussion and head injury 26 (0.4) 0 (0) 15 (0.4) NA
 Pneumonia 571 (8.4) 11 (13.3) 542 (13.6) 0.97 (0.51-1.86)
 Parkinsonism 21 (0.3) 0 (0) 18 (0.5) NA
 Depressive disorders 540 (8.0) 7 (8.4) 259 (6.5) 1.22 (0.55-2.71)
 Dementia 23 (0.3) 0 (0) 23 (0.6) NA
 Number of GP visits (mean, SD) 5.7 (±5.0) 6.9 (±4.7) 5.7 (±4.8) 1.04 (1.00-1.08)
 Home bound lifestyle 58 (1.1) 3 (1.9) 42 (1.0) 3.32 (0.97-11.4)
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Table 1(b) Patient characteristics at time of cohort entry and characteristics for cases (renal failure) and controls
Characteristics
COPD cohort
N=6,788 (%)
Cases
N=83 (%)
Control moments 
N=3,975 (%)
Matched OR
(95% CI)*
Concomitant medication (current vs. non use)
Central nervous system drugs
 Opioids 122 (2.3) 4 (4.8) 92 (2.3) NA
 Hypnotics and sedatives 519 (9.8) 8 (9.6) 393 (9.9) 0.95 (0.45-2.00)
 Anxiolytics 504 (9.5) 8 (9.6) 316 (7.9) 1.24 (0.59-2.59)
 Antipsychotics (typical, atypical) 49 (0.9) 0 (0) 41 (1.0) NA
 Antidepressants (SSRI) 189 (3.6) 3 (3.6) 100 (2.5) NA
 Antiepileptic drugs 65 (1.2) 2 (2.4) 58 (1.5) NA
Anticholinergic drugs (except respiratory) 155 (2.3) 5 (6.0) 103 (2.6) 2.22 (0.87-5.64)
Drugs affecting cerebrovascular and cardiovascular diagnosis
 Nitrates 380 (5.6) 10 (12.0) 249 (6.3) 1.80 (0.90-3.59)
 Platelet inhibitors 1,022 (15.1) 24 (28.9) 827 (20.8) 1.61 (0.99-2.62)
 Anti-arrhythmics 70 (1.0) 4 (4.8) 76 (1.9) NA
 Anti-hypertensives 2,361 (34.8) 55 (66.3) 1,668 (42.0) 2.77 (1.74-4.40)
  Diuretics 1,187 (17.5) 32 (38.6) 810 (20.4) 2.35 (1.48-3.72)
  β-blockers 738 (10.1) 15 (18.1) 438 (11.0) 1.74 (0.98-3.10)
  Calcium channel blockers 671 (9.9) 17 (20.5) 478 (12.0) 2.01 (1.16-3.46)
  ACE - inhibitors 1,046 (15.4) 32 (38.6) 833 (21.0) 2.54 (1.61-4.01)
 Corticosteroids (systemic) 579 (8.5) 11 (13.3) 371 (9.3) 1.57 (0.82-3.00)
 Estrogens 197 (2.9) 2 (2.4) 32 (0.8) NA
 Antibiotics 741 (10.9) 11 (13.3) 358 (9.0) 1.50 (0.78-2.88)
 NSAIDs 519 (7.6) 11 (13.3) 266 (6.7) 1.89 (0.99-3.64)
 Vitamin K antagonists 385 (5.7) 17 (20.5) 384 (9.7) 2.60 (1.51-4.49)
 Lipid lowering drugs 620 (9.1) 25 (30.1) 451 (11.3) 3.93 (2.39-6.46)
Other respiratory drugs
 Antihistamines 188 (2.8) 2 (2.4) 125 (3.1) NA
 Mucolytics 393 (5.8) 10 (12.0) 266 (6.7) 1.94 (0.99-3.80)
 Cough suppressants 190 (2.8) 4 (4.8) 70 (1.8) NA
 Leukotriene receptor antagonists 16 (0.2) 0 (0) 20 (0.5) NA
 Systemic β2 agonists 23 (0.3) 0 (0) 13 (0.3) NA
 Short-acting β2 agonists 1,427 (21.0) 21 (25.3) 836 (21.0) 1.03 (0.58-1.84)
 Long-acting β2 agonists 768 (11.3) 17 (20.5) 946 (23.8) 0.73 (0.39-1.35)
 Inhaled corticosteroids 1,919 (28.3) 24 (28.9) 1,413 (35.5) 0.79 (0.45-1.39)
 Xanthines (theophyline) 182 (2.7) 5 (6.0) 112 (2.8) 2.09 (0.82-5.32)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA= not applicable as fewer 
than 5 exposed subjects)
*Matched on age, gender and index date.
Abbreviations: GP (general practitioner), NSAIDs (non-steroid anti-inflammatory drugs), OR (odds ratio), SD 
(standard deviation).
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Table 2 Inhaled anticholinergics and renal failure
Drug class*
Cases
N=83(%)
Control 
moments
N=3,975(%)
Matched OR 
(95%CI)**
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI) 
Model 2
Inhaled Anticholinergics1
 No use 29 (34.9) 1,372 (34.5) Reference Reference Reference
 Current use 25 (30.1) 1,321 (33.2) 0.90 (0.52-1.55) 0.77 (0.42-1.43) 0.78 (0.43-1.42)
 Recent past* 13 (15.7) 406 (10.2) 1.45 (0.74-2.84) 1.30 (0.63-2.69) 1.30 (0.63-2.66)
 Distant past* 16 (19.3) 876 (22.0) 0.78 (0.42-1.46) 0.78 (0.41-1.51) 0.81 (0.42-1.56)
Individual inhaled anticholinergics
 Current use tiotropium 5 (6.0) 172 (4.3) 1.22 (0.45-3.33) 1.01 (0.36-2.84) 1.01 (0.36-2.82)
 Current use ipratropium 19 (22.9) 1,123 (28.3) 0.83 (0.46-1.49) 0.71 (0.36-1.37) 0.71 (0.37-1.36)
 Combined use of tiotropium 
and ipratropium
1 (1.2) 26 (0.7) NA NA NA
Dosage (ipratropium only)
 Low 2 (2.4) 268 (6.7) NA NA NA
 Middle 16 (19.3) 841 (21.2) 0.92 (0.49-1.71) 0.79 (0.39-1.59) 0.80 (0.40-1.59)
 High 2 (2.4) 40 (1.0) NA NA NA
Formulation (ipratropium only)
 Aerosol 8 (9.6) 551 (13.9) 0.66 (0.30-1.46) 0.54 (0.23-1.29) 0.56 (0.24-1.33)
 Powder 10 (12.0) 552 (13.9) 0.93 (0.45-1.94) 0.88 (0.40-1.94) 0.87 (0.40-1.90)
 Nebulizer 2 (2.4) 46 (1.2) NA NA NA
Cumulative duration
 < 30 days 2 (2.4) 44 (1.1) (0.7) NA NA NA
 ≥ 30 and <365 days 8 (9.6) 404 (10.2)) 0.93 (0.42-2.05) 0.78 (0.34-1.82) 0.77 (0.34-1.76)
 ≥ 365 days 15 (18.1) 873 (22.0) 0.83 (0.44-1.56) 0.69 (0.34-1.40) 0.71 (0.35-1.43)
Mutually exclusive groups
Current use LABA or SABA*** 10 (12.0) 745 (18.7) Reference Reference Reference
Current use inhaled 
anticholinergic drugs***
9 (10.8) 488 (12.3) 1.35 (0.54-3.35) 1.41 (0.57-3.52) 1.42 (0.57-3.54)
Current use of Xanthines*** 1 (1.2) 17 (0.4) NA NA NA
Current use of combinations of 
drug classes*** (either fixed or 
individual preparations)
18 (21.7) 854 (21.5) 1.58 (0.72-3.44) 1.62 (0.73-3.60) 1.69 (0.76-3.74)
Reference category “no use” is different for the different drug exposure groups and this implicates that the 
OR are not comparable across the drugs of interest. ORs are not displayed if fewer than 5 subjects exposed to 
comparison of interest (NA= not applicable as fewer than 5 exposed subjects)
**Matched on age, gender and index date
*** Might include use ICS
Model 1: adjusted for severity of COPD at index date, duration of COPD and smoking
Model 2: adjusted for severity of COPD one year prior to the index date, duration of COPD and smoking
Model 2 is the final model in the analysis.
1 Additionally adjusted for use of β2 agonists, mucolytics, antihypertensive drugs, lipid lowering drugs, GP visits 
and heart failure.
Ana BW 4.indd   87 03-03-11   12:30
88
Table 3 Inhaled anticholinergics and renal failure – stratified by acute renal failure or chronic kidney disease
Chronic Kidney Disease
Drug class*
Cases
N=73(%)
Control 
moments
N=3,420(%)
Matched OR 
(95%CI)**
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI) 
Model 2
Inhaled Anticholinergics1
 No use 27 (37) 1,165 (34.1) Reference Reference Reference
 Current use 21 (28.8) 1,136 (33.2) 0.80 (0.45-1.43) 0.75 (0.39-1.45) 0.74 (0.39-1.42)
 Recent past* 12 (16.4) 350 (10.2) 1.41 (0.69-2.84) 1.30 (0.61-2.77) 1.30 (0.61-2.76)
 Distant past* 13 (17.8) 769 (22.5) 0.66 (0.33-1.29) 0.65 (0.32-1.32) 0.67 (0.33-1.35)
Mutually exclusive groups
Current use LABA or SABA*** 8 (11.0) 644 (18.8) Reference Reference Reference
Current use inhaled 
anticholinergic drugs***
9 (12.3) 428 (12.5) 1.65 (0.63-4.31) 1.75 (0.66-4.61) 1.77 (0.67-4.66)
Current use of Xanthines*** 1 (1.4) 15 (0.4) NA NA NA
Current use of combinations of 
drug classes*** (either fixed or 
individual preparations)
14 (19.2) 724 (21.2) 1.55 (0.64-3.73) 1.69 (0.69-4.14) 1.78 (0.80-3.97)
Acute Renal Failure
Drug class*
Cases
N=10(%)
Control 
moments
N=555(%)
Matched OR 
(95%CI)**
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI) 
Model 2
Inhaled Anticholinergics1
 No use 2 (20.0) 207 (37.3) Reference Reference Reference
 Current use 4 (40.0) 185 (33.3) 2.23 (0.40-12.40) 0.83 (0.09-7.83) 1.21 (0.14-10.41)
 Recent past* 1 (10.0) 56 (10.1) NA NA NA
 Distant past* 3 (30.0) 107 (19.3) 2.74 (0.45-16.73) 2.49 (0.24-25.92) 4.96 (0.42-46.89)
Mutually exclusive groups
Current use LABA or SABA*** 2 (20.0) 101 (18.2) Reference Reference Reference
Current use inhaled 
anticholinergic drugs***
0 60 (10.8)
NA NA NA
Current use of Xanthines*** 0 2 (0.4) NA NA NA
Current use of combinations of 
drug classes*** (either fixed or 
individual preparations)
4 (40.0) 130 (23.4) NA NA NA
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA= not applicable as fewer 
than 5 exposed subjects)
* Including fixed combination products, **Matched on age, gender and index date, *** Might include use ICS
Model 1: adjusted for severity of COPD at index date, duration of COPD and smoking
Model 2: adjusted for severity of COPD one year prior to the index date, duration of COPD and smoking
Model 2 is the final model in the analysis.
1 Additionally adjusted for use of β2 agonists, mucolytics, antihypertensive drugs, lipid lowering drugs, GP visits 
and heart failure.
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current use of inhaled anticholinergics, as compared to no-use, was not associated with an 
increased risk. Due to low exposure numbers, the association between current use of inhaled 
anticholinergic drugs, using inhaled β2-agonists as reference category, and the risk of acute 
renal failure could not be investigated.
Discussion
In this study, we did not observe an increased risk of renal failure (either acute or chronic) in 
patients currently using inhaled anticholinergic drugs. We did observe a slightly increased 
risk - although not statistically significant - of CKD in patients currently exposed to inhaled 
anticholinergic drugs using current use of inhaled β2-agonists as reference category.
In animals, the cholinergic vasodilator - acetylcholine - has been shown to produce de-
creases in both afferent and efferent arteriolar resistance when infused into rats [165], dogs 
[166] and rabbits, through a relaxation of both interlobular arteries as well as glomerular 
arterioles [167]. In addition, Vander et al [168] and Yun et al [169] demonstrated that the renal 
vasodilatation in animals, could be blocked by administration of an acetylcholine receptor 
antagonist, suggesting a role of the muscarinic receptor in the renal vasodilatory response 
[169]; probably of M3 subtype [170]. Wierema et al also demonstrated that atropine blocked 
the acetylcholine-induced vasodilatation in the human kidney [171]. By analogy, one could 
expect a similar mechanism for anticholinergic drugs such as ipratropium and tiotropium 
used for the treatment of COPD but this is not confirmed by our findings.
Few data exist on the association between the use of inhaled anticholinergic drugs and 
the risk of renal failure. Kesten et al conducted a pooled analysis of adverse events reported 
from phase III and phase IV tiotropium HandiHaler® clinical trials and found a non-significant 
risk difference for renal failure (as serious adverse event) in patients treated with tiotropium 
compared to placebo (RD 0.07, 95% CI -0.06,0.20) [154]. To our knowledge, the association be-
tween the used of ipratropium and the risk of renal failure has not been published. Based on 
the mechanism as described above, the association between the use of inhaled anticholiner-
gic drugs and risk of renal failure is assumable. If anticholinergic drugs impair the renal blood 
flow, and through this mechanism, induce renal failure, one would expect that especially the 
systemic administration of anticholinergic drugs is associated with the highest risk. As part 
of our analysis, we investigated the association between the current use of non-respiratory 
drugs with anticholinergic effects (such as tricyclic antidepressants, antipsychotics, drugs 
given for the treatment of overactive bladder). In the crude analysis, use of these drugs was 
associated with a two-fold increased risk of renal failure but this association was not statis-
tically significant and might be confounded by underlying co-morbidity. When stratifying 
between acute or CKD, the association between current used of inhaled anticholinergics, as 
compared to inhaled β2-agonists, increased slightly but was still not statistically significant. 
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From the available literature, it is hard to tell whether use of inhaled anticholinergic drugs 
would mainly increase the risk of CKD as opposed to acute renal failure. If the association is 
real, use of inhaled anticholinergic drugs probably does not cause noticeable dramatic drop 
in renal blood flow, making the association with acute renal failure less likely.
As for all observational studies, our study has strengths, but also limitations. The main 
strength is the quality of our data. Great emphasis was put on the validity of the disease 
severity and endpoints that were all manually validated by at least two medically trained per-
sons. The external validity of our data is also a strong point. Being observational, the study is 
sensitive to bias and confounding. We tried to avoid information bias and misclassification of 
the outcome by manually reviewing the electronic medical records of all cases by two medi-
cally trained researchers who were blinded to drug exposure and unaware of the research 
hypothesis. In case of doubt, a third medically trained person overruled the validation. Only 
the definite cases of renal failure were included in our analysis. In order to stratify by type of 
renal failure, all cases of renal failure were categorized into acute or CKD. Using primary care 
data, this categorization is not easy as criteria to decide whether an event is acute or chronic 
might be missing. Misclassification of exposure might be an issue in our study as exposure 
was assessed based on the prescription data, rather than dispensing data or actual patient 
intake, and could thus underestimate or overestimate patient exposure. In addition, in a 
chronic disease such as COPD, prescriptions initiated by the specialist may have been missed. 
Our main limitation was the low number of exposed cases making our study underpowered 
to identify a statistically significant association between the use of anticholinergic drugs and 
the risk of renal failure.
In conclusion, from our data, we cannot conclude that the use of inhaled anticholinergic 
drugs increases the risk of renal failure. As COPD is a very prevalent disease requiring chronic 
treatment with bronchodilating drugs including anticholinergic agents, further research on 
this topic is needed, preferably in a much larger dataset allowing stratification into acute or 
CKD and stratification by type of inhaled anticholinergic drugs (long or short acting ones).
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Tiotropium and the risk of 
cardiovascular events and all cause 
mortality
Abstract
Background: Results from previous research hypothesized that the use of tiotropium might 
be associated with an increased risk of mortality and/or cardiovascular (CV) events. The safety 
of tiotropium was closely monitored by the FDA and based on recent data they stated in 2010 
that the available data do not support an association between tiotropium and an increased 
risk of death or CV events. This potential association has not yet been investigated under 
routine clinical care.
Methods: We conducted 2 nested case-control studies in a COPD cohort using data from the 
Dutch IPCI database. The cohort consisted of COPD patients, ≥ 40 years, with at least 1 year 
of valid history. In the first case-control study, cases had a cardiovascular or cerebrovascular 
endpoint (CCVE): stroke and TIA, myocardial infarction, heart failure, and/or ventricular ar-
rhythmia. In the second case-control study, cases were all patients who died. To each case, 
all eligible controls were matched on age, sex and index-date. Conditional logistic regression 
analysis was used to calculate adjusted odds ratios (ORadj) with 95% confidence intervals (CI) 
for use of tiotropium with LABA as reference.
Results: Within the COPD cohort of 6,788 patients, 784 cases with a CCVE were identified 
and 1,032 patients died. Compared to current use of LABA, current use of tiotropium was not 
associated with an increased risk of a CCVE (ORadj 0.89, 95% 0.55-1.44) nor with an increased 
risk of death (ORadj 0.79, 95% CI 0.49-1.28).
Conclusions: Use of tiotropium in COPD patients is not associated with an increased risk of a 
CCVE or mortality, when compared to LABA.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and 
mortality worldwide. According to data from the World Health Organization (WHO), COPD 
is expected to become the third leading cause of death by 2020. According to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, bronchodilators are the 
mainstay of symptomatic management of COPD [59]. Bronchodilator treatments include 
β2-agonists, anticholinergics (AC), and methylxanthines, used alone or in combination. Long-
acting bronchodilators are found to be more effective and convenient than the short-acting 
agents [59]. Tiotropium (marketed as Spiriva®) is a long-acting inhaled AC bronchodilator 
developed for the long term, once daily, maintenance treatment of COPD. The efficacy and 
safety of tiotropium have been described in randomized controlled trials, with imprecise 
reductions observed for mortality and a significantly lower risk observed for COPD exacerba-
tions [62].
In March 2008, the FDA made an early communication on a small excess risk of stroke (2 
cases per 1,000) with tiotropium over placebo based on a pooled analysis of 29 clinical trials. 
In the same year, 2 other publications reported an increased risk for mortality and/or cardio-
vascular (CV) events in patients who received inhaled ACs (ipratropium or tiotropium) [118, 
119]. In 2008 the result of the UPLIFT study (Understanding Potential Long term Impacts on 
Function with Tiotropium) were published showing a reduced risk of cardiovascular events 
in the tiotropium group as compared to the placebo group (RR 0.84, 95% CI 0.73-0.98). In 
addition, this study showed a non-significant trend for a decrease of death from any cause in 
tiotropium treated patients compared to placebo treated patients (HR 0.89, 95 % CI 0.79-1.02) 
for the intention to treat analysis and a significant reduction in mortality (HR 0.87, 95% CI 
0.76-0.99) for the on-treatment analysis [68]. In November 2009, the FDA convened a meeting 
of the Pulmonary – Allergy Drugs Advisory Committee to discuss the data on cardiovascular 
risk and mortality. The FDA concluded that the current data do not support the conclusion 
that there is an increased risk of stroke, heart attack or death associated with tiotropium 
Handihaler® [120].
As tiotropium continues to be used in a wider population, there is a need to better examine 
safety under non-experimental real-life conditions. For this reason, we studied the cardiovas-
cular safety and risk of mortality of tiotropium compared to LABA in a cohort of well-defined 
COPD patients from the general population in clinical practice.
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Methods
Setting
The study was conducted in the Integrated Primary Care Information Project (IPCI) database. 
IPCI is a population-based longitudinal observational database that contains the complete 
computer-based medical records of more than 400 General Practitioners (GPs) throughout 
the Netherlands, who voluntarily chose to supply data to the database [86]. In the Dutch 
health care system, patients are registered with a single GP who acts as a gatekeeper of 
medical care and information from primary care visits, hospital admission and outpatient 
visits. At present, the ICPI database contains information on more than 1 million active 
patients. The IPCI database contains anonymized patient identification information (age, 
sex, patient identification number, and GP registration information), narratives, symptoms, 
signs, GP and specialist diagnoses, prescriptions, physical findings, laboratory values and 
summaries of specialist letters. The International Classification of Primary Care (ICPC) is the 
coding system for patient complaints and diagnoses, but they can also be entered as free 
text [162]. Therefore, the medical records do not only capture GP diagnosis and symptoms, 
but also the results and summaries of specialist care. Prescription data encompass product 
name, quantity dispensed, dosage regimens, strength and indication. The National Database 
of drugs, maintained by the Royal Dutch Association for the Advancement of Pharmacy, 
enables the coding of prescriptions, according to the Anatomical Therapeutic Chemical (ATC) 
classification scheme recommended by the WHO [90]. This system complies with European 
Union guidelines on the secondary use of health care data for medical research and has been 
proven valid for pharmaco-epidemiological research [91]. Guidelines on good pharmaco-
epidemiological research are rigorously followed by all researchers working on the IPCI 
database [92].
Source population
The source population consisted of all patients in the IPCI database who were 40 years of 
age or older, and with at least one year of valid history available in the database. This meant 
that the practice had contributed data to the IPCI database and that patients had registered 
with the GP for at least one year. A one-year pre-enrollment period was required in order to 
be able to characterize the patients. The study period started in January 2000 and ended in 
May 2007.
COPD cohort
COPD patients were identified from diagnoses and narratives. The medical records of all 
potential cases were reviewed by a medical doctor and classified as: definite COPD - diag-
nosis by a specialist or a GP diagnosis confirmed by spirometry (FEV1/FVC<70%); probable 
COPD - COPD diagnosed by the GP with at least two records of COPD within one year of the 
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first record of COPD. All doubtful COPD patients were further reviewed and classified by a 
pulmonologist (GB). All remaining COPD patients were further categorized into prevalent 
or incident COPD. Pa tients with a COPD diagnosis prior to cohort entry were classified as 
prevalent (existing) COPD. If patients were disease free in the pre-enrollment period and 
developed COPD during the study period, they were considered as having incident (newly 
onset) COPD. The COPD cohort entry date was the first date of diagnosis of COPD for incident 
COPD patients and for prevalent COPD patients the date of study entry (1st January 2000), the 
date of the 40th birthday or the date at which one year of valid database history was reached, 
whichever occurred last.
COPD severity was assessed at the time of cohort entry and changes in COPD severity were 
captured during follow-up. If spirometry was available, severity of COPD was determined 
according to the GOLD guidelines; in all other patients, previously published algorithms for 
COPD severity assessment were used [76-78]. In summary, patients were considered to have 
mild COPD at the time of their first symptoms of COPD, moderate COPD if patients were 
on regular bronchodilatory treatment (defined as at least 2 prescriptions of the same drug 
class within 6 months of the first prescription), and severe COPD if they were hospitalized for 
COPD, or at the time they had their third courses of antibiotics for the treatment of respira-
tory infections in one year time, or at the time they had their second systemic corticosteroid 
course for the treatment of COPD exacerbations. Finally, patients were considered to have 
very severe COPD when they were prescribed oxygen therapy or were scheduled for lung 
transplantation because of COPD.
Design
In the cohort of COPD patients, two case control studies were nested, one to study the asso-
ciation with cardio-cerebrovascular endpoints and one to study the association with death.
Cases
Cardiovascular endpoints
Within the cohort of COPD patients, all newly (re)occurring cases of the following cardio-
cerebrovascular endpoints (CCVE) were identified: stroke & TIA, myocardial infarction, heart 
failure, and/or ventricular arrhythmia (ventricular tachycardia, ventricular fibrillation/flutter 
and Torsade de Pointes). Potential cases were identified through a detailed search on both 
diagnosis codes and narratives. Potential cases were independently reviewed by 2 medical 
doctors according to a predefined algorithm. In case of doubt, a final review was done by 
a third medical doctor. Patients with a medical history of heart failure prior to cohort entry 
were excluded from the analysis. The index date was the date of the first CCVE since cohort 
entry.
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Death
Mortality was studied separately from CCVE. All deaths recorded in the COPD cohort were 
identified and the complete medical files, including patient’s referral and discharge letters, 
were reviewed to classify cause of death as respiratory, cardiovascular or death due to other 
reasons. The cause of death, as adjudicated by the medical doctors, was verified with the GP 
in an initial sample of 10% of respiratory or CV related deaths. Since the positive predictive 
value was high (>90%), confirmation of the cause of death by the GP was not requested for 
the remaining deaths.
Controls
To each case, all available controls were matched from the COPD cohort on index date, 
gender and year of birth. Due to this sampling approach (similar to Cox-survival analysis), 
controls could be re-sampled at different moments in time. Therefore, contribution repre-
sents person-time (moments) rather than subjects.
Exposure
Exposure was categorized by type of drug, timing, duration and dose. All information was 
obtained from the prescription records. The following types of bronchodilating and anti-
inflammatory drugs were considered as study drugs: tiotropium as long-acting AC (LAAC), 
short-acting AC (SAAC), single-ingredient long-acting β2-agonists (LABA), single-ingredient 
short-acting β2-agonists (SABA), inhaled corticosteroids (ICS), xanthines and fixed combina-
tion therapies (corticosteroids and bronchodilators). Drugs were grouped in order to investi-
gate class effects. The ACs as a class consisted of LAAC and SAAC, and the class of β2-agonists 
comprised of SABA and LABA. ICS was either classified separately or adjusted for depending 
on the analysis (patients with fixed combinations of steroids and bronchodilators counted in 
the respective bronchodilator class). Drug exposure was further categorized by timing of use 
in current use (last prescription covered the index date or ended less than 30 days prior to the 
index date), past use (last prescription ended more that 30 days prior to the index date), or no 
use. In the analysis, we compared the effect on CCVE events and death between current use 
of tiotropium and LABA while controlling for other drug use and comorbidities.
Covariates
As potential confounders we considered the severity of COPD as well as various co-morbid-
ities and concomitant drug use. For the primary analysis we used the COPD severity status 
one year prior to the index date since severity could be an intermediate factor between the 
exposure and CV events and/or death. In addition, we conducted a sensitivity analysis in 
which we adjusted for severity just prior to the index date.
Other covariates included were smoking history, use of concomitant medication (at least 
use in the month prior to the index date) and concomitant diseases such as heart diseases, 
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diabetes mellitus, lipid disorders, malignancies and diseases affecting the central nervous 
system. Finally, resource use, by means of the number of GP office and home visits as well as 
a home bound life style (two or more home visits in the last month prior to the index date) 
were taken into account.
Analysis
To study potential differences in co-morbidity between patients being prescribed LABA, 
tiotropium, or LABA and tiotropium together (same prescription dates), we compared patient 
characteristics between the three groups at the time of the first prescription of any of these 
drugs after cohort entry. Differences in co-morbidity and use of concomitant medication 
were tested using a non-parametric, Mann-Whitney U test for continuous variables and the 
Chi Square test for categorical variables.
Conditional logistic regression analysis was used to estimate the matched unadjusted and 
adjusted risk estimates and 95% CI for the comparison between tiotropium and LABA. All 
models were adjusted for at least COPD severity, duration of COPD, and smoking. In addition 
we adjusted for all factors that were univariately associated with the outcomes (p<0.10), and 
also changed the effect estimate of tiotropium by more than 5%. Stratified analyses were 
conducted by gender, calendar year, severity of COPD (mild/moderate versus severe/very 
severe) and, incident or prevalent COPD at study entry. We tested effect modification by 
adding an interaction term in the conditional logistic regression model (multiplicative inter-
action). Only if the interaction term based on the effect modifier of interest and current use 
of tiotropium turned out to be statistically significant (p<0.05) in the adjusted model, effect 
measure modification was considered to be present. All statistical analyses were conducted 
with the statistical software packages SPSS/PC 15.0 (SPSS Inc, Chicago, Ill).
Results
COPD Cohort
From the source population of 185,325 participants 40 years and older, 6,788 patients were 
diagnosed with COPD of which 23% were newly diagnosed during the study period (incident 
COPD). The median follow-up time per COPD patient was 3.5 years, with a total follow-up 
time of 23.930 person-years. Baseline characteristics of the COPD cohort are described in 
table 1. For 30% of COPD patients we could estimate the severity based on FEV1 (spirometry). 
In the remaining 70%, the severity of COPD was a proxy as described above. Up to 80% of 
patients had mild or moderate COPD at cohort entry. Since COPD has lately been recognized 
as a systemic disease, we thoroughly characterized extra-pulmonary co-morbidities in the 
COPD cohort. The most frequent co-morbidities were angina pectoris, hypertension, heart 
failure, hyperlipidemia, diabetes mellitus and tumors (table 1).
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Table 1 Patient characteristics at time of cohort entry and at time of first prescriptions for LABA or tiotropium or 
tiotropium plus LABA during the study period
At cohort entry At start of first prescription during follow-up
Characteristics
COPD cohort 
No.(%)
Tiotropium 
No.(%)*#
LABA No.(%)*
Tiotropium plus 
LABA No.(%)*#1
Number of patients 6,788 1,048 3,214 153
Gender
 ♂ 3,889 (57.3) 639 (61.0) 1,829 (56.9) 84 (54.9)
 ♀ 2,899 (42.7) 409 (39.0) 1,385 (43.1) 69 (45.1)
Age (mean, SD) 67.3 (±12.2) 69.1 (±11.0) 67.6 (±11.9) 67.3 (±11.0)
 40-59 (No.,%) 1,797 (26.5) 225 (21.5) 863 (26.9) 39 (25.5)
 60-69 (No.,%) 1,739 (25.6) 278 (26.5) 828 (25.8) 43 (28.1)
 70+ (No.,%) 3,252 (47.9) 545 (52.0) 1,523 (47.3) 71 (46.4)
Smoking history
 no smoking 525 (7.7) 82 (7.8) 265 (8.2) 6 (3.9)
 current smoking 2,737 (40.3) 520 (49.6) 1,413 (44.0) 66 (43.1)
 past smoking 417 (6.1) 105 (10.0) 202 (6.3) 11 (7.2)
 smoking unknown 3,101 (45.7) 340 (32.4) 1,334 (41.5) 70 (45.8)
COPD Severity at cohort entry**
 Mild 2,694 (39.7) 237 (22.6) 763 (23.8) 29 (19.0)
 Moderate 2,713 (40.0) 489 (46.7) 1,508 (46.9) 70 (45.8)
 Severe 1,280 (18.9) 301 (28.7) 874 (27.2) 50 (32.7)
 Very Severe 101 (1.5) 21 (2.0) 69 (2.1) 4 (2.5)
Co-morbidity
History of asthma 1,042 (15.4) 176 (16.8) 625 (19.4) 17 (11.1)
History of myocardial infarction 457 (6.7) 80 (7.6) 231 (7.2) 13 (8.5)
Angina pectoris 994 (14.6) 166 (15.8) 518 (16.1) 26 (17.0)
Ischemic heart disease 188 (2.8) 46 (4.4) 98 (3.0) 5 (3.3)
History of stroke or TIA 391 (5.8) 69 (6.6) 193 (6.0) 7 (4.6)
Peripheral arterial disease 441 (6.5) 107 (10.2) 233 (7.2) 20 (13.1)
Heart failure 793 (11.7) 136 (13.0) 395 (12.3) 17 (11.1)
Ventricular arrhythmia 335 (6.3) 9 (0.9) 15 (0.5) 0
Hypertension 1,422 (21.0) 266 (25.4) 334 (10.4) 22 (14.4)
Lipid disorder 1,769 (26.1) 387 (36.9) 937 (29.2) 58 (37.9)
Diabetes 767 (11.3) 151 (14.4) 382 (11.9) 22 (14.4)
Renal insufficiency 184 (2.7) 37 (3.5) 85 (2.6) 4 (2.6)
History of malignancy 673 (10.0) 147 (14.0) 389 (12.1) 22 (14.4)
Pneumonia 571 (8.4) 149 (14.2) 353 (11.0) 18 (11.8)
Parkinsonism 21 (0.3) 4 (0.4) 4 (0.1) 1 (0.7)
Depressive disorders 540 (8.0) 105 (10.0) 305 (9.5) 24 (15.7)
Dementia 23 (0.3) 3 (0.3) 14 (0.4) 2 (1.3)
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Table 1 also describes the characteristics of cohort members starting with LABA, tiotro-
pium or tiotropium & LABA (same prescription dates), during follow-up. Approximately 47% 
of COPD patients had moderate COPD at the time of first prescription of tiotropium and or 
LABA during follow-up (table 1). The number of patients with severe or very severe COPD 
at time of first prescription was higher for patients who started on a combination of tiotro-
pium and LABA (32.7% were severe and 2.6% very severe), than in patients who started with 
tiotropium or LABA alone. The CV risk profile was quite similar between LABA, tiotropium 
and tiotropium plus LABA group; apart from a medical history of hypertension, renal failure, 
pneumonia which were more frequently observed in patients being treated with tiotropium. 
Patients starting on LABA more frequently had a medical history of asthma (19.4% vs. 16.8 
% in tiotropium users). Tiotropium users had a higher prevalence of ipratropium use (41.8% 
vs. 34.8 in LABA users) while LABA users had a higher prevalence of ICS use (71.3% vs. 51.8% 
in tiotropium users). Differences in age, smoking history, COPD severity and medical history 
between tiotropium and LABA users were statistically significant (table 1). In general, patients 
receiving tiotropium were slightly older and had more co-morbidities than patients starting 
on LABA, whereas the combined LABA and tiotropium group had more severe COPD than the 
patients starting on either LABA or tiotropium alone.
Table 1 (continued)
At cohort entry At start of first prescription during follow-up
Characteristics
COPD cohort 
No.(%)
Tiotropium 
No.(%)*#
LABA No.(%)*
Tiotropium plus 
LABA No.(%)*#1
Number GP visits (mean, SD) 5.7 (±5.0) 6.2 (±4.8) 6.2 (±5.1) 5.9 (±5.2)
Home bound lifestyle 58 (1.1) 9 (0.9) 7 (0.2) 1 (0.7)
Previous use of drugs
 Ipratropium 1,393 (20.5) 438 (41.8) 1,117 (34.8) 39 (25.5)
 SABA 1,427 (21.0) 394 (37.6) 1,190 (37.0) 49 (32.0)
 ICS 1,919 (28.3) 543 (51.8) 2,290 (71.3) 114 (74.5)
 Xanthines 182 (2.7) 48 (4.6) 127 (4.0) 5 (3.3)
 Oral steroids 579 (8.5) 561 (44.0) 990 (30.8) 52 (34.0)
 Leukotriens 0 0 0 0
The values in bold were statistic significant in Chi-square test comparing tiotropium, or Tiotropium+LABA 
against LABA. Patients can only appear in Tiotropium and in LABA group if with different dates, but not in 
the Tiotropium+LABA group and then Tiotropium alone or LABA alone. *First prescription of tiotropium in 
tiotropium group or LABA in LABA group. #LABA is the reference category. #1 First prescription of tiotropium and 
LABA at the same date.
** For 30% of COPD patients severity was based on FEV1 (spirometry). In all other patients, previously published 
algorithms for COPD severity assessment were used.
Abbreviations: ICS (inhaled corticosteroids), GP (general practitioner), LABA (long-acting β2-agonists), SABA 
(short-acting β2-agonists), TIA (transient ischemic attack), SD (standard deviation)
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Table 2(a) Characteristics for cases and controls for a combined cardiovascular and cerebrovascular endpoint & 
death
Combined cardiovascular and 
cerebrovascular endpoint
Death
Characteristics
Cases
N=784 (%)
Control 
moments 
N=25,899 
(%)
Matched OR*
(95% CI)
Cases
N=1,032 
(%)
Control 
moments 
N=40,615 
(%)
Matched OR*
(95% CI)
Male 490 (62.5) 18,844 (72.8) 681 (66.0) 30,946 (76.2)
Age (mean,SD) 74.6 (9.4) 73.2 (7.3) 78.1 (9.2) 75.9 (6.9)
Smoking history
 Never 75 (9.6) 2,598 (10) Reference 38 (3.7) 3,978 (9.8) Reference
 Current 291 (37.1) 9,659 (37.3) 1.1 (0.85-1.43) 342 (33.1) 13,538 (33.3) 2.86 (2.03-4.04)
 Past 47 (6) 1,964 (7.6) 0.94 (0.65-1.37) 41 (4.0) 3,216 (7.9) 1.58 (1.01-2.48)
 Unclear 371 (47.3) 11,653 (45) 0.94 (0.73-1.22) 609 (59.0) 19,847 (48.9) 2.77 (1.98-3.89)
 Passive 0 (0) 25 (0.1) NA 2 (0.2) 36 (0.1) NA
COPD severity
 Mild 184 (23.5) 5,941 (22.9) Reference 98 (9.5) 8,319 (20.5) Reference
 Moderate 358 (45.7) 12,595 (48.6) 0.89 (0.74-1.06) 365 (35.4) 19,391 (47.7) 1.51 (1.20-1.89)
 Severe 212 (27) 6,991 (27) 0.95 (0.77-1.16) 468 (45.3) 12,114 (29.8) 3.17 (2.54-3.97)
 Very severe 30 (3.8) 360 (1.4) 2.70 (1.80-4.06) 101 (9.8) 782 (1.9) 11.4 (8.52-15.4)
Number of GP visits (mean, SD) 6.7 (5.0) 5.4 (4.5) 1.04 (1.03-1.06) 11.6 (9) 6 (4.9) 1.12 (1.11-1.13)
Home bound lifestyle 30 (3.8) 177 (0.7) 4.69 (3.08-7.13) 327 (31.7) 480 (1.2) 36.4 (30.4-43.6)
Co-morbidity
 Prior myocardial infarction 68 (8.7) 1,786 (6.9) 1.39 (1.07-1.79) 282 (27.3) 8,479 (20.9) 1.32 (1.14-1.52)
 Angina pectoris 170 (21.7) 4,034 (15.6) 1.48 (1.24-1.77) 45 (4.4) 1,838 (4.5) 1.01 (0.74-1.38)
 Other ischemic heart disease 35 (4.5) 1,051 (4.1) 1.16 (0.82-1.64) 134 (13) 4,037 (9.9) 1.30 (1.08-1.58)
 Peripheral arterial disease 73 (9.3) 2,179 (8.4) 1.07 (0.84-1.38) 180 (17.4) 4,116 (10.1) 1.68 (1.41-1.99)
 Stroke 75 (9.6) 1,401 (5.4) 1.85 (1.44-2.39) 174 (16.9) 5,221 (12.9) 1.27 (1.07-1.51)
 Arrhythmia (atrial fibrillation, other) 108 (13.8) 2,144 (8.3) 1.69 (1.36-2.09) 248 (24) 10,539 (25.9) 0.89 (0.77-1.03)
 Hypertension 242 (30.9) 6,481 (25) 1.34 (1.15-1.57) 420 (40.7) 8,021 (19.7) 2.53 (2.21-2.9)
 Hyperlipidemia 262 (33.4) 8,485 (32.8) 1.20 (1.03-1.41) 264 (25.6) 13,488 (33.2) 0.83 (0.72-0.96)
 Diabetes mellitus (type I, type II) 129 (16.5) 3,368 (13) 1.33 (1.1-1.62) 188 (18.2) 6,310 (15.5) 1.27 (1.08-1.50)
 Renal disease 49 (6.3) 669 (2.6) 2.71 (1.99-3.69) 82 (7.9) 2,103 (5.2) 1.60 (1.26-2.03)
 Migraine 10 (1.3) 269 (1) 1.02 (0.53-1.94) 10 (1) 404 (1) 0.92 (0.49-1.74)
 Concussion and head injury 5 (0.6) 131 (0.5) 1.34 (0.55-3.28) 9 (0.9) 176 (0.4) 2.26 (1.15-4.48)
 Pneumonia (year prior) 104 (13.3) 3,289 (12.7) 1.05 (0.85-1.3) 228 (22.1) 5,815 (14.3) 1.62 (1.39-1.89)
 Parkinsonism 7 (0.9) 111 (0.4) 1.71 (0.79-3.74) 16 (1.6) 218 (0.5) 2.14 (1.25-3.65)
 Depressive disorders 83 (10.6) 2,099 (8.1) 1.17 (0.92-1.48) 150 (14.5) 3,281 (8.1) 1.75 (1.46-2.10)
 Dementia 6 (0.8) 98 (0.4) 1.59 (0.68-3.74) 20 (1.9) 275 (0.7) 2.13 (1.30-3.49)
 Tumors (non-cerebral) 110 (14) 3,853 (14.9) 0.92 (0.74-1.13) 313 (30.3) 6,653 (16.4) 2.33 (2.03-2.68)
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Table 2(b) Characteristics for cases and controls for a combined cardiovascular and cerebrovascular endpoint & 
death
Combined cardiovascular and 
cerebrovascular endpoint
Death
Central nervous system drugs
 Opioids 21 (2.7) 596 (2.3) 1.18 (0.76-1.84) 231 (22.4) 991 (2.4) 10.90 (9.20-12.90)
 Hypnotics and sedatives 93 (11.9) 2,445 (9.4) 1.09 (0.87-1.36) 212 (20.5) 4,429 (10.9) 1.88 (1.6-2.21)
 Anxiolytics 99 (12.6) 2,301 (8.9) 1.36 (1.09-1.7) 204 (19.8) 3,509 (8.6) 2.48 (2.1-2.92)
 Antipsychotics (typical, atypical) 8 (1) 250 (1) 0.90 (0.44-1.86) 66 (6.4) 373 (0.9) 6.18 (4.63-8.25)
 Antidepressants (SSRI) 30 (3.8) 717 (2.8) 1.21 (0.83-1.76) 55 (5.3) 1,148 (2.8) 1.82 (1.36-2.42)
 Antiepileptic drugs 8 (1) 343 (1.3) 0.74 (0.37-1.51) 35 (3.4) 581 (1.4) 2.38 (1.68-3.39)
Anticholinergic drugs (except respiratory)
 Cholinesterase inhibitors 1 (0.1) 23 (0.1) NA 0 (0) 56 (0.1) NA
 Parkinson drugs: anticholinergics 2 (0.3) 28 (0.1) NA 1 (0.1) 34 (0.1) NA
 Disopyramide 1 (0.1) 15 (0.1) NA 0 (0) 31 (0.1) NA
 Antispasmodics 1 (0.1) 8 (0) NA 1 (0.1) 23 (0.1) NA
 Atropine 0 (0) 0 (0) NA 0 (0) 0 (0) NA
 Tricylic/tetracyclic antidepressants 12 (1.5) 387 (1.5) 0.94 (0.52-1.69) 24 (2.3) 498 (1.2) 1.71 (1.12-2.61)
 H1-antihistamines 1 (0.1) 29 (0.1) NA 8 (0.8) 55 (0.1) 3.60 (1.62-7.97)
 Anticholinergics (overactive 
bladder)
12 (1.5) 196 (0.8) 1.83 (1.01-3.3) 12 (1.2) 452 (1.1) 1.07 (0.60-1.91)
Drugs affecting cerebro- and cardiovascular dx
 Nitrates 63 (8) 1,243 (4.8) 1.55 (1.18-2.04) 129 (12.5) 3,063 (7.5) 1.5 (1.23-1.82)
 Platelet inhibitors 178 (22.7) 4,412 (17) 1.51 (1.27-1.8) 213 (20.6) 8,700 (21.4) 0.94 (0.81-1.1)
 Anti-arrhythmics 22 (2.8) 329 (1.3) 2.43 (1.56-3.78) 26 (2.5) 863 (2.1) 1.36 (0.91-2.03)
 Anti-hypertensives 350 (44.6) 9,411 (36.3) 1.35 (1.17-1.57) 574 (55.6) 17,940 (44.2) 1.55 (1.36-1.76)
 Corticosteroids (systemic): 133 (17) 2,211 (8.5) 2.15 (1.77-2.61) 278 (26.9) 3,971 (9.8) 3.40 (2.94-3.93)
 Estrogens 14 (1.8) 290 (1.1) 1.13 (0.64-1.97) 6 (0.6) 389 (1) 0.47 (0.21-1.06)
 Antibiotics 112 (14.3) 2,059 (8) 1.92 (1.56-2.37) 228 (22.1) 3,536 (8.7) 2.82 (2.41-3.29)
 NSAIDs 69 (8.8) 1,830 (7.1) 1.24 (0.96-1.6) 101 (9.8) 2,759 (6.8) 1.36 (1.10-1.69)
 Vitamin K antagonists 67 (8.5) 1,519 (5.9) 1.52 (1.18-1.97) 132 (12.8) 3,831 (9.4) 1.45 (1.20-1.76)
 Lipid lowering drugs 87 (11.1) 2,720 (10.5) 1.22 (0.97-1.53) 75 (7.3) 4,543 (11.2) 0.73 (0.58-0.93)
Other respiratory drugs
 Antihistamines 29 (3.7) 817 (3.2) 1.16 (0.79-1.70) 65 (6.3) 1,292 (3.2) 1.98 (1.53-2.58)
 Mucolytics 78 (9.9) 1,578 (6.1) 1.72 (1.35-2.2) 148 (14.3) 2,746 (6.8) 2.36 (1.96-2.83)
 Cough suppressants 20 (2.6) 439 (1.7) 1.57 (1-20.48) 33 (3.2) 693 (1.7) 2.13 (1.49-3.05)
 Leukotrien receptor antagonists 4 (0.5) 176 (0.7) NA 10 (0.1) 267 (0.7) 1.51 (0.80-2.87)
 Systemic β2 agonists 2 (0.3) 79 (0.3) NA 10 (1.0) 167 (0.4) 1.79 (0.88-3.63)
 Short-acting anticholinergics 240 (30.6) 6,746 (26) 1.29 (1.08-1.54) 348 (33.7) 11,032 (27.2) 1.84 (1.56-2.18)
 Short-acting β2 agonists 198 (25.3) 5,461 (21.1) 1.11 (0.92-1.36) 313 (30.3) 8,661 (21.3) 1.9 (1.58-2.27)
 Inhaled corticosteroids 307 (39.2) 9,267 (35.8) 0.99 (0.83-1.17) 337 (32.7) 14,214 (35) 1.1 (0.93-1.3)
 Xanthines 26 (3.3) 600 (2.3) 1.51 (1.01-2.27) 75 (7.3) 1,205 (3) 3.05 (2.38-3.9)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA= not applicable as fewer 
than 5 exposed subjects)
*matched on age, gender and indexdate
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Cardiovascular endpoint
Within the COPD cohort, 784 (11.5%) new cases of a CCVE (254 cases of stroke & TIA, 116 
cases of MI, 413 cases of heart failure and 6 cases of ventricular arrhythmia) were identified. 
CV co-morbidity as well as the use of concomitant CV drugs were associated with CCVE (table 
2) among cases and control moments. Severity of COPD was not associated with CCVE apart 
from a significantly increased risk in patients with very severe COPD (OR matched 2.70, 95% 
CI 1.80-4.06). Current use of respiratory drugs was not associated with an increased risk of 
a CV endpoint apart from mucolytics, cough suppressants and short acting AC drugs. Table 
3 describes the association between current use of tiotropium and the risk of a CCVE using 
current use of LABA as reference category. In this analysis, SABA is an exposure category only 
Table 3 Associations for mutually exclusive bronchodilating drug use with a combined cardiovascular and 
cerebrovascular endpoint (independent of ICS and SABA)
Mutually exclusive groups 
(LABA as reference)
Cases
No. (%)
N=784
Control 
moments No. 
(%) N=25,899
Matched OR (95% 
CI)**
Adjusted OR 
(95%CI)
Model 1
Adjusted OR 
(95%CI)
Model 2 (main 
model)
Current use LABA* 115(14.7) 3,590 (13.9) Reference Reference1 Reference1
Current use Tiotropium*1 21 (2.7) 656 (2.5) 0.92 (0.57-1.49) 0.88 (0.54-1.43) 0.89 (0.55-1.44)
Duration of use
 LABA <30 days 9 (1.1) 97 (0.4) Ref. Ref. Ref.
 Tiotropium <30 days 2 (0.3) 56 (0.2) NA NA NA
 LABA ≥30 days 106(13.5) 3,493 (13.5) Ref Ref Ref
 Tiotropium ≥30 days 19 (2.4) 600 (2.3) 0.95 (0.57-1.58) 0.92 (0.55-1.53) 0.93 (0.56-1.54)
Current use Ipratropium* 143(18.2) 4,393 (17) 1.05 (0.82-1.35) 1.01 (0.78-1.30) 1.02 (0.79-1.32)
Current use of Xanthines* 6 (0.8) 192 (0.7) 1.11 (0.48-2.56) 1.00 (0.43-2.33) 1.03 (0.44-2.38)
Current use combinations of 
drug classes*** (either fixed or 
individual preparations)
120(15.3) 3,098 (12) 1.23 (0.95-1.6) 1.12 (0.86-1.47) 1.14 (0.87-1.5)
Current use SABA (when 
used without any other 
bronchodilating drug)
54 (6.9) 1,830 (7.1) 0.96 (0.69-1.34) 0.94 (0.68-1.32) 0.95 (0.68-1.32)
Past use of respiratory drugs**** 226(28.8) 9,218 (35.6) 0.75 (0.6-0.95) 0.77 (0.61-0.97) 0.77 (0.61-0.97)
No use of respiratory drugs 99 (12.6) 2,922 (11.3) 1.09 (0.82-1.43) 1.01 (0.75-1.37) 1.01 (0.75-1.35)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA = not applicable if fewer 
than 5 exposed cases)
*might include use ICS and/or SABA
** matched on age, gender and indexdate
***combinations of fixed or individual respiratory preparations other than SABA
**** past use is always overruled by current use
Model 1 Adjusted for COPD severity at index date, duration of COPD and smoking
Model 2 Adjusted for COPD severity 1 year prior to index date, duration of COPD and smoking
Model 2 is the final model in the analysis
1: Additionally adjusted for use of systemic corticosteroids
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Table 4 Stratified and sensitivity analyses on association between Tiotropium vs. LABA and the association with a 
combined cardiovascular and cerebrovascular endpoint (independent of ICS use and SABA)
Current use Tiotropium*
Cases
No. (%)
Control moments
No. (%)
Adjusted OR
(95%CI)
Subgroup analyses (pre-specified)
Gender
 Female 6 (2) 176 (2.5) 1.02 (0.42-2.49)
 Male 15 (3.1) 480 (2.5) 0.83 (0.47-1.49)
Calendar time
 <2002 (prior to Tiotropium marketing) NA NA NA
 >2002 21 (4.3) 656 (4.3) 0.93 (0.56-1.54)
COPD severity#
 Mild & Moderate 18 (3.3) 469 (2.5) 0.96 (0.56-1.64)
 Severe & Very severe 3 (1.2) 187 (2.5) NA
Incident vs. Prevalent COPD
 Incident COPD 10 (6) 244 (5.2) 1.28 (0.55-2.98)
 Prevalent COPD 11 (1.8) 412 (1.9) 0.74 (0.38-1.43)
Smoking status##
 Ever smoker 12 (3.6) 392 (3.4) 0.72 (0.36-1.46)
 Never smoker 3 (4.0) 66 (2.5) NA
 Smoking status unclear 6 (1.6) 198 (1.7) 0.83 (0.33-2.04)
Sensitivity analyses focusing on assessing effect of choice in methods
COPD severity assessment
 By Spirometry 6 (2.2) 306 (3.2) 0.55 (0.22-1.35)
 Proxy assessment 15 (2.9) 350 (2.1) 1.14 (0.63-2.07)
Certainty COPD diagnosis
 Definite COPD 12 (2.4) 422 (2.6) 0.91 (0.48-1.73)
 Probable COPD 9 (3.1) 234 (2.4) 0.89 (0.41-1.92)
Consultation with pulmonologist vs. no consultation with pulmonologist
 Patients seen by pulmonologist 9 (2) 356 (2.5) 0.73 (0.35-1.52)
 Patients not seen by pulmonologist 12 (3.5) 300 (2.5) 0.88 (0.44-1.73)
Asthma vs. no Asthma
 Patients with asthma 2 (1.8) 77 (2.2) NA
 Patients without asthma 19 (2.8) 579 (2.6) 0.85 (0.51-1.42)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA = not applicable if fewer 
than 5 exposed cases) *might include use ICS and/or SABA
Adjusted for COPD severity 1 year prior to index date, duration of COPD, smoking and use of systemic 
corticosteroids
#: Adjusted for duration of COPD, smoking and use of systemic corticosteroids
##: Adjusted for COPD severity 1 year prior to index date, duration of COPD and use of systemic corticosteroids
NA= not applicable as tiotropium registered from 2002 on
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if it is not used in combination with another bronchodilating drug. Current use of tiotropium 
was not associated with an increased risk of a CCVE (ORadj 0.89, 95% CI 0.55-1.44), nor was any 
current use of other bronchodilating drugs.
We conducted stratified and sensitivity analysis to inspect effect modification, but no 
major change in effect estimates of tiotropium against LABA was seen across different age, 
calendar time, smoking and severity strata (table 4).
Mortality
Within the COPD cohort, 1,032 (15.2%) patients died. Cause of death was distributed as 
following: 245 cases of CV related death (23.0% of total number of deaths), 346 cases of 
respiratory related death (33.0%), 83 cases of CV & respiratory related death (8.0%), 111 cases 
Table 5 Associations between COPD drug use and all-cause death (mutually exclusive bronchodilator use but 
independent of ICS and SABA)
Mutually exclusive groups 
(LABA as reference)
Cases 
n=1,032 No. 
(%)
Control 
moments 
n=40,615
No. (%)
Matched OR 
(95%CI)**
Adjusted OR 
(95% CI)
model 1
Adjusted OR 
(95% CI)
model 2
Current use LABA* 116 (11.2) 5,378 (13.2) Reference Reference1 Reference1
Current use of Tiotropium* 23 (2.2) 1,265 (3.1) 0.74 (0.46-1.18) 0.79 (0.49-1.28) 0.79 (0.49-1.28)
Duration of use
 LABA <30 days 6 (0.6) 165 (0.4) Ref Ref Ref
 Tiotropium <30 days 1 (0.1) 91 (0.2) NA NA NA
 LABA ≥30 days 110 (10.7) 5,213 (12.8) Ref Ref Ref
 Tiotropium ≥30 days 22 (2.1) 1,174 (2.9) 0.77 (0.48-1.25) 0.83 (0.51-1.37) 0.84 (0.51-1.38)
Current use of Ipratropium* 201 (19.5) 6,883 (16.9) 1.34 (1.06-1.69) 1.13 (0.89-1.45) 1.17 (0.91-1.49)
Current use of Xanthines* 22 (2.1) 349 (0.9) 3.04 (1.88-4.93) 2.11 (1.27-3.50) 2.20 (1.33-3.64)
Current use of combinations of 
drug classes*** (either fixed or 
individual preparations)
183 (17.7) 5,406 (13.3) 1.59 (1.25-2.02) 0.96 (0.75-1.24) 1.01 (0.78-1.30)
Current use of SABA 66 (6.4) 2,620 (6.5) 1.12 (0.82-1.53) 1.11 (0.81-1.53) 1.10 (0.8-1.52)
Past use of respiratory 
drugs****
344 (33.3) 14,702(36.2) 1.03 (0.83-1.28) 1.30 (1.04-1.63) 1.27 (1.02-1.59)
No use of respiratory drugs 77 (7.5) 4,012 (9.9) 0.85 (0.63-1.14) 1.63 (1.17-2.26) 1.46 (1.06-2.01)
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA = not applicable if fewer 
than 5 exposed cases)
*might include use ICS and/or SABA
** matched on age, gender and indexdate
***combinations of fixed or individual respiratory preparations other than SABA
**** past use is always overruled by current use
Model 1: adjusted for severity of COPD at index date, duration of COPD and smoking
Model 2: adjusted for severity of COPD one year prior to the index date, duration of COPD and smoking
Model 2 is the final model in the analysis
1: Additionally adjusted for use of AHT drugs, systemic corticosteroids, and mucolytics
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Table 6 Stratified and sensitivity analyses on association between mutually exclusive COPD bronchodilating drug 
use and the association with death independent of ICS use and SABA
Current use Tiotropium*
Cases 
No. (%)
Control moments No. (%)
Adjusted OR 
(95%CI)
Subgroup analyses (pre-specified)
Gender
 Female 6 (1.7) 255 (2.6) 0.97 (0.4-2.36)
 Male 17 (2.5) 1,010 (3.3) 0.73 (0.41-1.29)
Calendar time
 <2002 (prior to Tiotropium marketing) NA NA NA
 >2002 23 (3.2) 1,265 (4.6) 0.82 (0.5-1.34)
COPD severity#
 Mild & Moderate 8 (1.7) 896 (3.2) 0.54 (0.24-1.21)
 Severe & Very severe 15 (2.6) 369 (2.9) 0.90 (0.48-1.71)
Incident vs .Prevalent COPD
 Incident COPD 6 (3.8) 416 (5.4) 0.64 (0.22-1.87)
 Prevalent COPD 17 (1.9) 849 (2.6) 0.86 (0.49-1.51)
Smoking status##
 Ever smoker 13 (3.4) 675 (4) 0.66 (0.32-1.39)
 Never smoker 0 (0) 159 (4) NA
 Smoking status unclear 10 (1.6) 431 (2.2) 1.01 (0.49-2.05)
Sensitivity analyses focusing on assessing effect of choice in methods
COPD severity assessment
 By Spirometry 9 (3) 567 (4) 0.69 (0.30-1.59)
 Proxy assessment 14 (1.9) 698 (2.7) 0.91 (0.49-1.69)
Certainty COPD diagnosis
 Definite COPD 14 (2.1) 817 (3.2) 0.74 (0.39-1.37)
 Probable COPD 9 (2.4) 448 (2.9) 0.92 (0.4-2.12)
Consultation with pulmonologist vs. no consultation with pulmonologist
 Patients seen by pulmonologist 15 (2) 718 (3.1) 0.91 (0.51-1.6)
 Patients not seen by pulmonologist 8 (2.9) 547 (3.1) 0.76 (0.3-1.89)
Asthma vs. no Asthma
 Patients with asthma 4 (4.2) 153 (3) NA
 Patients without asthma 19 (2) 1,112 (3.1) 0.75 (0.44-1.27)
Types of death
 Cardiovascular death 4 (1.6) 258 (2.5) NA
 Respiratory related death 11 (3.2) 459 (3.2) 1.09 (0.52-2.28)
 Cardiovascular & Respiratory related death 2 (2.4) 99 (3.3) NA
 Cancer related death 4 (3.6) 209 (4.5) NA
 Death due to other cause 0 (0) 70 (2.6) NA
 Cause of death unknown 2 (1.2) 170 (2.9) NA
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of cancer related death (11.0%), 78 cases of death due to other causes (7.5%), and 169 cases 
with unknown cause of death (16.4%). Co-morbidity and use of concomitant medication 
(as proxy for underlying co-morbidity) were related to death (table 2). COPD severity was 
a strong risk factor for dying especially in the severe to very severe COPD category. Table 5 
describes the association between current use of tiotropium and the risk of death using cur-
rent use of LABA as reference category. In this analysis, SABA is an exposure category only if 
it is not used in combination with another bronchodilating drug. Compared to LABA, current 
use of tiotropium (ORadj 0.79, 95% CI 0.49-1.28), ipratropium (ORadj 1.17, 95% CI 0.91-1.49), 
SABA (ORadj 1.10, 95% CI 0.80-1.52) and the combination of respiratory drugs (ORadj 1.01, 95% 
CI 0.78-1.30) was not associated with an increased risk of death. Current use of xanthines 
increased the risk of dying compared to LABA (ORadj 2.20, 95% CI 1.33-3.64). Past use or no use 
of respiratory drugs increased the risk of death (table 5).
Stratified analyses were conducted to inspect effect modification, however no major 
heterogeneity in effect estimates of tiotropium against LABA was seen across different age, 
calendar time, smoking and severity strata (table 6).
Subananalyses were conducted to assess whether there is a potential association between 
tiotropium and the causes of death namely: CV, respiratory, CV & respiratory, cancer related 
deaths, death due to other causes and cause of death unknown. Due to low numbers; this 
analysis did not inform on the potential association between the current use of tiotropium 
and risk of dying from specific causes (table 6).
Discussion
Since long acting bronchodilators, including the long-acting anticholinergic tiotropium 
(Spiriva®) are the main stem in the treatment of patients with moderate to very severe COPD 
(GOLD stage II till IV), it is crucial to explore any potential safety signals. Pooled analysis of 
data from randomized controlled trials provided conflicting information on the potential of 
CV events in patients being treated with inhaled ACs. We conducted a nested case control 
study in a cohort of COPD patients to further elaborate the potential CV risks of tiotropium. 
We did not observe an increased risk for CCVE and/or mortality in patients currently treated 
with tiotropium and we had the power to exclude excess risks of more than 50%.
ORs are not displayed if fewer than 5 subjects exposed to comparison of interest (NA = not applicable if fewer 
than 5 exposed cases) *might include use ICS and/or SABA #: Adjusted for duration of COPD, smoking and use 
of systemic corticosteroids, AHT drugs, and mucolytics ##: Adjusted for COPD severity 1 year prior to index date, 
duration of COPD and use of systemic corticosteroids, AHT drugs and mucolytics Adjusted for COPD severity 1 
year prior to index date, duration of COPD, smoking, use of systemic corticosteroids, AHT drugs and mucolytics
NA= not applicable as tiotropium registered from 2002 on
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The debate on the potential association between the use of inhaled ACs and the risk of CV 
events started in 2002 with the publication of the results of the 5-year Lung Health Study. 
That study illustrated that ipratropium did not reduce mortality compared to placebo. In con-
trast, the proportion of patients with CV events and CV death was higher in the ipratropium 
arm compared to placebo but this was mainly observed in the non-compliant patients [172, 
173]. Lee et al and Macie et al, both studied the CV safety of ipratropium using a nested case 
control study in a cohort of COPD patients, using data from the U.S. Veterans Health Admin-
istration health care system and the Canadian Manitoba Health database respectively and 
found that ipratropium was associated with an increased risk of death (OR 1.34, 95% CI 1.22-
1.47) and hospitalization for CV events mainly heart failure (OR 1.47, 95% CI 1.31-1.64). [118, 
174] It should be noted however, that the study from Macie et al included as well asthma, 
COPD and bronchitis patients and did not include information on smoking status. Lee et al 
conducted his study in a cohort of patients newly diagnosed with COPD but lacked informa-
tion on COPD severity and smoking status, and therefore the results could be explained by 
residual confounding. In March 2008, the FDA released an early communication on a poten-
tial increased risk of stroke in patients being treated with tiotropium based on a preliminary 
report by Boehringer-Ingelheim (manufacturer of Spiriva) [121]. This report was based on 
an analysis of 29 clinical trials that showed an excess rate of stroke of 2/1,000 in patients 
treated with tiotropium compared to patients being treated with placebo. Soon after the 
FDA communication, the meta-analysis of Singh et al was published showing an increased 
risk (RR 1.58, 95% CI 1.21-2.06) of composite CV endpoints (stroke, MI and CV death) in pa-
tients being treated with inhaled ACs, including tiotropium, compared to patients receiving 
control therapy. [119] Later that year, the results of the UPLIFT study were published [68]. This 
randomized double blind trial compared 4 years of therapy with either tiotropium or placebo 
in 6,000 patients with COPD who were permitted to use all respiratory medication except 
inhaled AC drugs. At 4 years, there was a non-significant trend for a decrease in death from 
any cause in tiotropium treated patients compared to placebo treated patients (HR 0.89, 95 
% CI 0.79-1.02). Regarding combined CV endpoints (angina pectoris, atrial fibrillation, cardiac 
failure, congestive heart failure, coronary artery disease and myocardial infarction); there was 
a reduced incidence in the tiotropium group as compared to the placebo group (3.56 vs. 
4.21 per 100 PY, RR 0.84, 95% CI 0.73-0.98). The meta-analysis by Singh et al, also published 
in 2008, was strongly criticized because of methodological flaws such as the integration of 
placebo controlled trials with active controlled trials, the ignorance of the effect of differen-
tial discontinuation and the fact that most of the evidence (weight) was provided by a single 
study namely the Lung Health Study [119, 172]. In the mean time, the meta-analysis of Singh 
has been repeated by 3 different groups taking into account more recent studies including 
the UPLIFT study. These updated meta-analyses did no longer find an increased risk for CV 
events and mortality associated with the use of tiotropium. [175-177] Based on the available 
evidence, the FDA concluded in January 2010, that the available data do not support an as-
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sociation between the use of tiotropium and an increased risk of stroke, heart attack or death 
from CV causes [120].
Most of the safety information on tiotropium is based on data from randomized controlled 
trials (RCTs) which hampers external validity as RCTs use stringent inclusion and exclusion 
criteria. Also, sample size and time of follow-up is often limited which reduces the chance 
to detect rare safety or long term events. Few observational studies studied the effective-
ness and safety of tiotropium in real life. De Luise et al studied the risk of CV and respiratory 
hospitalizations and mortality in COPD patients treated with tiotropium using data from the 
Danish healthcare registries. Compared to no use of tiotropium (but allowing use of other 
respiratory drugs), tiotropium was associated with a reduced respiratory and overall mortal-
ity rate and was not associated with increased cardiac mortality. [178] Jara et al compared 
the risk of total mortality and CV safety in tiotropium users compared to users of LABA using 
data from the UK THIN database. [179] The authors concluded that both exposure groups had 
similar risks regarding overall mortality and CV endpoints. These observational studies had 
methodological limitations as information on important confounders such as smoking status 
and COPD severity was lacking. In addition, Jara et al did not restrict the study population 
to patients with COPD but included patients being treated with long acting bronchodila-
tors whatever the indication for use. To our knowledge, our study is the first to study the 
association between the use of tiotropium and CV events and mortality in clinical practice. 
In addition we did put great efforts in identifying important confounders such as smoking 
history and COPD severity. It should be noted however that information on smoking status 
is often incomplete in health care databases as this is not routinely asked for nor reported in 
a consistent manner.
As for all observational studies, our study has strengths, but also limitations. The main 
strengths are the size and quality of our data. Great emphasis was put on the assessment 
of COPD, the COPD severity and clinical endpoints. The external validity of our data can be 
deducted by the fact that our risk estimates are in line with published data. Being observa-
tional, the study is sensitive to bias and confounding. We tried to adjust for COPD severity as 
much as possible, by assessing COPD severity longitudinally which allowed for flexibility in 
the timing for adjustment. Despite these measures, remaining confounding by indication, 
including severity might still be an issue. In addition, as COPD severity was assessed either 
via spirometry, using GOLD criteria, or via proxy using a pre-defined algorithm, potential mis-
classification of COPD severity was a concern. For this reason, we used current use of LABA 
as reference category, as long acting bronchodilators (including LABA) are indicated in COPD 
stage GOLD II-IV and users of LABA and tiotropium had similar CV risk profiles. To control for 
misclassification of the outcome we conducted a broad search and used a strict validation 
algorithm. In addition, all endpoints were validated by 2 medically trained researchers who 
were blinded to the exposure and were unaware of the research hypothesis. In case of doubt, 
the validation was overruled by a third medically trained person. Remaining misclassifica-
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tion of the outcome can never be completely overruled. If present, this misclassification is 
probably non-differential resulting meaning that the observed OR is a conservative estimate 
(shifted towards the 1) meaning that the actual effect is probably lower. Due to the nature 
of the database, exposure was based on prescription data rather than on actual drug intake. 
In chronic diseases like COPD, we might have missed prescriptions initiated by the specialist. 
To study the potential of exposure bias, we conducted a sensitivity analysis, stratifying on 
patients seen by the GP only. For this group of patients, all prescriptions for respiratory drugs 
are available in the database - the results within this stratum were similar to the results of the 
overall dataset suggesting that exposure bias is minimal.
In conclusion, our analyses in a cohort of well-defined COPD patients did not show an 
increased risk of CV endpoints or mortality in COPD patients being treated with tiotropium 
compared to use of LABA.
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β-blockers and the risk of severe COPD 
exacerbation in patients with COPD
Abstract
Background: Contrary to the traditional dogma that the use of β-blockers is dangerous in 
patients with chronic obstructive pulmonary disease (COPD), there is emerging evidence that 
treatment with β-blockers, particularly those that are cardioselective, might be safe and well 
tolerated and may produce good clinical outcomes in patients with COPD, especially if they have 
co-existing heart failure. Although there is reason to believe there may be some potential ben-
eficial effect, we believe that the recently published degree of protection by Rutten et al. might 
be too optimistic and due to various design issues such as confounding and immortal time bias.
Objectives: To study the effect of β-blockers on the risk of severe COPD exacerbations lead-
ing to hospitalization in patients with COPD.
Methods: We conducted several analyses to study the effects of β-blockers on exacerbations 
by 1) mimicking the design of the previously published study by Rutten et al.; 2) avoidance 
of immortal time bias and fixed exposure bias by conducting a nested case-control study in 
a cohort of COPD patients; 3) reducing of confounding by indication for β-blockers by re-
stricting the case control analyses to patients who had received a β-blocker during the study 
period. All studies were based on data from the Dutch Integrated Primary Care Information 
(IPCI) medical record database during the period 2000 to 2007. Cases were all COPD patients 
with a first COPD exacerbation requiring hospitalization. To each case, all eligible controls 
were matched on age, gender and index-date. Cox proportional hazard regression analysis 
(cohort) and conditional logistic regression analyses (case-control) were used.
Results: Within the cohort of 6,788 COPD patients, 619 patients had at least one COPD exac-
erbation requiring hospitalization. Current use of β-blockers significantly reduced the risk of 
severe COPD exacerbations by in the first analysis mimicking Rutten et al. (adjusted hazard 
ratio (HR) 0.73, 95%CI 0.60-0.90). When applying a case control analyses the use of β-blockers 
reduced the risk of exacerbations by 40% (ORadj 0.60, 95% CI 0.44-0.82). When dealing by 
confounding by indication in the third analysis the protective effect was much attenuated 
(ORadj 0.87, 95% CI 0.52-1.45). However, in patients with co-existing heart failure a significant 
protective effect was still observed (ORadj 0.15, 95% CI 0.03-0.80).
Conclusions: The design is important when assessing the effect of β-blockers on COPD 
outcomes, especially since they were contra-indicated for a long time. Overall there may be a 
small protective effect, which is more pronounced in patients with co-existing heart failure.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and 
mortality worldwide, with a marked negative impact on quality of life as well as increased 
hospitalization and mortality rates [105]. The disease is often complicated by frequent and 
recurrent exacerbations that ensue with increasing severity [54] and contribute to declining 
lung function [55]. Exacerbations contribute considerably to the morbidity associated with 
COPD [104]. Moreover, exacerbations lead to an increase in health care costs, disability, and 
result in premature death. As a consequence, exacerbations are currently considered to be 
one of the most relevant outcome parameters in randomized controlled trials in patients with 
COPD [103].
COPD is accompanied by systemic inflammation [105] which leads to atherosclerotic 
disease progression independent of age, smoking, or other cardiovascular risk factors [180]. 
Hence, patients with COPD are prone to develop cardiovascular diseases, which account for 
the majority of deaths in these patients [180, 181]. Heart failure is very common in patients 
with COPD as both conditions are diseases of the elderly and have the same risk factors, in 
particular smoking. In addition it is very difficult to differentiate between COPD and heart 
failure where symptoms of breathlessness might be interpreted as COPD-related symptoms 
and vice-versa [182, 183].
Treatment with cardiovascular drugs, especially β-blockers is known to improve the 
survival of patients with a large spectrum of cardiovascular diseases, including heart failure 
[184]. The traditional belief states however that β-blockers are contra-indicated in patients 
with COPD because of their presumed broncho-constrictive properties and their competi-
tion with β2-agonists [185], which leads to lower prescription rates in COPD patients [186]. 
However, COPD as contra-indication for the use of β-blockers is currently revisited since 
β-blockers may actually have beneficial effects in patients with COPD through tempering of 
the sympathetic nervous system or by reducing the ischemic burden [187]. Meta-analyses of 
20 randomized blinded clinical trials that studied the effects of cardioselective β-blockers in 
patients with COPD, have demonstrated that especially cardioselective β-blockers are well 
tolerated in patients with COPD [188]. In addition, two observational studies have shown 
that β-blocker use in patients with COPD and concomitant cardiovascular disease reduces 
the risk of dying [189, 190]. In their observational retrospective study of 3,371 patients who 
underwent vascular surgery, van Gestel et al. concluded that cardioselective β-blockers were 
associated with reduced mortality in patients with COPD undergoing vascular surgery [190]. 
In their observational study using hospital claims data from 201,752 patients with myocardial 
infarction, Gottlieb et al. concluded that after myocardial infarction, patients with conditions 
that are often considered contra-indications for β-blockade such as COPD, benefit from a 
beta-blocker therapy [189]. More recently, a small observational cohort study in the Nether-
lands showed that β-blockers might reduce the risk of exacerbations and improve survival 
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in patients with COPD, possibly as a result of dual cardiopulmonary protective properties. 
However time varying exposure exposure was not handled correctly and immortal time bias 
was an issue [191]. We hypothesized that the study of Rutten et al. on the protective effect of 
β-blockers on the risk of COPD exacerbation might suffer from exposure and immortal bias 
plus residual confounding. For this reason, we first mimicked the study by Rutten et al. to see 
whether we would obtain similar results, and subsequently we conducted two studies with 
better designs to capture biases. The conducted studies were a 1) nested case-control study 
in a cohort of COPD patients and 2) a nested case control study in a cohort of COPD patients 
who received β-blockers during the study period. In all analyses we have stratified by heart 
failure.
Methods
Setting
The study was conducted in a cohort of COPD patients from the Integrated Primary Care 
Information Project (IPCI) database. IPCI is a population-based longitudinal database that 
contains the complete computer-based medical records of currently more than 400 Gen-
eral Practitioners (GPs) throughout the Netherlands [86]. In the Dutch health care system, 
patients are registered with a single GP who acts as a gatekeeper of medical care. Therefore 
the medical records do not only capture GP diagnoses and symptoms, but also the results 
and summaries of specialist care. At present, the IPCI database contains information on 
more than 1 million patients. This database contains anonymized patient identification 
information (age, sex, patient identification number, and GP registration information), nar-
ratives, symptoms, signs, GP and specialist diagnoses, prescriptions, laboratory values, and 
summaries of specialist letters [86, 88]. The system complies with European Union guidelines 
on the secondary use of healthcare data for medical research and has been proven valid for 
pharmaco-epidemiological studies [91]. All observational research on the IPCI database is 
being conducted according to good pharmaco-epidemiological guidelines [92].
The source population consisted of all patients in the IPCI database who were 40 years of 
age or older, and with at least one year of valid history available in the database. The study 
period started in January 2000 and ended in May 2007. Practices included in the previous 
Dutch paper were not included in this study.
Design
In this study we used three designs to study the effects of β-blockers on COPD exacerba-
tions and to explore the effects of design choices and confounding. The designs were 1) a 
fixed cohort design in COPD patients similar to Rutten et al. where follow-started at COPD 
cohort entry and use of β-blockers during follow-up was used to assign patients to expo-
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sure cohorts; 2) a nested case control study in a cohort of COPD patients, where follow-up 
started at COPD cohort entry; 3) a nested case control study in a cohort of COPD patients 
who received β-blockers during the study period, where follow-up started at the day of first 
β-blocker prescription after the diagnosis of COPD. We hypothesized that the first design 
would overestimate the effect of β-blockers on exacerbations due to exposure misclassifica-
tion such as immortal time bias [192].
COPD cohort
COPD patients were identified from diagnoses and narratives. The medical records of all po-
tential cases were reviewed by a medical doctor and classified as: definite COPD - diagnosis 
by a specialist or a GP diagnosis confirmed by spirometry (FEV1/FVC<70%); probable COPD 
- COPD diagnosed by the GP with at least two records of COPD within one year of the first 
record of COPD. All doubtful COPD patients were further reviewed and classified by a pulmo-
nologist (GB). All COPD patients were further categorized into prevalent or incident COPD. 
Patients with a COPD diagnosis prior to study entry were classified as prevalent (existing) 
COPD. If patients were disease free at cohort entry and developed COPD during the study 
period, they were considered as having incident (newly onset) COPD.
COPD severity was assessed at the time of cohort entry and changes in COPD severity were 
captured during follow-up. If spirometry was available, severity of COPD was determined 
according to the GOLD guidelines; in all other patients, previously published algorithms for 
COPD severity assessment were used [59, 76-78]. In summary, patients were considered to 
have mild COPD at the time of their first symptoms of COPD, moderate COPD if patients were 
on regular bronchodilatory treatment (defined as at least 2 prescriptions of the same drug 
class within 6 months of the first prescription), and severe COPD if they were hospitalized 
for COPD, had a third course of antibiotics for the treatment of respiratory tract infections 
in one year time, or had a second systemic corticosteroid course for the treatment of COPD 
exacerbations. Finally, patients were considered to have very severe COPD when they were 
prescribed oxygen therapy or were scheduled for lung transplantation because of COPD.
All COPD patients were followed from cohort entry until transferring out, last data down-
load, the end of the study period, the first COPD exacerbation requiring hospitalization, 
death or end of follow-up, whichever event occurred the earliest.
Cases and controls
All COPD exacerbations were identified in the electronic medical records and adjudicated by 
two medical doctors, a third doctor arbitrated in case of discrepancies. For this study we only 
considered COPD exacerbations resulting in hospitalization. The index date was the date of 
the first COPD exacerbation leading to hospitalization after study entry.
For the case control studies to each case we matched all available controls from the COPD 
cohort on index date (controlling for differences between calendar years), gender and year 
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of birth. Due to this greedy sampling approach, controls could be re-sampled at different 
moments in time and their contribution should be considered in person-time (moments) 
rather than subjects (32).
Exposure to β-blockers
Exposure to β-blockers was categorized by type of drug (cardioselective and non-cardiose-
lective β-blockers), timing, duration and dose. Drug exposure was categorized by timing of 
use in current use (last prescription covered the index date or ended less than 30 days prior to 
the index date), past use or no use, we distinguished also between those switched between 
types. For current users of β-blockers, the effect of daily dose and time since first use were 
investigated. Daily dose was expressed in daily doses (DDD); 1DDD is the average dose of a 
drug for an adult for the main indication, as defined by the WHO [89]. To study the effect of 
time since first use, we categorized current users of β-blockers into recent starters (patients 
who received their prescriptions for a β-blocker within 2 weeks prior to the index date) and 
chronic users (patients currently using β-blockers for more than 2 weeks).
Covariates
Heart failure was identified from ICPC specific codes for heart failure (K77, K82) and free text. 
Two medical doctors adjudicated all potential cases of heart failure, and a third doctor arbi-
trated in case of discrepancies. Heart failure was defined as being present in case of diagnosis 
by the specialist (cardiologist or specialist in internal medicine) or GP diagnosis, according to 
the Framingham criteria for the diagnosis of congestive heart failure [193].
As other covariates we considered the severity of COPD as well as underlying co-morbidities 
and concomitant drug use. These covariates included smoking history, use of concomitant 
medication (at least use in the month prior to the index date) and concomitant diseases such 
as heart diseases (excluding heart failure), diabetes mellitus, lipid disorders, malignancies 
and diseases affecting the central nervous system. Finally, resource use, by means of the 
number of GP office and home visits as well as a homebound lifestyle (two or more home 
visits in the last month prior to the index date) was taken into account.
Analysis
To mimic the paper by Rutten et al., we conducted a fixed cohort study with Cox proportional 
hazards regression analyses to calculate crude (unadjusted) and adjusted hazard ratios (HR) 
and their 95% confidence intervals (95%CI) for the risk of COPD exacerbations requiring 
hospitalization associated with the use of β-blockers. Exposure was classified on the basis of 
the first β-blocker prescription during follow-up and follow-up started at COPD cohort entry 
even if β-blockers were prescribed much later during follow-up. Adjusted HRs were calcu-
lated after correction for the following (potential confounding) variables: age, sex, smoking 
history, heart failure and history of cardiovascular disease (excluding heart failure).
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In the case control studies, we used conditional logistic regression analysis for estimat-
ing the matched unadjusted and adjusted risks and 95% CI. The risk of exacerbation during 
current use of β-blockers was compared to the risk during no use (analysis 2) or past use 
of β-blockers (analysis 3). The third analysis was conducted in the cohort of COPD patients 
who received a β-blocker prescription during follow up. All models were adjusted for at least 
COPD severity, duration of COPD, and smoking. In addition we adjusted for all factors that 
changed the effect estimate of β-blockers by more than 5%.
Stratified analyses were conducted for co-existing heart failure in the final design. We 
tested effect modification by adding an interaction term in the conditional logistic regression 
model (multiplicative interaction). Only if the interaction term based on the effect modifier of 
interest and use of β-blockers turned out to be statistically significant (p<0.05) in the adjusted 
model, effect measure modification was considered to be present.
All statistical analyses were conducted with the statistical software packages SPSS/PC 15.0 
(SPSS Inc, Chicago, Ill).
Results
COPD Cohort
From the source population of 185,325 participants 40 years and older, 6,788 patients were 
diagnosed with COPD of which 23% were newly diagnosed during the study period (incident 
COPD). The median follow-up time per COPD patient was 3.5 years, with a total follow-up time 
of 23.930 person-years. Baseline characteristics of the COPD cohort are described in table 1. 
The most frequent co-morbidities were hyperlipidemia, hypertension, angina pectoris, heart 
failure, diabetes mellitus and tumors.
Approximately 23% of the cohort received a prescription of a β-blocker during follow-up 
(including use of β-blocker at time of cohort-entry). Characteristics of patients at time of first 
prescription during follow-up (including use at time of cohort-entry) were compared to the 
general COPD cohort (table 1). Patients receiving a β-blocker tended to be older mainly had 
moderate COPD and had more cardiovascular comorbidity. Use of concomitant medications, 
including other cardiovascular drugs and respiratory drugs, was also more present in patients 
being prescribed a β-blocker.
β-blocker and hospitalization for COPD exacerbation
Within the COPD cohort, 619 patients were hospitalized for a COPD exacerbation of which 
351 (56.7%) were male (table 2). The mean age of the cases was 72.2 (SD=±10.2) years. COPD 
severity (severe/very severe) was strongly related to hospitalization for COPD. Underlying 
co-morbidities that increased the risk of hospitalization were angina pectoris, peripheral 
arterial disease, heart failure, renal disease and depression. Use of concomitant medication 
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Table 1(a) Patients characteristics at cohort entry and at start of first presciption during follow-up
At cohort entry At start of first prescription during FU
COPD cohort No.(%) β-blocker No.(%)
Number of patients 6,788 1,553
 ♂ Male 3,889 (57.3) 880 (56.7)
 ♀ Female 2,899 (42.7) 673 (43.3)
Age (mean,SD) 67.3 (±12.1) 70.7 (±10.6)
 40-59 (No.,%) 1,797 (26.5) 252 (16.2)
 60-69 (No.,%) 173 (25.6) 414 (26.7)
 70+ (No.,%) 3,252 (47.9) 887 (57.1)
Smoking history
 no smoking (reference) 525 (7.7) 137 (8.8)
 current smoking 2,737 (40.3) 630 (40.6)
 past smoking 417 (6.1) 117 (7.5)
 smoking unspecified 3,101 (45.7) 669 (43.1)
 passive smoking 8 (0.1)
Severity at cohort entry
 mild (GOLD I) 2,694 (39.7) 508 (32.7)
 moderate (GOLD II) 2,713 (40.0) 727 (46.8)
 severe (GOLD III) 1,280 (18.9) 306 (19.7)
 very severe (GOLD IV) 101 (1.5) 12 (0.8)
Co-morbidity /history
 History of asthma 1,042 (15.4) 233 (15.0)
 History of myocardial infaction 457 (6.7) 247 (15.9)
 Angina pectoris 994 (14.6) 524 (33.7)
 Ischemic heart disease 188 (2.8) 95 (6.1)
 History of stroke or TIA 391 (5.8) 185 (11.9)
 Peripheral arterial disease 441 (6.5) 164 (10.6)
 Heart failure 793 (11.7) 322 (20.7)
 Ventricular arrhythmia 401 (5.9) 19 (1.2)
 Hypertension 1,422 (21.0) 642 (41.3)
 Hyperlipidemia (TC>5) 1,769 (26.1) 692 (44.6)
 Diabetes mellitus 767 (11.3) 269 (17.3)
 Renal insufficiency 184 (2.7) 87 (5.6)
 Migraine 95 (1.4) 32 (2.1)
 Concussion and head injury 26 (0.4) 13 (0.8)
 History of malignancy 673 (10.0) 201 (12.9)
 Pneumonia 571 (8.4) 144 (9.3)
 Parkinsonism 21 (0.3) 4 (0.3)
 Depressive disorders 540 (8.0) 138 (8.9)
 Dementia 23 (0.3) 7 (0.5)
Number of GP visits (mean,SD) 5.7 (±5.0) 7.2 (±5.1)
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(as proxy for underlying co-morbidities) such as opioids, hypnotics & sedatives, anxiolytics, 
and antidepressants were also related to the outcome (table 2).
According to the methods mimicking the design of Rutten et al, the risk of severe COPD 
exacerbation was 27% lower in patients being treated with β-blockers (crude HR 0.73, 
95%CI 0.60-0.90), some covariates had strong effects (table 3). The fully adjusted HR for any 
Table 1(b) Patients characteristics at cohort entry and at start of first prescription during follow-up
At cohort entry At start of first prescription during FU
COPD cohort 
All No. (%)
β-blocker No. (%)
Previous use of drugs
Central nervous system drugs
 Opioids (N02A) 122 (2.3) 123 (7.9)
 Hypnotics and sedatives (N05C) 519 (9.8) 231 (14.9)
 Anxiolytics (N05B) 504 (9.5) 301 (19.4)
 Antipsychotics (typical, atypical) (N05A) 49 (0.9) 17 (1.1)
 Antidepressants (SSRI) (N06AB) 189 (3.6) 78 (5.0)
 Antiepileptic drugs (N03) 65 (1.2) 40 (2.6)
 Anticholinergic drugs (no respiratory) 155 (2.3)
Drugs affecting cerebrovascular and cardiovascular dx
 Nitrates (C01DA) 380 (5.6) 311 (20.0)
 Platelet inhibitors (B01AC) 1,022 (15.1) 602 (38.8)
 Anti-arrhythmics (C01) 70 (1.0) 41 (2.6)
 Anti-hypertensives noBB (C03/C08/C09) 2,084 (30.7) 816 (52.5)
 Corticosteroids (systemic): (H02) 579 (8.5) 373 (24.0)
 Estrogens (G03) 197 (2.9) 68 (4.4)
 Antibiotics (J01) 741 (10.9) 549 (35.4)
 NSAIDs (M01A) 519 (7.6) 358 (23.1)
 Diuretics 1,187 (17.5) 543 (35.0)
 Vitamin K antagonists (B01AA) 385 (5.7)
 Lipid lowering drugs (C10) 620 (9.1) 380 (24.5)
Other respiratory drugs
 Antihistaminics (R06) 188 (2.8)
 Mucolytics (R05CB) 393 (5.8) 173 (11.1)
 Cough suppressants (R05D) 190 (2.8) 157 (10.1)
 Anticholinergics 1,560 (23.0) 612 (39.4)
 Systemic β2 agonists 23 (0.3) 10 (0.6)
 Leukotriene receptor antagonists (R03DC) 16 (0.2) 20 (1.3)
 Inhaled β2 agonists 2,195 (32.3) 710 (45.7)
 Inhaled corticosteroids 1,919 (28.3) 652 (42.0)
 Xanthines 182 (2.7) 38 (2.4)
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Table 2(a) Patients characteristics for cases (COPD exacerbations requiring hospitalization) and controls
Outcome = COPD Exacerbation requiring hospitalization
Cases No.(%) Controls No. (%) Matched OR* (95%CI)
Number of patients 619 24,820
Gender
 ♂ Male 351 (56.7) 17,055 (68.7)  Nap
 ♀ Female 268 (43.3) 7,765 (31.3)  Nap
Age (mean,SD) 70.1 (±10.1) 70.7 (±7.9)
 40-59 (No.,%) 109 (17.6) 2,761(11.1)  Nap
 60-69 (No.,%) 159 (25.7) 6,730 (27.1)  Nap
 70+ (No.,%) 351 (56.7) 15,329 (61.8)  Nap
Smoking history
 no smoking (reference) 43 (6.9) 2,510 (10.1) Reference
 current smoking 260 (42.0) 9,361 (37.7) 1.59 (1.14-2.21)
 past smoking 27 (4.4) 1,896 (7.6) 0.89 (0.54-1.45)
 smoking unspecified 289 (46.7) 11,033 (44.5) 1.46 (1.05-2.03)
 passive smoking 0 (0.0) 20 (0.10) NA
Severity at cohort entry
 mild (GOLD I) 67 (10.8) 5,648 (22.8) Reference
 moderate (GOLD II) 155 (25.0) 12,503 (50.4) 1.03 (0.77-1.34)
 severe (GOLD III) 344 (55.6) 6,305 (25.4) 4.75 (3.64-6.21)
 very severe (GOLD IV) 53 (8.6) 358 (1.4) 12.2 (8.33-18.0)
Co-morbidity /history
 History of asthma 117 (18.9) 3,355 (13.5) 1.37 (1.10-1.68)
 History of myocardial infaction 60 (9.7) 2,346 (9.5) 1.17 (0.89-1.54)
 Angina pectoris 134 (21.6) 4,444 (17.9) 1.33 (1.09-1.63)
 Ischemic heart disease 24 (3.9) 1,044 (4.2) 1.01 (0.67-1.54)
 History of stroke or TIA 52 (8.4) 2,140 (8.6) 0.98 (0.73-1.32)
 Peripheral arterial disease 71 (11.5) 2,175 (8.8) 1.36 (1.05-1.75)
 Heart failure 181 (29.2) 3,759 (15.1) 2.56 (2.11-3.09)
 Ventricular arrhythmia 57 (9.2) 2,559 (10.3) 0.88 (0.67-1.17)
 Hypertension 145 (23.4) 6,319 (25.5) 0.88 (0.73-1.06)
 Hyperlipidemia (TC>5) 174 (28.1) 8,584 (34.6) 0.78 (0.65-0.94)
 Diabetes mellitus 103 (16.6) 3,595 (14.5) 1.22 (0.98-1.51)
 Renal insufficiency 34 (5.5) 1,029 (4.1) 1.46 (1.02-2.10)
 History of malignancy 109 (17.6) 3,633 (14.6) 1.27 (1.03-1.58)
 Pneumonia 152 (24.6) 3,053 (12.3) 2.29 (1.89-2.77)
 Parkinsonism 3 (0.5) 90 (0.4) 1.19 (0.37-3.80)
 Depressive disorders 71 (11.5) 2,004 (8.1) 1.31 (1.02-1.69)
 Dementia 0 (0.0) 128 (0.5) NA
 Number of GP visits (mean, SD) 7.8 (±6.3) 5.7 (±4.7) 1.07 (1.06-1.08)
 Home bound lifestyle 26 (±4.2) 221 (±0.9) 4.83 (3.15-7.40)
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β-blockers was 0.73, 95%CI 0.60-0.90, which is similar to the estimates provided by Rutten et 
al.
In the case control study in the COPD cohort (analysis 2) current use of β-blockers seemed 
to reduce the risk of COPD exacerbation requiring hospitalizations (table 4). No clear dose-
response relationship was observed. In the third analysis that controlled most strictly for con-
Table 2(b) Patients characteristics for cases (COPD exacerbations requiring hospitalization) and controls
Outcome = COPD Exacerbation requiring hospitalization
Cases No. (%) Controls No. (%) Matched OR* (95%CI)
Previous use of drugs
Central nervous system drugs
 Opioids 40 (6.5) 615 (2.5) 2.59 (1.85-3.63)
 Hypnotics and sedatives 96 (15.5) 2,524 (10.2) 1.54 (1.23-1.94)
 Anxiolytics 83 (13.4) 2,206 (8.9) 1.49 (1.18-1.90)
 Antipsychotics (typical, atypical) 3 (0.5) 204 (0.8) 0.61 (0.19-1.92)
 Antidepressants (SSRI) 31 (5) 755 (3) 1.51 (1.04-2.19)
 Antiepileptic drugs 8 (1.3) 357 (1.4) 0.87 (0.43-1.76)
 Anticholinergic drugs (except respiratory) 19 (3.1) 608 (2.4) 1.25 (0.78-1.99)
Drugs affecting cerebrovascular and cardiovascular dx
 Nitrates 52 (8.4) 1,481 (6.0) 1.43 (1.06-1.92)
 Platelet inhibitors 118 (19.1) 4,749 (19.1) 1.08 (0.88-1.33)
 Anti-arrhythmics 6 (1.0) 432 (1.7) 0.65 (0.29-1.45)
 Anti-hypertensives (β-blocker excluded) 555 (53.8) 16,259 (40.0) 1.69 (1.48-1.92)
 Corticosteroids (systemic): 207 (33.4) 2,044 (8.2) 5.93 (4.97-7.09)
 Estrogens 16 (2.6) 366 (1.5) 1.18 (0.70-1.99)
 Antibiotics 147 (23.7) 2,030 (8.2) 3.50 (2.89-4.25)
 NSAIDs 35 (5.7) 1,834 (7.4) 0.73 (0.52-1.03)
 Diuretics 181 (29.2) 4,980 (20.1) 1.66 (1.38-1.99)
 Vitamin K antagonists 56 (9.0) 2,013 (8.1) 1.20 (0.90-1.59)
 Lipid lowering drugs 60 (9.7) 2,862 (11.5) 0.87 (0.66-1.15)
Other respiratory drugs
 Antihistaminics 18 (2.9) 758 (3.1) 0.92 (0.57-1.47)
 Mucolytics 105 (17.0) 1,454 (5.9) 3.52 (2.82-4.39)
 Cough suppressants 17 (2.7) 472 (1.9) 1.46 (0.89-2.38)
 Anticholinergics 100 (16.2) 1,109 (4.5) 4.67 (3.56-6.14)
 Systemic β2 agonists 3 (0.5) 77 (0.3) 1.62 (0.50-5.21)
 Leukotriene receptor antagonists 15 (2.4) 137 (0.6) 4.58 (2.63-7.97)
 Inhaled β2 agonists 379 (61.2) 9,635 (38.8) 2.53 (2.15-2.99)
 Inhaled corticosteroids 274 (44.3) 8,718 (35.5) 1.50 (1.28-1.77)
 Xanthines 44 (7.1) 636 (2.6) 3.27 (2.37-4.52)
*matched on age, gender and indexdate
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Table 3 Crude and adjusted risk ratios for COPD exacerbations requiring hospitalization according to β-blocker 
use in patients with COPD according to the design by Rutten et al.
Variable Any β-blocker
Cardioselective 
β-blocker
Nonselective β-blocker
IPCI data
Unadjusted (crude) 0.77 (0.63-0.93) 0.75 (0.61-0.93) 0.90 (0.64-1.27)
Covariates included in Cox model for HR +
 Age 0.72 (0.59-0.88) 0.72 (0.58-0.89) 0.85 (0.60-1.20)
 Sex 0.72 (0.59-0.88) 0.72 (0.58-0.89) 0.85 (0.60-1.20)
 Smoking 0.72 (0.59-0.88) 0.72 (0.58-0.89) 0.84 (0.59-1.18)
 Diabetes, hypertension, cardiovascular diseases 0.70 (0.57-0.85) 0.69 (0.56-0.86) 0.83 (0.56-1.17)
 Cardiovascular drugs other than β-blockers 0.68 (0.56-0.83) 0.68 (0.54-0.85) 0.82 (0.58-1.16)
 Respiratory drugs 0.71 (0.58-0.87) 0.71 (0.57-0.88) 0.85 (0.60-1.19)
GP visits 0.69 (0.57-0.85) 0.69 (0.56-0.87) 0.83 (0.59-1.17)
Referral to a pulmonologist 0.73 (0.60-0.90) 0.74 (0.54-0.92) 0.84 (0.59-1.18)
Estimates by Rutten et al. (reference)
Crude 0.73 (0.63-0.83) 0.75 (0.65-0.87) 0.72 (0.57-0.90)
Fully adjusted 0.71 (0.60-0.83) 0.78 (0.66-0.92) 0.74 (0.58-0.94)
Table 4 Association between use of β-blockers (no use as reference category) and COPD exacerbations requiring 
hospitalization using a nested case control design in a cohort of COPD patients
β-blocker use
Cases n=619 
(%)
Controls 
n=24,820 (%)
Matched OR (95%CI) Adjusted OR* (95% CI)
No use of β-blocker* 496 (80.1) 18,599 (74.9) reference reference
Current use of β-blocker 51 (8.2) 3,002 (12.1) 0.64 (0.47-0.85) 0.60 (0.44-0.82)
 Recent start (<= 1 month) 2 (0.3) 82 (0.3) NA NA
 Non-recent start (> 1 month) 49 (7.9) 2,920 (11.8) 0.63 (0.46-0.84) 0.58 (0.42-0.80)
Dosage
 PDD ≤ 0.5 (low) 26 (4.2) 1,426 (5.7) 0.69 (0.46-1.02) 0.58 (0.38-0.88)
 PDD > 0.5 (moderate-normal) 25 (4.0) 1,576 (6.3) 0.59 (0.39-0.89) 0.62 (0.41-0.96)
Type of β-blocker
 Cardioselective no switching 33 (5.3) 2,215 (8.9) 0.54 (0.38-0.81) 0.49 (0.34-0.72)
 Cardioselective with switching 4 (0.6) 144 (0.6) 1.03 (0.38 – 2.82) 0.89 (0.31-2.56)
 Non-Cardioselective no switching 11 (1.8) 602 (2.4) 0.79 (0.43-1.44) 0.78 (0.42-1.46)
 Non-Cardioselective with 
switching
1 (0.2) 59 (0.2) NA NA
 Combination 2 (0.3) 24 (0.1) NA NA
Past use of β -blockers 72 (11.6) 3,219 (13.0) 0.81 (0.63-1.04) 0.76 (0.58-0.99)
*adjusted for smoking, COPD severity, duration COPD, GP visits, angina, heart failure, diuretics, xanthines 
(covariates assessed at index date)
NA: not assessable as less than 3 exposed cases
Ana BW 4.indd   119 03-03-11   12:30
120
Table 5 Association between use of β-blockers (past use as reference category) and COPD exacerbations 
requiring hospitalization using a nested case control design in a cohort of COPD patients who received a 
β-blocker prescription during follow-up
β-blocker use Cases n=90 (%)
Controls n=5,121 
(%)
Matched OR 
(95%CI)
Adjusted OR* 
(95% CI)
Past use of β-blocker* 39 (43.3) 2,110 (41.3) Reference Reference
Current use of β-blocker 51 (56.7) 3,002 (58.7) 0.96 (0.61-1.51) 0.87 (0.52-1.45)
 Recent start (<= 1 month) 2 (2.2) 82 (1.6) NA NA
 Non-recent start (> 1 month) 49 (54.5) 2,920 (57.1) 0.95 (0.60-1.50) 0.86 (0.51-1.44)
Dosage
 PDD ≤ 0.5 (low) 26 (28.9) 1,426 (27.9) 1.01 (0.58-1.75) 0.84 (0.46-1.55)
 PDD > 0.5 (moderate-normal) 25 (27.8) 1,576 (30.8) 0.91 (0.53-1.57) 0.90 (0.48-1.69)
Type of β-blocker
 Cardioselective no switching 33 (36.7) 2,215 (43.3) 0.84 (0.51-1.40) 0.72 (0.41-1.29)
 Cardioselective with switching 4 (4.4) 144 (2.8) 1.05 (0.30-3.66) 1.41 (0.32-6.15)
 Non-Cardioselective no switching 11 (12.2) 560 (11.0) 1.24 (0.60-2.61) 1.19 (0.52-2.76)
 Non-Cardioselective with switching 1 (1.1) 59 (1.2) NA NA
 Combination 2 (2.2) 24 (0.5) NA NA
Patients without heart failure
Cases n=57 (%)
Controls n=3,912 
(%)
Matched OR 
(95%CI)
Adjusted OR* 
(95% CI)
Past use of β-blocker* 20 (35.1) 1,558 (39.8) Reference Reference
Current use 37 (64.9) 2,354 (60.2) 1.32 (0.71-2.47) 1.13 (0.55-2.33)
Type of β-blocker
 Cardioselective no switching 23 (40.3) 1,750 (44.7) 1.11 (0.57-2.19) 0.86 (0.38-1.96)
 Cardioselective with switching 3 (5.3) 110 (2.8) 1.39 (0.28-6.89) 2.64 (0.36-19.1)
 Non-Cardioselective no switching 8 (14.0) 437 (11.2) 1.80 (0.69-4.68) 1.80 (0.62-5.29)
 Non-Cardioselective with switching 1 (1.8) 35 (0.9) NA NA
 Combination 2 (3.5) 22 (0.6) NA NA
Patients with heart failure
Cases n=33 (%)
Controls n=1,200 
(%)
Matched OR 
(95%CI)
Adjusted OR* 
(95% CI)
Past use of β-blocker* 19 (57.6) 552 (46.0) Reference Reference
Current use 14 (42.4) 648 (54.0) 0.39 (0.15-1.02) 0.15 (0.03-0.80)
Type of β -blocker
 Cardioselective no switching 10 (30.3) 465 (38.7) 0.40 (0.14-1.12) 0.12 (0.02-0.82)
 Cardioselective with switching 1 (3.0) 34 (2.8) NA NA
 Non-Cardioselective no switching 3 (9.1) 123 (10.3) 0.38 (0.07-2.05) 0.19 (0.01-3.85)
 Non-Cardioselective with switching 0 (0) 24 (2.0) NA NA
 Combination 0 (0) 2 (0.2) NA NA
*adjusted for smoking, COPD severity, duration COPD, GP visits 4 weeks prior to BB, duration BB, depression, 
hypnotics and sedatives, corticosteroids, diuretics
NA: not assessable as less than 3 exposed cases
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Chapter 4.5: β-blockers and the risk of severe COPD exacerbation in patients with COPD
founding by contra-indication current use of β-blockers was not associated with a significant 
reduced risk of exacerbations (ORadj 0.87, 95% CI 0.52-1.45). Only in patients with co-existing 
heart failure, the protective effect of β-blockers remained (ORadj 0.15, 95% CI 0.03-0.80), very 
small in terms of numbers (table 5).
Discussion
In this observational study we demonstrated that studying the effect of β-blocker use on 
the risk of severe COPD exacerbations is highly dependent on design choice. Confounding 
is very strong; the protective effect disappeared when limiting the analysis to patients ever 
prescribed a β-blocker, comparing current use of a β-blocker to past use, although in heart 
failure patients still some effect was observed.
COPD is a chronic condition with systemic manifestations including cardiovascular diseases 
[194]. In patients with COPD, right heart failure – the so called cor pulmonale, is common, 
especially in patients with more severe COPD but the evidence on the association between 
COPD and left heart failure is less convincing. Overlapping sigs and symptoms complicated 
the diagnosis of heart failure in COPD. In addition, it is very difficult to distinguish acute COPD 
exacerbations from symptoms related to decompensated heart failure. As we hypothesize that 
COPD patients with or without heart failure consist of a totally different population group with 
differences in treatment response and outcomes, we stratified our analysis in COPD patients 
with or without co-existing heart failure at the time of the index date. Our final data showed 
that β-blockers significantly reduced the risk of severe COPD exacerbations in patients with 
co-existing heart failure but not in COPD patients without heart failure. These findings might in 
part be explained by misclassification of the outcome, where GPs or specialists label the event 
as being a COPD exacerbation whereas the underlying symptoms of cough and breathlessness 
are probably related to decompensated heart failure. Apart from the difficulties to distinguish 
acute COPD exacerbations from decompensated heart failure, decompensated heart failure 
might trigger COPD exacerbation through congestion of the lung parenchyma. In contrast to 
our findings, Rutten et al. did not observe a difference in risk estimate for COPD exacerbation 
in patients with or without underlying cardiovascular disease. It should be noted however that 
Rutten et al. grouped all cardiovascular diseases together namely angina pectoris, myocardial 
infarction, coronary artery bypass grafting, percutaneous coronary intervention, atrial fibrilla-
tion, heart failure, peripheral arterial disease, stroke or diabetes whereas the protective effect of 
β-blockers on mortality has only been described for patients with co-existing heart failure [195].
Our data showed that the risk of COPD exacerbations was mainly reduced in patients using 
cardioselective β-blockers, both in patients with or without heart failure. These findings are in 
line with studies that have shown that cardioselective β-blockers can be safely used in COPD 
patients with heart failure, as they do not alter pulmonary function on the short term [196].
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In contrast to the study by Rutten et al., we did not only conduct a Cox regression analysis, 
but also analyzed our data via a case-control approach. This case-control design not only 
reduces misclassification of exposure through time-varying exposure assessment but also 
tackles the issue of immortal time bias [197]. The cohort analysis conducted by by Rutten et 
al. suffered from immortal time as β-blocker exposed COPD patients who received β-blockers 
during follow-up; by definition have an event free survival starting from cohort-entry until 
the time of first prescription. Our first case-control analysis showed that taking out immortal 
time bias did not adequately control for all potential distortions, such as confounding as the 
strong protective effect remained. This effect of β-blockers attenuated in our second case-
control analysis when using past use as reference category. This shows that confounding by 
contra-indication is strong. In patients with COPD, β-blockers are probably only prescribed to 
patients with a better pulmonary function and thus less at risk of COPD exacerbation.
As for all observational studies, our study has strengths, but also limitations. The main 
strengths are the size and quality of our data. Great emphasis was put on the assessment of 
COPD, and the disease severity and endpoints that were all manually validated by at least 2 
medically trained persons. Being observational, the study is sensitive to bias and confound-
ing. We tried to adjust for COPD severity as much as possible, by assessing COPD sever-
ity longitudinally, which allowed for flexibility in the timing for adjustment. Despite these 
measures, remaining confounding by indication and/or contraindication, including severity 
might still be an issue. Conducting a sensitivity analysis comparing current use of β-blockers 
to past use further controlled for this remaining confounding by underlying COPD severity. In 
the overall analysis, the protective effect of current use of β-blockers disappeared and could 
only be observed in the sub-set of COPD patients with co-existing heart failure. To control for 
misclassification of the outcome we conducted a broad search and used a strict validation 
algorithm. In addition, two medically trained researchers who were blinded to the exposure 
and were unaware of the research hypothesis validated all endpoints. In case of doubt, a 
third medically trained person overruled the validation. Due to the nature of the database, 
exposure was based on prescription data rather than on actual drug intake. In chronic dis-
eases like COPD, we might have missed prescriptions initiated by the specialist. To study the 
potential of exposure bias, we conducted a sensitivity analysis, stratifying on patients seen 
by the GP only. For this group of patients, all prescriptions are available in the database - the 
results within this stratum were similar to the results of the overall dataset suggesting that 
exposure bias is minimal.
To conclude, we found that β-blockers may have some protective effect on exacerbations 
in patients with COPD, but due to the confounding and potentially biases utmost care should 
be taken in designing studies addressing this question.
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Chapter 5: General Discussion
Background
Chronic obstructive pulmonary disease (COPD) is a leading and still-increasing cause of 
chronic morbidity and mortality worldwide [3]. Chapman et al. [80] and Mannino et al. [15] 
projected that in 2020, COPD will become the third most common cause of death worldwide. 
Over the last decades, many interesting studies on the epidemiology of COPD have been 
published. Some of the epidemiology data were based on results from cross-sectional stud-
ies. These studies are often debated due to limitations in their design, including the impos-
sibility to distinguish between cause and effect in the association between an exposure and 
disease, the often-unequal distribution of confounding factors between the groups being 
compared, and errors in the recall of exposures in patients with the disease. 
Alternatively, the “gold standard”, randomized controlled trials (RCTs), also present weak-
nesses. They are often expensive and cumbersome to perform, have a short follow-up time 
and regularly use surrogate endpoints, rather than clinical outcomes, and involve a limited 
number of highly selected participants, which may hinder the extrapolation of the results into 
clinical practice [198]. Observational database studies include a large representative sample 
of the general population and often have a long duration of follow-up. These characteristics 
make these studies well suited to study the epidemiology and management of COPD, and to 
explore the effectiveness and safety of respiratory drugs under real life circumstances.
The aims of the studies described in this thesis were 1) to study the epidemiology of COPD, 
and 2) to explore the effectiveness and safety of drugs given for the treatment of COPD, using 
data from the Integrated Primary Care Information (IPCI) project, a general practitioners (GP) 
database in the Netherlands. For this research, we defined three different cohorts of COPD. 
I) For the study on the association between the use of inhaled anticholinergic drugs and 
the risk of acute urinary retention; COPD was defined based on the presence of ICPC codes 
specific to COPD (ICPC R95 or R91), a diagnosis of COPD as free text and/or the use of at least 
2 bronchodilating drugs during follow-up (chapter 4.2). II) For the studies on the a) epide-
miology of COPD, b) the effectiveness study and the c) safety studies of tiotropium and the 
use of β-blockers in patients with COPD, we used data from 2000-2007 and defined a cohort 
of COPD patients based on a broad automated search on COPD specific ICPC codes and free 
text. All potential COPD patients were manually validated based on a strict algorithm. Of all 
potential COPD patients, only 6,788 remained: (chapters 2, 3, 4.3, 4.4 and 4.5). III) Finally, to 
study the association between the use of tiotropium Respimat® vs. tiotropium HandiHaler® 
and risk of dying, we defined a cohort of tiotropium users (either tiotropium Respimat® or 
tiotropium HandiHaler®). The study period ran from 2000 to 2010. Within this cohort, COPD 
was defined as a patient characteristic based on the presence of COPD specific ICPC codes 
(ICPC R95 or R91) or a free text search on “COPD” or “emphysema” (chapter 4.1).
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In this discussion, the most important findings are summarized and the study setting and 
related methodological considerations are clarified. In addition, the clinical implications of 
this research and potential directions for future research are discussed.
Main findings
I) Epidemiology: Prevalence, incidence and mortality of COPD
Since 2002, large-scale epidemiologic studies on COPD, such as the Latin America Project 
for the Investigation of Obstructive Lung Disease (PLATINO) [12] and the worldwide project 
namely Burden of Obstructive Lung Diseases (BOLD) [11], have provided better estimates of 
the prevalence of COPD in different countries. Only few studies investigated the incidence of 
COPD and its related mortality.
In chapter 2 we describe the prevalence, incidence, mortality and lifetime risk of COPD as a 
function of age and sex in the general population.
In our population-based cohort study in the general Dutch population of 40 years and 
older and registered in the IPCI database, we identified 7,308 COPD patients, including 1,713 
(23%) incident cases. The overall prevalence of COPD was 3.02% (95%CI 2.94-3.10%). The 
prevalence estimates were higher in men than in women, and rose progressively with age 
until the age of 81 years in men and 83 years in women.
The overall incidence rate (IR) of diagnosed COPD was 2.92/1,000 person-years (PY). Similar 
to the prevalence pattern, the IR was higher in men than in women (with a relative risk (RR) 
of 1.5 in men). The incidence rate increased almost 10-fold from 0.78/1,000PY at the age 
of 40-44 to 6.82/1,000PY at the age of 75-79. Other studies investigated the incidence and 
prevalence of COPD as well, using data from healthcare databases [22-24]. The most recent 
Canadian study on the incidence of COPD reported higher rates of incidence and prevalence 
(even after standardization) [24]. Our COPD incidence rate and prevalence can be compared 
to other Dutch data, namely data from the Rotterdam Study, a population based prospective 
cohort study with spirometry data and medical records. The overall COPD incidence rate in 
the Rotterdam study was 9.2/1,000PY. Our age standardized rate was 35% lower showing the 
level of under-diagnosis due to lack of systematic spirometry data in clinical practice [17]. Our 
IR is in line with results from the United Kingdom General Practitioners Research Database 
(GPRD), a general practitioner medical record based system, which is similar to IPCI. In GPRD 
the overall incidence rate (40-89 years) was 2.6/1,000PY.
Based on our data, the risk to be diagnosed with COPD in the coming 40 years was 12.7% 
for a 40-year-old man and 8.3% for a 40-year-old woman – assuming that COPD diagnostic 
work-up and awareness would remain similar. Mortality was high, especially in very severe 
COPD patients. In very severe COPD patients, the one-year mortality risks were nearly 10-fold 
that of non-COPD subjects of the same age. Mortality rates were 2.0-fold higher for COPD 
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patients than for the age and sex matched reference population, and increased with COPD 
severity. Our mortality rate of 6.1% in COPD patients is much in line with the data from So-
riano et al. [28], who reported an overall death rate of 8.5% per year, and Gershon et al. [24], 
who described mortality rates between 5.7% in 1996 and 4.3% in 2007.
II) Effectiveness: Risk of COPD exacerbations requiring hospitalization in COPD patients 
treated with tiotropium versus LABA
In chapter 3 we compared the effectiveness of tiotropium to that of long-acting β2-agonists 
(LABA) in the prevention of hospitalization for COPD exacerbation in clinical practice.
In a cohort of 6,788 COPD patients from the IPCI database, 619 patients were hospitalized 
for a COPD exacerbation during the follow-up period. In this cohort we demonstrated that 
tiotropium reduced the risk of COPD exacerbations leading to hospitalizations in COPD pa-
tients as compared to LABA (ORadj 0.69; 95%CI 0.40-1.19). Most of the published RCTs have 
shown that both LABA and tiotropium were efficacious in reducing the risk of hospitaliza-
tion related to COPD compared to placebo with risk estimates around 0.70 [68, 70, 71, 107, 
131]. Only few RCTs compared the effect of long-acting bronchodilators on intermediate 
or surrogate endpoints. The few RCTs who did, reported that tiotropium is more effective 
than LABA in preventing COPD exacerbations, which is in line with our findings [72, 73, 131].
III) Safety studies
1) Mortality in tiotropium users by type of formulation
In the past, use of tiotropium HandiHaler® has been associated with an increased risk of dying 
and cardio-cerebro vascular events. In 2010, based on data from the UPLIFT study, the FDA 
revised their safety warning on the use of tiotropium HandiHaler®, stating that “the available 
data did no longer support an association between the use of tiotropium HandiHaler® and 
an increased risk of stroke, heart attack or death from cardiovascular causes” [120]. As the 
UPLIFT study only included a treatment regimen of tiotropium HandiHaler® versus placebo, 
the current available data does not allow drawing strong conclusions on the risk of mortality 
in patients treated with tiotropium Respimat® SMI. In their communication to the FDA, Boeh-
ringer Ingelheim, the manufacturer of tiotropium, reported an increased risk of mortality 
with tiotropium Respimat® SMI device based on unpublished data from 3 one-year placebo 
controlled trials [120]. These facts triggered us to conduct an observational study on the risk 
of dying in users of tiotropium Respimat® SMI versus HandiHaler®. (chapter 4.1)
Within an IPCI source population of patients, 40 years or older, we defined a cohort of 11,753 
tiotropium users. 272 patients died while being exposed to either tiotropium HandiHaler® or 
Respimat® SMI. Use of tiotropium Respimat® SMI, compared to tiotropium HandiHaler®, was 
not associated with an increased risk of dying with a HRadj of 1.21 (95%CI 0.85-1.73). Upon 
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stratification by cause of death, use of tiotropium Respimat® SMI was not associated with an 
increased risk of cardiovascular and cerebrovascular death (HRadj 0.97, 95%CI 0.46-2.04). 
2) Risk of acute urinary retention, renal failure, cardiovascular events and all cause mortality 
associated with the use of tiotropium
So far, tiotropium is the only long-acting inhaled anticholinergic bronchodilator, which can 
be used once daily for long-term maintenance treatment of COPD. The efficacy and safety of 
tiotropium have been demonstrated in several RCTs including RCTs with active comparisons 
such as ipratropium and LABA [60, 61, 63-71, 107, 131, 154], with imprecise reductions ob-
served for mortality [131], reduced risk for cardiovascular events [68], and strong associations 
for unintended adverse events such as dry mouth and urinary retention [68, 70]. Safety data 
from RCTs hamper external validity as RCTs use stringent inclusion and exclusion criteria. 
Also, sample size and time of follow-up is often limited which reduces the chance to detect 
rare safety issues or long-term events. Observational studies offer the advantage to explore 
the safety of drugs in real life but few observational studies on tiotropium have been con-
ducted so far.
A) In chapter 4.2) we investigated the association between use of inhaled anticholinergic 
drugs and the risk of acute urinary retention (AUR). Case series and RCTs reported on the 
risk of AUR in patients treated with inhaled anticholinergic drugs, but this association had 
never been quantified. Within a cohort of 22,579 COPD patients, 45 years or older, 209 cases 
of AUR were indentified. Use of inhaled anticholinergic drugs increased the risk of AUR with 
40% (ORadj 1.40, 95%CI, 1.21-7.98). The risk was the highest in recent starters, in men with be-
nign prostatic hyperplasia (BPH) (ORadj 4.67, 95%CI, 1.56-14.0) and in those using nebulizers 
(ORadj 2.92, 95%CI, 1.17-7.31). Moreover, there were no differences in the risk of AUR between 
tiotropium and ipratropium (ORadj 1.55, 95%CI, 0.80-3.00 and ORadj 1.37, 95%CI, 0.96-1.98, 
respectively).
B) In 2009, data from a pooled analysis on the safety of tiotropium reported the occur-
rence of renal failure related to the use of tiotropium against placebo [154]. In chapter 4.3) 
we conducted a nested-case control study in the thoroughly validated COPD cohort of 6,788 
patients (see chapter 3) to compare the risk of renal failure, in patients treated with tiotro-
pium compared to no use or to the use of inhaled β2-agonists. Within our COPD cohort, 83 
new cases of renal failure were identified. We did not observe an increased risk of renal failure 
(either acute or chronic) in patients currently using inhaled anticholinergic drugs, ORadj 0.78, 
95%CI 0.43-1.42 (compared to no use of anticholinergic drugs), and ORadj 1.42, 95%CI 0.57-
3.54 (compared to current use of β2-agonists). When stratifying between acute renal failure 
and chronic kidney disease, the risk of chronic kidney disease increased in current users of 
anticholinergics, using current use of β2-agonists as reference (ORadj 1.77, 95%CI 0.67-4.66), 
but this association was  not statistically significant. Based on animal models, human studies, 
and a few case reports on renal failure in patients treated with tiotropium, we hypothesized 
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on the association between the use of inhaled anticholinergic drugs and the risk of renal 
failure, which could not be confirmed by our data. As acetylcholine is important for the pres-
ervation of renal blood flow, it seems plausible that inhibition of renal blood flow, through 
anticholinergic drugs, might increase the risk of renal failure. Further research on this topic 
might be warranted preferably not only considering inhaled anticholinergic drugs and also 
stratifying between acute renal failure and chronic kidney disease.
C) In 2008, concerns were raised on the cardiovascular and cerebrovascular safety of tiotro-
pium. These concerns were based on 1) a report to the FDA, issued by Boehringer Ingelheim, 
the manufacturer of tiotropium, on pooled data from 29 placebo-controlled trials showing 
an increased risk of stroke in patients treated with tiotropium, and 2) a meta-analysis and 
case-control study reporting an increased risk for mortality and/or cardiovascular events in 
patients who received inhaled anticholinergics (ipratropium or tiotropium) [112, 118, 119]. In 
January 2010, the FDA warning on the use of tiotropium HandiHaler® was overruled, based 
on data from the UPLIFT study and updated meta-analysis (including data from the UPLIFT 
study), stating that the available data did no longer support an association between the 
use of tiotropium HandiHaler® and an increased risk of stroke, heart attack or death from 
cardiovascular causes [120]. Very few observational studies that investigated the association 
between the use of tiotropium and risk of cardiovascular events are generated from data 
from RCTs. In chapter 4.4) we describe the cardiovascular safety and risk of mortality in 
patients with COPD using tiotropium compared to LABA, under real life circumstances, using 
data from our cohort of validated COPD patients. Within our COPD cohort of 6,788 patients, 
784 new cases of a cardiovascular endpoint (254 cases of stroke and transient ischemic attack 
(TIA), 116 cases of myocardial infarction, 413 cases of heart failure and 6 cases of ventricular 
arrhythmia) were identified, and 1,032 patients died during follow-up. We did not observe 
an increased risk for cardiovascular endpoint and/or mortality in patients currently treated 
with tiotropium compared to no use. Compared to LABA, current use of triotropium was not 
associated with an increased risk of a cardiovascular endpoint (ORadj 0.89, 95%CI 0.55-1.44) 
neither with an increased risk of death (ORadj 0.79, 95%CI 0.49-1.22).
3) Risk of COPD exacerbations requiring hospitalization in patients treated with β-blockers
Treatment with cardiovascular drugs, especially the use of β-blockers is known to improve 
the survival of patients with a large spectrum of cardiovascular diseases, including heart fail-
ure [184]. The traditional belief states that β-blockers are contra-indicated in COPD because 
of their presumed broncho-constrictive properties and their competition with β2-agonists 
[185], which leads to lower prescription rates in COPD patients [186]. However, COPD as 
contra-indication for the use of β-blockers is currently revisited as β-blockers could actually 
have beneficial effects in patients with COPD through tempering of the sympathetic nervous 
system or by reducing the ischemic burden [187]. More recently, Rutten et al. showed that 
β-blockers might reduce the risk of exacerbations and improve survival in patients with 
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COPD, possibly as a result of dual cardiopulmonary protective properties [191]. The study 
from Rutten et al. suffered from major methodological weaknesses such as immortal time 
bias and residual confounding. For this reason, we investigated the association between the 
use of β-blockers and risk of COPD exacerbation requiring hospitalization, first by mimicking 
the study of Rutten et al., using a fixed cohort approach with immortal time bias. Subse-
quently we conducted two nested-case control studies. The first case-control approach 
eliminated the issue of immortal time bias and in the second case-control study, we only 
considered COPD patients ever exposed to β-blocker to deal with confounding by indication 
(or contra-indication). Results of these analyses are described in chapter 4.5) Within the COPD 
cohort, 619 patients were hospitalized for a COPD exacerbation. When mimicking the analy-
sis of Rutten et al., current use of β-blockers significantly reduced the risk of severe COPD 
exacerbations (HRadj 0.73, 95%CI 0.60-0.90). In the case-control analysis, we found that the 
use of β-blockers reduces the risk of severe COPD exacerbations by 40% (ORadj 0.60, 95%CI 
0.44-0.82). When controlling for confounding-by-indication, the protective effect was greatly 
attenuated (ORadj 0.87, 95%CI 0.52-1.45). However, in patients with co-existing heart failure, a 
significant protective effect was still observed (ORadj 0.15, 95%CI 0.03-0.80) but the numbers 
became very low. 
Methodological considerations
Population based COPD research
For all studies in this thesis, data was obtained from the Integrated Primary Care Information 
(IPCI) database that contains information from computer-based records of more than 400 GPs 
in the Netherlands. The anonymized medical records of approximately one million patients 
registered with GPs consist of detailed data on patient demographics, symptoms, diagnosis, 
lab results, referrals, drug prescription and hospitalizations [86, 91]. The IPCI database is 
representative for the Dutch population regarding age and sex. In the Netherlands, GPs act 
as gatekeepers for secondary care [87]. Consequently, their records can be considered to hold 
most relevant medical information about a patient. No paper records are being kept by GPs 
participating in the project except for hardcopy specialist letters, which can be requested for 
the case validation process. IPCI has been used and proven valid for pharmacoepidemiologi-
cal research [199].
Using data from the IPCI project was essential to study the epidemiology of COPD for the 
following reasons. First of all, we had access to a very large population of COPD patients that 
were followed over time. Furthermore, as the IPCI project contains the complete medical 
records of all patients, it gave us good insight into the patient’s characteristics, comorbidity 
and treatment of patients with COPD. However, as data was collected in relation to routine 
primary care, some information such as COPD severity was often incomplete. In addition, 
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not all data in the IPCI database was coded which made the case identification, through free 
text validation very labor-intensive. Finally, as the IPCI database is not linked to a pharmacy 
database, we did not have information on drug dispensing. Neither did we have information 
on “over-the-counter” drug use or actual drug intake [200]. This implies that we might have 
under- or overestimated the pharmacological treatment.
IPCI COPD cohorts
For this research, we defined three different cohorts. I) The first cohort of COPD patients was 
defined, between 1996 and 2006, to study the association between inhaled anticholinergic 
drugs and the risk of acute urinary retention (AUR). In this cohort of 22,579 patients - ≥ 45 
years - with COPD (both incident and prevalent), a patient was considered to have COPD 
if there was a coded diagnosis for COPD (International classification of primary care (ICPC) 
R95 or R91), a diagnosis of COPD in the narratives (free text search) or the use of at least two 
bronchodilating drugs during follow-up [137]. Disease severity was defined by the algorithm 
of Ernst et al. [75] (chapter 4.2). II) The second cohort was later defined, with a study period 
between 2000 and 2007. A cohort of patients - ≥ 40 years - with potential COPD was defined 
based on information from diagnoses and narratives. All potential cases were then classified 
in definite COPD - diagnosis by a specialist or a GP diagnosis confirmed by spirometry (FEV1/
FVC<70%); probable COPD - diagnosis by the GP with at least two records of COPD within 
one year of the first record of COPD. All doubtful COPD patients were further reviewed and 
classified by a pulmonologist (GB). And this led to two different cohorts: in chapters 3, 4.3, 4.4 
and 4.5, we had 6,788 definite COPD patients, and in chapter 2, 7,308 definite COPD patients, 
as 520 doubtful cases were later revised and included as definite COPD patients. In addi-
tion, patients were classified as prevalent COPD if they had a COPD diagnosis prior to entry 
in the source population; and were classified as incident COPD if they were disease free at 
time of start, and later developed COPD. III) In chapter, 4.1 a third - tiotropium - cohort was 
defined. All patients who received a prescription for tiotropium between 2000 and 2010 were 
included. This cohort differed from the previously described ones, as for reasons of power, we 
considered all prescriptions of tiotropium, irrespective of indication of use. Co-existing COPD 
was considered a separate variable in the analysis.
Within these 3 COPD cohorts, COPD severity was assessed based on the GOLD criteria, for 
patients having data on lung function, or based on proxies based on published algorithms 
for the validation of COPD severity.
Study design
Our research on the epidemiology and treatment effects of COPD applied descriptive and 
analytical epidemiological techniques. Descriptive epidemiological studies focus on the 
occurrence of a disease in a population [201] and thus this method we used to study the 
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incidence, prevalence and lifetime risk of COPD in the general population and to study the 
risk of dying in patients with COPD.
If the aim of the research is to investigate the determinants or risk factors of the disease, 
analytical epidemiological designs are used [201, 202]. Analytical studies can be divided into 
observational or intervention studies (clinical trials). In observational studies, the natural 
course of events are studied through case-control or cohort designs [200]. Both designs were 
used in our research.
Cohort study
In cohort studies, subjects are classified on the basis of the presence of exposure to a particu-
lar factor and then followed for a specific period of time to determine the development of 
disease in each exposure group.
Using data from the IPCI database, we retrospectively defined a disease cohort of COPD 
patients to study the incidence and prevalence of COPD and, it’s related mortality. Within 
this cohort, we studied the hazard ratio of COPD exacerbations requiring hospitalization in 
patients exposed to β-blockers versus non-exposed patients. Finally we defined a cohort of 
tiotropium users (either tiotropium HandiHaler® or tiotropium Respimat® SMI) to study the 
association between the use of tiotropium Respimat® SMI and risk of dying, using tiotropium 
HandiHaler® as reference category.
Case-control study
In a case-control study, a group of patients who have the outcome of interest and a control 
group of individuals without the outcome at the time of case occurrence are studied, and 
the odds of exposure in each group are compared. This design is particularly efficient to 
investigate of time varying exposures and multiple exposures. In our research we applied 
a nested case-control design where case-control studies were “nested” in a cohort of COPD 
patients. This design was applied for all safety studies and for the study on the effectiveness 
of tiotropium in the prevention of severe COPD exacerbations.
Internal and external validity
The internal validity of a study refers to the appropriateness of the design to answer the 
research question [203]. Observational studies on the association between drugs and several 
outcomes, using data from electronic medical record database, is challenging due to a vari-
ety of potential biases and mechanisms of confounding. In all observational studies, various 
types of bias, such as selection bias, protopathic bias, information bias, immortal time bias 
and confounding may hamper the internal validity [201, 202, 202, 205].
Selection bias results from an absence of comparability between the groups that are being 
compared due to differential participation rates [200-202, 204, 205]. As the IPCI data encom-
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passes the total population and patients do not need to be asked for participation (opt-out 
system) the magnitude of selection bias is negligible.
Information bias, also known as observation, recall or misclassification bias, results from 
an incorrect determination of outcome or exposure [205]. This information bias might be 
random (non-differential) or systematic (differential). Non-differential misclassification bias 
usually shifts the risk towards 1 (except for dose response), whereas differential misclassifica-
tion may result in an overestimation as well as an underestimation of the actual risk [200, 
202, 204]. To minimize the potential effect of information bias by misclassification of the 
outcome, a three-step validation process, if feasible, was undertaken on all of the studied 
outcomes. First, all potential cases were identified by means of a broad search of coded 
diagnoses and free text narratives in the electronic medical records of all patients. Second, 
the complete electronic medical records of all potential cases were manually reviewed and 
validated by a medical doctor. All doubtful cases were further reviewed and classified by a 
specialist or a third independent MD. During the validation process, reviewers were blinded 
to drug exposure. Due to this extensive validation process, false positives are highly unlikely 
among the cases. Through this extensive validation process, we did encounter the risk of false 
negatives, which was not a concern in our safety studies but was an issue in our study on the 
incidence and prevalence of COPD. Misclassification of the exposure is a potential concern in 
our pharmacoepidemiological studies since we only used prescription data and did not have 
information on dispensing or actual drug intake. In addition, we missed prescriptions initi-
ated by the specialist. Since data were obtained from medical records, independent of the 
study question, the exposure misclassification is probably non-differential and therefore the 
reported risk estimates between drug use and outcome are an underestimate of the actual 
risk. To tackle potential misclassification of exposure, due to irregular intake, we performed 
sensitivity analysis in our studies by varying the exposure window and by excluding or strati-
fying for patients who were referred to specialists. 
Studies run the risk of protopathic bias when a pharmacological agent is prescribed for an 
early manifestation of a disease that has not yet been diagnosed [206]. In statistical analysis 
it may appear as if the drug is positively associated with the outcome [206] and thus one 
could erroneously conclude that the drug causes the outcome of interest. In our effective-
ness study, protopathic bias was a concern; as one could hypothesize that GPs initiate the use 
of long-acting bronchodilators as treatment for the first symptoms of COPD exacerbations. 
Conducting a sensitivity analysis only including those patients who used the drugs for more 
than 30 days addressed this bias.
Immortal time bias is a span of cohort follow-up time during which, because of exposure 
definition, the outcome under study cohort can not occur [192]. If exposure effects are then 
compared to non-use of the drugs, extreme protective effects result [207]. The study per-
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formed by Rutten et al. [191] suffered from immortal bias, in which the protective effect of the 
use of β-blockers on the risk of dying and COPD exacerbation is extreme (figure 1). In order to 
verify this we mimicked their study and subsequently conducted a case-control study, which 
avoided immortal time by design.
Confounding is one of the major concerns in epidemiological research, as it is one of the 
most difficult biases to detect and to control for. A confounding variable is a variable that can 
cause the disease under study and is also associated with the exposure of interest (figure 2). 
There are three criteria for a variable to be a confounder: 1) it must be an independent risk 
factor for the disease (also in the non-exposed), 2) it must be associated with the exposure 
(also in the non-diseased) and 3) it must not be an intermediate step in the causal pathway 
[200-202, 204, 205]. 
Confounding can lead to overestimation or underestimation of the true association be-
tween exposure and outcome, depending on the direction of the associations between the 
confounding factor and the exposure and outcome. It can be controlled for via restriction, 
matching, stratification or statistical adjustment such as mathematical modeling via multi-
variate logistic regression or proportional hazard analysis [200, 202, 205]. With restriction, 
the control of confounding is achieved by including only those individuals with certain 
homogeneous levels of potential confounders. Matching involves removing the effect of 
the confounder by making the case group and the control group equivalent regarding the 
confounders [200-202, 205]. Both techniques were applied as, first of all, we controlled for 
confounding by age by restricting our population to 40 years or older, and in the case-control 
studies, we matched on age, sex and index date (to control for calendar time).
Figure 1: Immortal time bias
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The risk of confounding by indication and confounding by COPD severity was substantial 
in our research. Confounding by indication may arise when the indication for the treatment 
is a risk factor for the outcome under study [208, 209], and it refers to an extraneous determi-
nant of the outcome parameter that is present if a perceived high risk or poor prognosis is an 
indication for medical intervention. In our studies, COPD severity is a confounder because it 
correlates with the drug prescription and is a risk indicator for the different outcomes [209]. 
To control for confounding by COPD severity, we first of all assessed COPD severity via lung 
function or via proxies based on predefined algorithms. In all our analysis, we then adjusted 
for COPD severity. In addition, we dealt with confounding by indication by using reference 
drugs having the same indication of use as the indication of use of the drug of interest. E.g. 
in our studies on the safety and effectiveness of tiotropium, we used LABA as reference cat-
egory because, similar to tiotropium, LABA is used for the symptomatic treatment of patients 
with moderate to severe COPD. For this same reason, the association between the use of 
tiotropium Respimat® SMI and the risk of dying was studied using tiotropium HandiHaler® as 
reference category. The high impact of confounding by indication is illustrated in the study 
on the use of β-blockers and the risk of severe COPD exacerbations where the strong protec-
tive effect disappears using past use of β-blockers as reference category.
The external validity of epidemiological research implies that the observed findings can 
be generalized to the general population. External validity can be an issue in RCTs, as par-
ticipating patients tend to be different from patients who wish or cannot participate, due to 
stringent inclusion and exclusion criteria [200, 205]. Since all our data rely on routine clinical 
care data, the external validity is high and our findings can be extrapolated to the general 
population of COPD patients, 40 years or older.
Figure 2: Confounding
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Clinical implications
In the study on the incidence, prevalence and survival in COPD, we found that in the Nether-
lands, around 3 on 1000 subjects are newly diagnosed with COPD per year, although the true 
incidence of COPD based on spirometry criteria, may be 30-40% higher. Moreover, mortality 
rates are substantially higher in patients with COPD compared to the general population, 
which emphasizes the need for better care, including control of underlying comorbidity in 
patients with COPD. Not only GPs should be aware of increasing number of COPD cases, and 
assess lung function at earlier symptoms, but also specialists should diagnose and start treat-
ing COPD at an early disease stage, re-inforcing the importance to stop smoking.
In the comparative effectiveness study, we demonstrated a statistically non-significant 
trend towards a reduced risk for COPD exacerbations requiring hospitalization for tiotropium 
compared to LABA (salmeterol or formeterol). To our knowledge, our data are the first to 
compare the effectiveness of tiotropium and LABA in clinical practice. This is an important 
finding as both bronchodilators are the mainstay for symptomatic management of COPD. 
In clinical practice, this could lead to a preference in tiotropium prescribing, as it seems to 
perform better than LABA and tiotropium is administered once daily whereas LABA’s twice 
a day. 
There have been some concerns on the safety of tiotropium, especially related to a potential 
increased risk of cardiovascular and cerebrovascular events and risk of dying. This discussion 
on the safety of tiotropium HandiHaler® already tempered after the publication of the UPLIFT 
study. Our findings enforce the recent communication from the FDA stating that “the avail-
able data did no longer support an association between the use of tiotropium HandiHaler® 
and an increased risk of stroke, heart attack or death from cardiovascular causes”.
Although there were concerns on the safety of tiotropium Respimat® SMI based on data 
from RCTs; this could not be confirmed by our data. This is of importance especially as tiotro-
pium Respimat® SMI has been introduced because it has a better lung drug deposition and 
it’s easiness of use. For these reasons, it is mainly prescribed to patients with more severe 
COPD and thus a more vulnerable patient group. Although our data need to be confirmed 
by other studies, it is important to know that the risk of dying is not higher for tiotropium 
Respimat® SMI versus HandiHaler® study.
We studied the association between the use of inhaled anticholinergic drugs and the risk 
of AUR and concluded that the risk of AUR is increased, especially in COPD patients with BPH. 
As BPH and COPD are highly prevalent diseases in elderly men, it might be advisable that GPs 
and urologists consider alternatives for anticholinergics (e.g. LABA) in COPD patients with 
BPH. 
Finally, in the β-blockers study, we found that β-blockers may have some protective effect 
on COPD exacerbations in patients with COPD, especially in patients with underlying heart 
failure. Due to the great impact of confounding by (contra) indication, this association was 
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difficult to be addressed with the common methods in pharmacoepidemiology. The available 
data suggests that it is safe to prescribe β-blockers in patients with COPD, but their protective 
effect is probably more of a cardiovascular than of a respiratory one.
Recommendations for future research
Widely recognized as self-inflicted by smoking, COPD was in the past a neglected area of 
research and drug development. At present, COPD has become the fifth leading cause of 
death worldwide; and it is known that approximately 210 million people suffer from COPD, 
numbers confirming for epidemic disease [198].
The studies described in this thesis show the advantages and limitations of the use of elec-
tronic medical records for assessing associations between drug use and several outcomes in 
patients with COPD.
RCTs are the gold standard to address the efficacy of a drug – observational studies, using 
million records of health care databases, allow us to study the safety and effectiveness of 
respiratory drugs under real life circumstances.
Because of the large size number and long-term follow-up, these studies also allow using 
hard clinical outcomes, such as severe COPD exacerbations, instead of surrogate endpoints, 
such as improvement of FEV1, which correlate poorly with quality of life and mortality. The 
introduction of the new long acting β2-agonist - indacaterol - and - aclidinium bromide - a 
new long-acting anticholinergic drug, drugs that so far have only been tested in small RCTs 
with limited follow-up time, warrant the importance of pharmaco-epidemiological studies 
to closely monitor the safety of these new drugs. The importance of safety studies in the 
field of COPD treatment is underlined by the recent FP7 call (HEALTH-2011-4.2-2: Adverse 
drug reaction research [210]) promoting research on the safety of bronchodilating and anti-
inflammatory drugs. In particular, this call stimulates research on the cardiovascular safety on 
anticholinergic drugs and research on the use of ICS and risk of pneumonia in patients with 
COPD.
Effectiveness studies in the field of COPD research have been criticized because of con-
cerns of remaining confounding by COPD severity, which might spur the associations. COPD 
severity is usually measured by means of pulmonary function, an assessment that, unfortu-
nately, is not routinely done in primary care, and often not registered in a uniform manner. 
To improve the validity of, not only the effectiveness but also the safety studies, we would 
recommend that GPs perform spirometry in all patients with respiratory symptoms and that 
these lung function results are registered in a uniform manner in the database. The GOLD 
guidelines define a fixed FEV1/FVC ratio below 0.7 to decide whether a patient has COPD 
or not. This fixed ratio overestimates COPD in the elderly and underestimates COPD in the 
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young. If pulmonary function becomes one of the parameters standard reported in primary 
care databases, it might be worthwhile considering the lower limit of normal to define COPD.
Genetics should be considered in COPD research, not only because of genetic variabil-
ity in COPD development and COPD progression but also in terms of genetic variability in 
treatment response. Enriching electronic health care databases with information on genetic 
status would be an added value. 
Gender is probably an important effect modifier in the association between respiratory 
drug exposure and outcome in patients with COPD. So far, we only addressed gender in our 
COPD incidence and prevalence studies. Although it is believed that gender also modifies 
the treatment response to respiratory drugs, very few data are available, as the existing RCTs 
were not designed to assess the impact of gender. In future research, the effect of gender 
should be further investigated and one of the topics that can be addressed by our data is the 
association between hormone replacement therapy and risk of COPD [49, 198].
Finally, the systemic inflammation observed in COPD implies that patients with COPD often 
suffer from other concomitant disease especially cardiovascular diseases. Studies on the epi-
demiology of both diseases and how they relate to each other in terms of disease progression 
would add great value. Within this field, treatment response to respiratory and cardiovascular 
drugs and effect modification by underlying disease and disease severity would be of utmost 
importance. 
To conclude, we are convinced that the use of data from RCTs, in combination with obser-
vational studies using data from large electronic health care databases is important to give 
both the health care professionals and the patients’ complete and up-to-date information on 
the safety and efficacy/ effectiveness of (respiratory) drugs.
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6.1
Summary
Chronic obstructive pulmonary disease (COPD) is a leading and still-increasing cause of 
chronic morbidity and mortality worldwide. It is estimated that by 2020 it will become the 
third most common cause of death. Because of its burden and the impact on health care, 
we studied the epidemiology of COPD, and explored the effectiveness and safety of drugs 
given for the treatment of COPD, using data from the Integrated Primary Care Information 
(IPCI) project, a general practitioners’ (GP) database in the Netherlands. For this research we 
defined different cohorts of COPD patients and tiotropium users. Within the IPCI database, 
these patients were followed over time until the end of study period or the endpoint of inter-
est whichever occurred first.
In chapter 1 we present a general introduction of COPD (definition, epidemiology, patho-
physiology, risk factors, and symptoms), the national history of COPD and COPD treatment.
In chapter 2 – epidemiology – we describe the incidence, prevalence, mortality, and lifetime 
risk of COPD, as a function of age and gender. In addition, we compared mortality rates, both 
in the general population and in the COPD cohort. The cohort consisted of 7,308 COPD pa-
tients of whom 1,713 were incident COPD cases. The overall incidence rate (IR) of diagnosed 
COPD was 2.92/1,000 person-years (PY) and the overall prevalence was 3.02% (95%CI 2.94-
3.10%). Mortality was high, especially in very severe COPD patients. The one-year mortality 
risk in patients with very severe COPD was nearly 10-fold that of non-COPD subjects of the 
same age and gender. Overall, mortality rates were 2-fold higher for COPD patients than for 
the age and sex matched reference population, and increased with COPD severity.
In chapter 3 – effectiveness – we investigated the association between the use of inhaled 
respiratory drugs and the risk of hospitalization for COPD exacerbations. The effectiveness 
of tiotropium, a long acting anticholinergic drug is compared with long-acting β2-agonists 
(LABA). Tiotropium reduced the risk of COPD exacerbations leading to hospital admission 
in COPD patients as compared to LABA, but this association was not statistically significant 
(ORadj 0.69; 95%CI 0.40-1.19).
In chapter 4 – safety – we present the results of our observational studies on the safety 
of respiratory drugs for the treatment of COPD. In addition, in this chapter, we describe the 
association between the use of β-blockers and the risk of COPD exacerbation requiring 
hospitalization.
Data from (unpublished) RCTs showed an increased risk of dying in patients treated with 
tiotropium Respimat® Soft Mist Inhaler versus placebo. Very few RCTs compared the safety 
and efficacy of tiotropium Respimat® Soft Mist Inhaler (SMI) versus tiotropium HandiHaler®, 
and the studies that did had a short duration of follow-up. We conducted a population 
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based cohort study to compare the mortality rates in users of tiotropium Respimat® Soft 
Mist Inhaler (SMI) versus users of tiotropium HandiHaler® under real life circumstances with 
maximal follow-up. The results of this study are described in part 4.1 of this chapter. In a co-
hort of 11,753 tiotropium users, 272 patients died while being exposed to either tiotropium 
Respimat® or HandiHaler®. In our study we found that, the risk of all-cause mortality was very 
similar in patients being exposed to Respimat® compared to tiotropium HandiHaler®, (HRadj 
1.21; 95%CI 0.85-1.73).
Results driven from RCTs have shown that use of tiotropium users developed unintended 
adverse events such as dry mouth and urinary retention. This association was not yet quanti-
fied nor investigated under real life circumstances. For this reason, we studied the association 
between the use of inhaled anticholinergic drugs and the risk of acute urinary retention 
(AUR) (chapter 4.2). Within a cohort of 22,579 COPD patients, 209 cases of AUR were identi-
fied. The use of inhaled anticholinergic drugs increased the risk of AUR with 40% (ORadj 1.40; 
95%CI 1.21-7.98). The risk was the highest in men with benign prostatic hyperplasia (ORadj 
4.67; 95%CI 1.56-14.0).
Data from a pooled analysis on tiotropium safety reported the occurrence of renal failure 
during use of tiotropium. In chapter 4.3 we describe a study on the association between the 
use of inhaled anticholinergic drugs and the risk of renal failure. Within a cohort of 6,788 
COPD patients, 83 new cases of renal failure were identified. We did not observe an increased 
of renal failure (either acute or chronic) in patients currently using inhaled anticholinergics 
(ORadj 0.78; 95%CI 0.43-1.42) compared to no use. A tendency for an increased risk of chronic 
kidney disease in current users of inhaled anticholinergics compared to current use of β2-
agonists was observed (ORadj 1.77; 95% CI 0.67-4.66). 
In part 4.4 we evaluate the cardiovascular safety and risk of death during the use of in-
haled anticholinergic drugs when compared to LABA. This research was driven by the safety 
warning issued by the FDA in 2008, on a small excess risk of stroke in patients treated with 
tiotropium compared to placebo. Within our cohort of 6,788 patients with COPD, 784 new 
cases of a cardiovascular endpoint (254 stroke, 116 myocardial infarction, 413 heart failure 
and 6 ventricular arrhythmia) were identified, and 1032 patients died during follow-up. 
Compared to LABA, current use of tiotropium was not associated with an increased risk of a 
cardiovascular endpoint (ORadj 0.89; 95%CI 0.55-1.44), neither with an increased risk of death 
(ORadj 0.79; 95%CI 0.49-1.22).
β-blockers are generally contra-indicated in COPD patients, but recently published stud-
ies reported on a protective effect on mortality and severe COPD exacerbations in COPD 
patients treated with β-blockers. As the study results may be prone to bias and residual 
confounding, we applied different research designs to study this association (chapter 4.5). 
Within a cohort of 6,788 COPD patients, 619 patients were hospitalized for a COPD exacerba-
tion during follow-up. Using a cohort analysis, current use of β-blockers significantly reduced 
the risk of severe COPD exacerbations (HRadj 0.73; 95%CI 0.69-0.90). This protective effect was 
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confirmed in a case-control design where the use of β-blockers reduced the risk of severe 
COPD exacerbations by 40% (ORadj 0.60; 95%CI 0.44-0.82). To control for confounding by 
(contra)-indication we repeated the analysis, only selecting those patients ever treated with 
a β-blocker. In this analysis the protective effect was greatly attenuated (ORadj 0.87; 95%CI 
0.52-1.45). This study shows the importance of the correct choice of study design for drugs 
where a huge impact of confounding by (contra)-indication is suspected.
Chapter 5 includes a general discussion in which the results and conclusions of the studies in 
this thesis are summarized and interpreted. Furthermore, methodological considerations are 
discussed and suggestions are given for future research.
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6.2
Samenvatting
Chronisch obstructief longlijden, wat we verder zullen benoemen als “COPD”,  is een 
chronische longaandoening die gepaard gaat met een belangrijke morbiditeit en een 
verhoogde mortaliteit. De voorspellingen zijn dat tegen 2020, COPD de derde belangrijkste 
doodsoorzaak is. De huidige behandeling van COPD bestaat uit een symptomatische aanpak 
van de respiratoire klachten via het toedienen van bronchodilatoren en anti-inflammatoire 
middelen.
COPD is een belangrijke kostenpost voor de gezondheidszorg. Om die reden vonden wij 
het belangrijk om de epidemiologie van COPD nader te onderzoeken en tevens de effecten 
van de geneesmiddelen die gebruikt worden bij COPD te bestuderen. Voor dit onderzoek 
werden de gegevens van de IPCI (Integrated Primary Care Information) database gebruikt. 
De IPCI database is een Nederlandse database met de electronische geanonimiseerde medi-
sche dossiers van ongeveer 1 miljoen patiënten. Binnen de IPCI database definieerden we 2 
verschillende COPD cohorten en één tiotropium gebruikers cohort. 
Hoofdstuk 1 geeft een algemene inleiding over COPD (definitie, epidemiologie, pathofy-
siologie, risico factoren en symptomen) en gaat dieper in op de  behandeling. 
In hoofdstuk 2 – epidemiologie – beschrijven we de incidentie, prevalentie, mortaliteit en 
de cumulatieve incidentie van COPD in functie van leeftijd en geslacht. Daarnaast wordt het 
risico op overlijden vergeleken tussen COPD patiënten en patiënten zonder COPD. Het COPD 
cohort bestond uit 7308 patiënten. De incidentie van COPD was 2.92/1,000 persoonsjaren 
en de prevalentie was 3.02% (95%CI 2.94-3.10%). Het risico op overlijden was hoog, vooral 
in patiënten met zeer ernstig COPD. Het risico op overlijden was namelijk 10 maal hoger 
in patiënten met zeer ernstig COPD in vergelijking met niet-COPD patiënten van dezelfde 
leeftijd en geslacht. Algemeen zagen we dat het risico op overlijden 2 maal hoger was voor 
COPD patiënten versus niet-COPD patiënten met dezelfde leeftijd en geslacht.
In hoofdstuk 3 – effectiviteit – onderzochten we de relatie tussen het gebruik van respira-
toire geneesmiddelen, toegediend via inhalatie, en het risico op hospitalisatie omwille van 
een COPD exacerbatie. In dit onderzoek werd het risico op hospitalisatie (voor COPD exacer-
batie) vergeleken tussen patiënten die behandeld werden met tiotropium HandiHaler®, een 
langwerkend anticholinergicum, en patiënten die behandeld werden met een langwerkend 
β2 agonist. Binnen het  COPD cohort werden 619 patiënten tenminste een keer opgenomen 
voor een COPD exacerbatie. Het risico op ziekenhuis opname was iets lager tijdens gebruik 
van tiotropium HandiHaler® dan tijdens het gebruik van een langwerkende β2 agonist maar 
deze associatie was niet statistisch significant (ORadj 0.69; 95%CI 0.40-1.19).
Hoofdstuk 4 – veiligheid – beschrijft de resultaten van de observationele studies naar de 
veiligheid van respiratoire geneesmiddelen ter behandeling van COPD. In dit hoofdstuk 
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wordt ook de relatie onderzocht tussen het gebruik van β-blockers en het risico op zieken-
huisopname vanwege een COPD exacerbatie. 
Aangezien er twijfel bestond over de veiligheid van tiotropium Respimat hebben we in 
deel 4.1 van dit hoofdstuk onderzocht of er een verschil is in mortaliteit tussen personen die 
tiotropium gebruiken via de HandiHaler of via de Respimat als toedieningsvorm. Binnen een 
cohort van 11,753 tiotropium gebruikers overleden 272 patiënten. In de niet geadjusteerde 
analyse was het risico op overlijden iets hoger voor gebruikers van tiotropium Respimat® 
maar dit effect verdween bijna geheel na correctie voor mogelijk verstorende factoren (HRadj 
1.21; 95%CI 0.85-1.73).
Uit klinische studies en uit spontane meldingen blijkt dat het gebruik van tiotropium geas-
socieerd is met een verhoogd risico op urine retentie. Dit risico was voorheen niet eerder 
gekwantificeerd noch onderzocht buiten studieverband. In deel 4.2 worden de resultaten 
besproken van de case-controle studie naar de associatie tussen het gebruik van inhalatie 
anticholinergica en het risico op acute urine retentie. Binnen een cohort van 22,579 COPD 
patiënten werden 209 nieuwe gevallen van acute urine retentie opgepikt tijdens de follow-
up. Het gebruik van inhalatie anticholinergica verhoogt het risico op acute urine retentie met 
40% (ORadj 1.40; 95%CI 1.21-7.98). Het risico op acute urine retentie was het hoogst bij COPD 
patiënten met benigne prostaat hyperplasie (ORadj 4.67; 95%CI 1.56-14.0).
Uit een gepoolde analyse naar de veiligheid van tiotropium bleek het risico op nierlijden 
hoger bij tiotropium vs. placebo maar dit verschil was niet statistisch significant. Deze as-
sociatie was tot dan niet onderzocht via observationeel onderzoek. Hoofdstuk 4.3 van dit 
proefschrift beschrijft de resultaten van de case-controle studie naar de associatie tussen ge-
bruik van inhaleerbare anticholinergica en het risico op nierlijden (zowel acuut als chronisch). 
Binnen het COPD cohort van 6788 patiënten traden 83 nieuwe gevallen van nierlijden op. Het 
risico op nierlijden (zowel acuut als chronisch) was niet hoger in patiënten die inhaleerbare 
anticholinergica gebruikten ten opzichte van patiënten die geen anticholinergica gebruikten 
(ORadj 0.78; 95%CI 0.43-1.42). Indien het optreden van nierlijden werd vergeleken tussen 
gebruikers van anticholinergica en gebruikers van β2-mimetica werd een licht verhoogd 
risico op chronisch nierlijden gevonden voor anticholinergica, maar deze associatie was niet 
statistisch significant (ORadj 1.77; 95% CI 0.67-4.66).
In deel 4.4 wordt de cardiovasculaire veiligheid en overlijden vergeleken tussen  gebruikers 
van inhalatie anticholinergica en gebruikers van langwerkende β2 mimetica. Dit onderzoek 
werd opgezet naar aanleiding van een waarschuwing van de FDA over een licht verhoogd 
risico op een beroerte bij patiënten die werden behandeld met tiotropium. Binnen het COPD 
cohort van 6,788 patiënten traden  784 nieuwe gevallen van cardiovascular uitkomsten (bijv. 
myocardinfarct, beroerte) opgepikt (254 beroertes, 116 myocard infarcten, 413 gevallen 
van hartfalen and 6 ventriculaire ritmestoornissen), 1032 patiënten overleden gedurende 
de follow-up. Het risico op een cardiovasculair eindpunt verschilde niet tussen gebruikers 
van tiotropium en patiënten die behandeld werden met een langwerkend β2 mimeticum 
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(ORadj 0.89; 95%CI 0.55-1.44). Ook het risico op overlijden was vergelijkbaar (ORadj 0.79; 95%CI 
0.49-1.22).
In deel 4.5 van dit hoofdstuk onderzochten we het risico op ernstige COPD exacerbaties in 
patiënten die behandeld met een β-blokker, β-blokkers zijn in principe gecontra-indicieerd 
in COPD patiënten maar recente studies laten zien dat er een beschermend effect kan zijn 
op overlijden en COPD exacerbaties. Omdat een contra-indicatie sterke vertekening kan 
geven hebben we verschillende onderzoeksopzetten geprobeerd. Uit de cohort analyse 
bleek inderdaad dat het risico op ziekenhuis opname duidelijk lager was bij gebruikers van 
β-blokkers dan bij niet-gebruikers (HRadj 0.73; 95%CI 0.69-0.90). Dit beschermende effect 
werd nog sterker als een case controle onderzoek werd gedaan (ORadj 0.60; 95%CI 0.44-0.82). 
Om te corrigeren voor confounding door (contra)indicatie herhaalden we de case-control 
analyse maar nu enkel bij die patiënten die gedurende follow-up behandeld werden met een 
β-blocker. In die analyse zagen we dat het beschermend effect op hospitalisatie voor COPD 
exacerbaties sterk was afgezwakt (ORadj 0.87; 95%CI 0.52-1.45). Uit deze studie blijkt dat de 
keuze van de studie opzet extreem belangrijk is voor het vaststellen van de effectiviteit van 
geneesmiddelen waar men een sterk risico op confounding door (contra)indication verwacht. 
Hoofdstuk 5 is een algemene discussie waarbij de belangrijkste resultaten en conclusies wor-
den besproken en in perspectief worden geplaatst. Ook worden methodologische aspecten 
toegelicht en wordt er ingegaan op toekomstige onderzoeksvragen.
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